Monday Research Poster Presentations

POSTER SESSION I:  
Poster Display Hours – 8:45-14:15  
Poster Author Discussion Hour – 13:15-14:15

POSTER SESSION II:  
Poster Display Hours – 15:45-19:45  
Poster Author Discussion Hour – 18:45-19:45

POSTER SESSION I:  
PMD: MEDICAL DEVICE/DIAGNOSTICS  ROWS A-F  
PCV: CARDIOVASCULAR DISORDERS  ROWS F-L  
PMH: MENTAL HEALTH  ROWS L-M  
PSS: SENSORY SYSTEMS DISORDERS  ROWS M-P

POSTER SESSION II:  
PCN: CANCER  ROWS A-L  
PRS: RESPIRATORY-RELATED DISORDERS  ROWS L-O  
PUK: URINARY/KIDNEY DISORDERS  ROWS O-P
Research Poster Presentations – Session I

<table>
<thead>
<tr>
<th>Acceptance Code</th>
<th>VIH Page #</th>
<th>Topic – Subtopic</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMD1–PMD23</td>
<td>A344</td>
<td>Medical Device/Diagnostics – Clinical Outcomes Studies:</td>
<td></td>
</tr>
<tr>
<td>PMD24–PMD99</td>
<td>A348</td>
<td>Medical Device/Diagnostics – Cost Studies:</td>
<td></td>
</tr>
<tr>
<td>PMD100–112</td>
<td>A362</td>
<td>Medical Device/Diagnostics – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
<td></td>
</tr>
<tr>
<td>PMD113–PMD165</td>
<td>A364</td>
<td>Medical Device/Diagnostics – Health Care Use &amp; Policy Studies:</td>
<td></td>
</tr>
<tr>
<td>PCV1–PCV58</td>
<td>A373</td>
<td>Cardiovascular Disorders – Clinical Outcomes Studies:</td>
<td></td>
</tr>
<tr>
<td>PCV59–PCV130</td>
<td>A383</td>
<td>Cardiovascular Disorders – Cost Studies:</td>
<td></td>
</tr>
<tr>
<td>PCV131–PCV146</td>
<td>A397</td>
<td>Cardiovascular Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
<td></td>
</tr>
<tr>
<td>PCV147–PCV183</td>
<td>A399</td>
<td>Cardiovascular Disorders – Health Care Use &amp; Policy Studies:</td>
<td></td>
</tr>
<tr>
<td>PMH1–PMH12</td>
<td>A406</td>
<td>Mental Health – Clinical Outcomes Studies:</td>
<td></td>
</tr>
<tr>
<td>PMH13–PMH32</td>
<td>A408</td>
<td>Mental Health – Cost Studies:</td>
<td></td>
</tr>
<tr>
<td>PMH33–PMH41</td>
<td>A412</td>
<td>Mental Health – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
<td></td>
</tr>
<tr>
<td>PMH42–PMH51</td>
<td>A413</td>
<td>Mental Health – Health Care Use &amp; Policy Studies:</td>
<td></td>
</tr>
<tr>
<td>PSS1–PSS12</td>
<td>A415</td>
<td>Sensory Systems Disorders – Clinical Outcomes Studies:</td>
<td></td>
</tr>
<tr>
<td>PSS13–PSS52</td>
<td>A417</td>
<td>Sensory Systems Disorders – Cost Studies:</td>
<td></td>
</tr>
<tr>
<td>PSS53–PSS68</td>
<td>A424</td>
<td>Sensory Systems Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
<td></td>
</tr>
<tr>
<td>PSS69–PSS77</td>
<td>A427</td>
<td>Sensory Systems Disorders – Health Care Use &amp; Policy Studies:</td>
<td></td>
</tr>
</tbody>
</table>

Research Poster Presentations – Session II

<table>
<thead>
<tr>
<th>Acceptance Code</th>
<th>VIH Page #</th>
<th>Topic – Subtopic</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCN1–PCN67</td>
<td>A429</td>
<td>Cancer – Clinical Outcomes Studies:</td>
<td></td>
</tr>
<tr>
<td>PCN68–PCN205</td>
<td>A441</td>
<td>Cancer – Cost Studies:</td>
<td></td>
</tr>
<tr>
<td>PCN206–PCN256</td>
<td>A466</td>
<td>Cancer – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
<td></td>
</tr>
<tr>
<td>PCN257–PCN358</td>
<td>A476</td>
<td>Cancer – Health Care Use &amp; Policy Studies:</td>
<td></td>
</tr>
<tr>
<td>PRS1–PRS15</td>
<td>A493</td>
<td>Respiratory-Related Disorders – Clinical Outcomes Studies:</td>
<td></td>
</tr>
<tr>
<td>PRS16–PRS54</td>
<td>A496</td>
<td>Respiratory-Related Disorders – Cost Studies:</td>
<td></td>
</tr>
<tr>
<td>PRS55–PRS63</td>
<td>A503</td>
<td>Respiratory-Related Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
<td></td>
</tr>
<tr>
<td>PRS64–PRS81</td>
<td>A504</td>
<td>Respiratory-Related Disorders – Health Care Use &amp; Policy Studies:</td>
<td></td>
</tr>
<tr>
<td>PUK1–PUK6</td>
<td>A508</td>
<td>Urinary/Kidney Disorders – Clinical Outcomes Studies:</td>
<td></td>
</tr>
<tr>
<td>PUK7–PUK19</td>
<td>A509</td>
<td>Urinary/Kidney Disorders – Cost Studies:</td>
<td></td>
</tr>
<tr>
<td>PUK20–PUK27</td>
<td>A511</td>
<td>Urinary/Kidney Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
<td></td>
</tr>
<tr>
<td>PUK28–PUK35</td>
<td>A513</td>
<td>Urinary/Kidney Disorders – Health Care Use &amp; Policy Studies:</td>
<td></td>
</tr>
</tbody>
</table>
MEDICAL DEVICE/DIAGNOSTICS - Clinical Outcomes Studies

**PMD1** A1  SYSTEMATIC REVIEW OF THERMAL MASSAGE THERAPY FOR THE TREATMENT OF DRY EYE SYNDROME  
Lee J, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea

**PMD2** A2  A COST ANALYSIS OF OPEN SPINA BIFIDA DETECTION IN THE FIRST-TRIMESTER  
Turcu-Stolica A, University of Medicine and Pharmacy Craiova, Romania, Craiova, Romania

**PMD3** A3  CYTOGENETICS AND DOPAMINE RECEPTOR (DRD2) GENE POLYMORPHISM IN SCHIZOPHRENIA PATIENTS  
Mahalaxmi I, Sasakia K, Arun M, Balachandar V, Bharathiar University, coimbatore, India, Bharathiar University, Coimbatore, India, BMHG, Coimbatore, India

**PMD4** A4  VIVASCOPE® FOR DIAGNOSING MELANOMA: A SYSTEMATIC REVIEW  

**PMD5** A5  CLINICAL AND ECONOMIC IMPACT OF THE IMPLEMENTATION OF HPV 16/18 GENOTYPING TEST FOR CERVICAL CANCER SCREENING IN MEXICAN HEALTHCARE SYSTEM  
Picó J, García-González R, Guirant-Corpi L, Uriz A, Corro A, Ramirez A, LifeSciences Consultants, Mexico, Mexico, Roche, Mexico, Mexico

**PMD6** A6  EXHALED NITRIC OXIDE FOR THE DIAGNOSIS OF ASTHMA IN ADULTS AND CHILDREN: A SYSTEMATIC REVIEW  
Haran S, Essat M, Gomersall T, Tappenden P, Wong R, Lawson R, Pavord I, Everard M, University of Sheffield, Sheffield, UK, Royal Hallamshire Hospital, Sheffield, UK, Oxford University, Oxford, UK, The University of Western Australia (M561), Australia, Australia

**PMD7** A7  HEALTH OUTCOMES EVALUATION OF NEW TECHNOLOGIES IN CLINICAL PRACTICE: THE CASE OF THE MINIMALLY INVASIVE INSERTABLE CARDIAC MONITOR  
Venturini E, Magri MR, Ambrosini F, Lodi MC, Lombardi F, Maggiore Policlinico Hospital Ca' Granda Foundation, Milano, Italy

**PMD8** A8  PUBLISHED DIAGNOSTIC DISCORDANCE OF LYMPHOMA AND POTENTIAL FOR IMPACT ON PATIENT CARE  
Heinrich K, Smallwood C, Becton, Dickinson and Company, Franklin Lakes, NJ, USA, Becton, Dickinson, and Company, Mississauga, ON, Canada

**PMD9** A9  THE CONSEQUENCES OF REPLACING THE FLEISCHNER GUIDELINES BY A SOFTWARE-BASED VOLUME DOUBLING TIME TECHNIQUE: AN EARLY-STAGE RESEARCH  
Schoutrop A, Broekhuizen H, Siesling S, IJzerman MJ, University of Twente, Enschede, The Netherlands, Comprehensive Cancer Centre the Netherlands (IKNL), Enschede, The Netherlands

**PMD10** A10  ASSESSING THE CLINICAL AND ECONOMIC IMPACT OF AN AUTOMATED, ON-DEMAND IMMUNOASSAY FOR THE DIAGNOSIS OF HEPARIN INDUCED THROMBOCYTOPENIA  

**PMD11** A11  ANALYSIS OF BREAST CANCERS PATIENTS’ CLINICAL PATHWAY BEING DIAGNOSED BY MAMMOGRAPHY  

**PMD12** A12  TELEMEDICINE CONSULTATION IN THE DIFFERENTIAL DIAGNOSIS SIMPLE CONTACT DERMATITIS DUE TO INCONTINENCE AND PRESSURE SORES IN IMMOBILIZED PATIENTS WITH URINARY INCONTINENCE - CLINICAL AND ECONOMIC ANALYSIS  
Vorobiev A, Vorobiev P, Krasnova L, Russian Society for Pharmacoconomics and Outcomes Research, Moscow, Russia

**PMD13** A13  MEASURING POST-PARTUM HEMORRHAGE IN LOW-RESOURCE SETTINGS: THE DIAGNOSTIC VALIDITY OF WEIGHTED BLOOD LOSS VERSUS QUANTITATIVE CHANGES IN HEMOGLOBIN  
Atukunda EC, Mugyenyi GR, Obua C, Atuhumuzza EB, Musinguzi N, Torres YF, Agaba AG, Siedner MJ, Mbarara University of Science and Technology, Mbarara, Uganda, Harvard Medical School, Boston, MA, USA

**PMD14** A14  THE SAFETY AND TOLERABILITY OF THE FENTANYL IONTOPHORETIC TRANSDERMAL SYSTEM COMPARED TO OTHER POST-OPERATIVE PAIN MODALITIES: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS (NMA)  

**PMD15** A15  THROMBECTOMY IN THE TREATMENT OF ACUTE ISCHEMIC STROKE: WHAT EFFECTS DO METHODOLOGICAL DIFFERENCES IN TRIAL DESIGN HAVE ON COMPARABILITY OF OUTCOMES?  
PMD16 A16 NETWORK META-ANALYSIS ON PREVENTION OF STROKE FOR PATENT FORAMEN OVALE CLOSURE
Aggarwal S1, Kumar S2, Topaloglu H2, NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PMD17 A17 COMPARISON OF T-PIECE RESUSCITATOR WITH OTHER FLOW – INFLATING BAGS FOR PROVIDING POSITIVE PRESSURE VENTILATION DURING NEONATAL RESUSCITATION: A SYSTEMATIC REVIEW
Dang S1, Kanukula R2, Likhar N2, Vsn M3, Dang A4, University of Kentucky, Lexington, KY, USA, 2MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

PMD18 A18 INNOVATIVE METHODS FOR EARLY DIAGNOSTIC OF CANCER
Sassykova A1, Gurtskaya G1, Kulkhan T1, Senshin S2, Republican Center for Health Development, Astana, Kazakhstan, 1LLP”Radian”, Almaty, Kazakhstan

PMD19 A19 THE EFFECTIVENESS OF WIDE FIELD FLUORESCEIN ANGIOGRAPHY: SYSTEMATIC REVIEWS
Kim SY1, National Evidence-based Collaborating Agency, Seoul, South Korea

PMD20 A20 COLONRECTAL CANCER EVALUATION OF ITALIAN SCREENING AND MORTALITY
Socievole G, Setola E, Garziera G, Johnson & Johnson Medical SpA, Rome, Italy

PMD21 A21 RISK EQUATION FOR ALCOHOL RELATED CONSEQUENCES
Hoertel N1, Lefeu H2, Blachier M2, Limosin F3, Corentin-Celton Hospital / Paris Descartes University, Issy les Moulineaux, France, 2PUBLIC HEALTH EXPERTISE, Paris, France

PMD22 A22 TO ACCESS INDEPENDENT RISK CAUSE OF SUDDEN CARDIAC DEATH IN HEMODIALYSIS PATIENTS
Kumar P1, Savant K1, Attur RP1, Department of Pharmacy practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal India,1Manipal, India, 2Department of Nephrology, Kasturba Medical College, Manipal University, Manipal, India

PMD23 A23 IDENTIFYING THE OPTIMAL USE OF CTCS IN THE EARLY STAGING PHASE OF BREAST CANCER
Berghuis AM, Koffijberg H, IJzerman MJ, University of Twente, Enschede, The Netherlands

MEDICAL DEVICE/DIAGNOSTICS - Cost Studies

PMD24 A24 A BUDGET IMPACT ANALYSIS TO ESTIMATE THE ECONOMIC CONSEQUENCES OF AN INCREASE OF MEDICATION COMPLIANCE RELATED TO A POTENTIAL IMPROVEMENT OF THE INHALATION TECHNIQUE WITH SPIROMAX® COMPARED WITH TURBUHALER® IN MODERATE TO SEVERE ASTHOMATIC PATIENTS IN SPAIN
Darba J1, Ramírez G2, Gómez S2, Bijedic A, Sánchez-de la Rosa R4, Garcia-Bujalance L4, Torvinen S3, Universitat de Barcelona, Barcelona, Spain, 2BCN HEALTH ECONOMICS & OUTCOMES RESEARCH SL, Barcelona, Spain, 3Teva Pharmaceuticals, Madrid, Spain, 4Teva Pharma Spain, Alcobendas-Madrid, Spain, 5Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands

PMD25 A25 BUDGET IMPACT ANALYSIS OF PHASED RADIOFREQUENCY (RF) CATHETER ABLATION SYSTEM IN THE TREATMENT OF ATRIAL FIBRILLATION (AF) IN TURKEY
Ozdemir AZ, Erdol S, Can H, Medtronic, Inc., Istanbul, Turkey

PMD26 A26 ESTIMATING THE ECONOMIC CONSEQUENCES OF AN INCREASED MEDICATION COMPLIANCE DUE TO A POTENTIAL IMPROVEMENT OF THE INHALER TECHNIQUE WITH SPIROMAX® COMPARED WITH TURBUHALER® IN MODERATE TO SEVERE PATIENTS WITH COPD IN SPAIN
Darba J1, Ramírez G2, Gómez S2, Bijedic A, Sánchez-de la Rosa R4, Garcia-Bujalance L4, Torvinen S3, Universitat de Barcelona, Barcelona, Spain, 2BCN HEALTH ECONOMICS & OUTCOMES RESEARCH SL, Barcelona, Spain, 3Teva Pharmaceuticals, Madrid, Spain, 4Teva Pharma Spain, Alcobendas-Madrid, Spain, 5Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands

PMD27 A27 BUDGET IMPACT ANALYSIS OF N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE TESTING FOR THE DIAGNOSIS AND PROGNOSIS OF HEART FAILURE IN GREECE
Athanasakis K1, Boubouchairopoulos N1, Naoum P1, Akalestos T2, Skroumpelos A3, Kyriopoulos J1, National School of Public Health, Athens, Greece, 3Roche Diagnostics (Hellas) S.A., Athens, Greece, 2Roche (Hellas) S.A., Athens, Greece

PMD28 A28 CLINICAL AND BUDGET IMPACT OF USING A MOLECULAR TEST TO DETECT KRAS MUTATIONS IN METASTATIC COLORECTAL CANCER PATIENTS IN DENMARK
Cheng I1, Hertz D2, Huang J3, Poulios N1, Roche Molecular Systems, Inc., Pleasanton, CA, USA, 2GfK, Wayland, MA, USA

PMD29 A29 INTRODUCTION OF AN ORGANIZATIONAL MODEL OF TELMEDECINE IN MANAGEMENT OF ORAL ANTICOAGULANT THERAPY: A BUDGET IMPACT ANALYSIS FROM ITALIAN PAYER PERSPECTIVE
Dionisi M1, Santomauro M2, Santagada V2, Santomauro MA2, Garofalo G2, Vosa C2, Paolini D1, Roche Diagnostics S.p.a., Monza, Italy, 2Federico II University of Naples, Napoli, Italy

PMD30 A30 BUDGET IMPACT ANALYSIS OF HIGH-RISK HPV DNA (HRHPV) TEST WITH 16/18 GENOTYPING AS A
PMD43  B10  COST CONSEQUENCES OF SINGLE-USE AND RE-USE OF URINARY CATHETERS AMONG PATIENTS PERFORMING DAILY INTERMITTENT CATHETERIZATION
Neovius K1, Håkansson M1, Lundqvist T2, Cyclo AB, Stockholm, Sweden, “Wellspect HealthCare, Mömlndal, Sweden

PMD44  B11  SELF-REPORTED MEDICATION COSTS IN PATIENTS RECEIVING SACRAL NEUROMODULATION FOR OVERACTIVE BLADDER
Williams MJ1, Hinnenthal J1, Zylstra S2, Mangel J1, Comiter C3, Bird E4, Griebling T5, Culkin D6, Sutherland S7, Noblett K8, Siegl S9, Medtronic, Minneapolis, MN, USA, 2Milford Regional Medical Center, Whittingtonville, MA, USA, 3MetroHealth Medical Center, Cleveland, OH, USA, 4Stanford University, Stanford, CA, USA, 5Scott and White Healthcare, Temple, TX, USA, 6University of Kansas, Kansas City, KS, USA, 7University of Oklahoma, Oklahoma City, OK, USA, 8University of Washington, Seattle, WA, USA, 9University of California, Riverside, CA, USA, 10Metro Urology, Woodbury, MN, USA

PMD45  B12  A NEXT-GENERATION FRAMEWORK: DECIDING ON THE ROLE OF COSTS IN THE CLINICAL USE OF TARGETED GENE PANELS, EXOME AND GENOME SEQUENCING
van Nimwegen K1, van Soest R1, Grutters J1, Veltman J1, Vissers L1, van Der Willt G1, Radboud university medical center, Nijmegen, The Netherlands

PMD46  B13  COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION (DBS) IN THE MANAGEMENT OF ADVANCED PARKINSON’S DISEASE: A SWEDISH PAYER PERSPECTIVE
Egginton S1, Brandt A2, Reimer Rasmussen E3, Grifi M4, Nyberg J5, Medtronic International Trading Sarl, Tolochenaz, Switzerland, 2Medtronic Danmark A/S, Copenhagen, Denmark, 3Medtronic International Trading Sàrl, Tolochenaz, Switzerland, 4Stortorgetts Neurologiomttagning, Helsingborg, Sweden

PMD47  B14  ECONOMIC BENEFITS OF ENDOMETRIAL RADIOFREQUENCY ABLATION COMPARED WITH OTHER ENDOMETRIAL ABLATION TECHNIQUES IN WOMEN WITH MENORRHAGIA: A RETROSPECTIVE ANALYSIS WITH GERMAN HEALTH CLAIMS DATA
Goergen C1, Soeder R2, Gloege T3, Neukirch B4, HGC GesundheitsConsult, Dusseldorf, Germany, 2Gynecological Joint Practice, Mainz, Germany, 3Hochschule Niederrhein - University of Applied Sciences, Krefeld, Germany

PMD48  B15  COSTS AND COST-EFFECTIVENESS OF NON-INVASIVE PRENATAL DIAGNOSIS (NIPT) FOR DETECTION OF TRISOMY 21 IN SWEDEN
Davidson T1, Iwarsson E2, Jacobsson B3, Dagerhamn J4, Heibert Arnlind M5, Linköping University, Linköping, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Sahlgrenska University Hospital, Gothenburg, Sweden, 4Swedish Council on Health Technology Assessment (SBU), Stockholm, Sweden

PMD49  B16  ESTIMATING THE ADDITIONAL INDIRECT COST SAVINGS OF A PROCALCITONIN-ALGORITHM IN ADULT ICU PATIENTS WITH SEPSIS, AS ACHIEVED THROUGH REDUCTION IN ANTIBIOTIC RESISTANCE AND C. DIFFICILE INFECTIONS
Van der Maas M1, Kip M2, Steunen L3, Panaxea B.V., Enschede, The Netherlands, 2University of Twente, Enschede, The Netherlands, 3University of Washington and Panaxea bv, Seattle, WA, USA

PMD50  B17  CLINICAL-ECONOMIC MODELING ANALYSIS OF HUMAN PAPILLOMAVIRUS (HPV) CO-TESTING WITH GENOTYPING VERSUS PRIMARY HPV TESTING FOR CERVICAL CANCER SCREENING
Felip JC1, Lacey MU2, Miller JD3, Lenhart GM4, Kulkarni R5, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, 2Truven Health Analytics, Cambridge, MA, USA

PMD51  B18  RECURRENT LARYNGEAL CARCINOMA PET STUDY (RELAPS): COST ANALYSIS OF 18F-FDG PET IN PATIENTS WITH SUSPECTED RECURRENT LARYNGEAL CANCER PREVIOUSLY TREATED WITH RADIOTHERAPY
Zaim R1, van der Putten L2, de Groot S3, van Tinteren H4, Boers M5, Comans E6, van der Laan B7, Janssen L8, Takes R9, van den Brekel M10, Oyen W11, Valdés-Olmos R12, Hobbelink M13, Wedman J14, Leemans C15, Hoekstra O16, de Bree R17, Uyl-de Groot C18, Erasmus University, Rotterdam, The Netherlands, 2VU University Medical Center, Amsterdam, The Netherlands, 3Netherlands Cancer Institute,Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands, 4University Medical Center Groningen, Groningen, The Netherlands, 5University Medical Center Utrecht, Utrecht, The Netherlands, 6Radboud University Medical Center, Nijmegen, The Netherlands

PMD52  B19  THE ECONOMIC BURDEN OF CARDIAC COMPLICATIONS OF PERCUTANEOUS CORONARY INTERVENTION IN ENGLAND: AN ANALYSIS OF HOSPITAL EPISODE STATISTICS
Gidman WK1, Burke T1, de Belder MA2, Hughes D3, HCD Economics, Daresbury, UK, 4The James Cook University Hospital, Middlesbrough, UK

PMD53  B20  COST OF GENOME ANALYSIS: THE SANGER SEQUENCING METHOD
Perrier L1, Heinz D2, Baffert S3, Zou Z4, Durand Zaleski I5, Rouleau E6, Wang Q7, Haddad V8, Bringuier P9, Merlio J10, Caumon C11, Lacroix L12, Marino P13, Borget I14, Cancer Centre Léon Bérard, Lyon, France, 2Institut Curie, Paris, France, 3Institut Gustave Roussy, Villejuif, France, 4AP-HP Santé Publique Hôpital Henri Mondor, Paris, France, 5Hospices Civils de Lyon, Lyon, France, 6CHU Bordeaux, Pessac, France, 7Institut Paoli Calmettes, Marseille, France

PMD54  B21  THE ECONOMICS OF CRITICAL CARE DIAGNOSTICS: THE CASE OF PROCALCITONIN-GUIDED CARE IN TREATMENT OF ACUTE RESPIRATORY INFECTIOIN IN THE U.S
Schneider JE1, Schuetz P2, Lacey M3, Stojanovic I4, Scheibling CM5, Avalon Health Economics, Morristown, NJ, USA, 2University of Basel, Basel, Switzerland
PMD55  B22  A MICROCOSTING STUDY OF RADIATION THERAPY IN LOCALIZED PROSTATE CANCER PATIENTS IN A HUNGARIAN TERTIARY ONCOLOGY CENTER  
Zemplényi A1, Kaló Z1, Boncz I1, Endrei D1, Mangel L1, University of Pécs, Pécs, Hungary, “Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary

PMD56  B23  ANALYSIS OF COSTS FOR DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF PATIENTS WITH POSSIBLE TEMPOROMANDIBULAR DISORDERS IN UKRAINE  
Telishevskaya O, Makeyev Y, Telishevskaya U, Shybinskyy V, Piniazhko O, Danylo Halutsky Lviv National Medical University, Lviv, Ukraine

PMD57  B24  FINDING THE OPTIMAL SCREENING PROGRAM FOR UNKNOWN ATRIAL FIBRILLATION USING SIMULATION MODELS  
Aronsson M, Levin L, Linköping University, Linköping, Sweden

PMD58  B25  HIGHER ACCURACY OF BLOOD GLUCOSE MONITORING SYSTEMS IN TYPE 2 INSULIN TREATED DIABETIC PATIENTS IN SPAIN: CLINICAL AND ECONOMIC IMPACT  
Khan-Miron A, Universität Pompeu Fabra, Barcelona, Spain

PMD59  B26  HEXAMINOEVULINATE BLUE-LIGHT FLEXIBLE CYSTOSCOPY IN ADDITION TO STANDARD WHITE-LIGHT CYSTOSCOPY IN THE FOLLOW-UP OF NON-MUSCLE INVASIVE BLADDER CANCER: COST-CONSEQUENCES DURING OUTPATIENT SURVEILLANCE IN SWEDEN  
Dansk V1, Malmström P2, Bläckberg M3, Malmenäs M4, PAREXEL, Stockholm, Sweden, Uppsala University, Uppsala, Sweden, Helsingborg Hospital, Helsingborg, Sweden

PMD60  B27  A DECISION TREE MODEL TO EVALUATE THE COSTS AND CONSEQUENCES OF USING DUAL ANTIBIOTIC BONE CEMENT VERSUS SINGLE ANTIBIOTIC BONE CEMENT IN HIP HEMIARTHROPLASTY  
Griffiths M1, Slater D2, Hanstein T1, Costello Medical Consulting Ltd, Cambridge, UK, Heraeus Medical GmbH, Wehrheim, Germany

PMD61  B28  THE ADDITION OF A NOVEL COLONOSCOPE DEVICE IMPROVES ADENOMA DETECTION IN A GERMAN SCREENING POPULATION WHICH MAY RESULT IN COST SAVINGS DUE TO FEWER CASES OF COLORECTAL CANCER  
Conway P1, Fischbach W2, Carr P J1, Amlani BM1, Johnson K1, Jones C3, Kay M4, Norgine Ltd, Harefield, UK, Klinikum Aschaffenburg, Aschaffenburg, Germany, Double Helix Consulting, Macclesfield, UK

PMD62  B29  COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS REMOTE MONITORING OF HEART FAILURE PATIENTS WITH CARDIAC ELECTRONIC IMPLANTABLE DEVICE  
Malbaski N1, Balazs T2, Dozza C3, Zima E4, Med-Econ Ltd, Veroce, Hungary, BIOTRONIK Hungary, Budapest, Hungary, University of Miskolc, Miskolc, Hungary, Semmelweis University, Budapest, Hungary

PMD63  B30  COST-EFFECTIVENESS OF CAPNGRAPHY MONITORING DURING GASTROINTESTINAL ENDOSCOPY TARGETING MODERATE SEDATION  
Saunders R1, Erslon MG2, Vargo J3, Ossian Health Economics and Communications GmbH, Basel, Switzerland, Medtronic, Boulder, CO, USA, Cleveland Clinic, Cleveland, OH, USA

PMD64  B31  COST-EFFECTIVENESS ANALYSIS OF CAPSULE ENDOSCOPY USING FOR DIAGNOSING SMALL BOWEL CROHN’S DISEASE  
Dozza C1, Malbaski N2, Borcsek B3, University of Miskolc, Miskolc, Hungary, Med-Econ Ltd, Veroce, Hungary

PMD65  B32  INCREASED COST-EFFECTIVENESS OF DIAGNOSTIC IMAGING IN PATIENTS WITH SUSPECTED CAD BY USING A NEW CLINICAL-BIOHUMORAL PREDICTIVE MODEL OF DISEASE  
Lorenzoni V1, Caselli C2, Rovai D3, Neglia D2, Turchetti G1, Scuola Superiore Sant’Anna, Pisa, Italy, National Research Council, Pisa, Italy

PMD66  B33  ECONOMIC EVALUATION OF INDIVIDUALLY VS VIAL-PACKAGED STRIPS FOR GLUCOSE MONITORING  
Martin Saborido C, Antón Rodriguez C, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain

PMD67  C1  ECONOMIC EVALUATION OF FOUR SCHEMES FOR SCREENING AND DIAGNOSIS OF TYPE 2 DIABETES IN ADULTS IN COLOMBIA  
Quitian H1, Aschner P2, Muñoz O3, Triana Romero PA1, Girón D1, Gomez-Restrepo C1, Rosell D2, Pontificia Universidad Javeriana, Bogota, Colombia, Pontificia Universidad Javeriana, Bogotá, Colombia

PMD68  C2  A PCT-ALGORITHM TO GUIDE ANTIBIOTIC THERAPY IN PATIENTS HOSPITALIZED WITH COPD EXACERBATIONS LEADS TO NET COST SAVINGS BY REDUCING FREQUENCY AND DURATION OF ANTIBIOTIC USE AS COMPARED TO CURRENT PRACTICE  
Van der Maas M1, Steuten L2, Panaxea B.V., Enschede, The Netherlands, Fred Hutchinson Cancer Research Center / University of Washington & Panaxea bv, Seattle, WA, USA

PMD69  C3  ECONOMIC ANALYSIS OF EPICUP, AN EPIGENETIC TEST TO PREDICT THE SOURCE OF ORIGIN IN CANCER OF UNKNOWN PRIMARY SITE, THE USA PAYORS PERSPECTIVE  
Gracia A1, Balahán C2, Kaskens L3, Chiavena S4, Matías-Guiu X5, Rubio-Rodríguez D6, Rubio-Terrés C7, Iglesias L8, Esteller M9, HEOR & MA Dpt Ferrer, Barcelona, Spain, Medical Oncology Dpt, ICO, Badalona, Spain, Ferrer Advanced Biotherapeutics, Barcelona, Spain, IRB, Lleida, Spain, Health Value, Madrid, Spain, Medical Oncology Dpt, 12 de Octubre Hospital, Madrid, Spain, IDIBELL, Barcelona, Spain

PMD70  C4  ECONOMIC EVALUATION OF ORAL ANTICOAGULATION THERAPIES (OAT) IN CHINA
**PMD71**  C5  **ECONOMIC ANALYSIS OF EPICUP, AN EPIGENETIC TEST TO PREDICT THE TISSUE OF ORIGIN IN CANCER OF UNKNOWN PRIMARY SITE, FROM THE SPANISH NHS PERSPECTIVE**

Gracia A1, Balañá C2, Kaskens L1, Chiavenna S3, Matias-Guiu X4, Rubio-Rodríguez D5, Rubio-Terrés C6, Iglesias L6, Esteller M7, HEOR & MA Dpt Ferrer, Barcelona, Spain, 8Medical Oncology Dpt, ICO, Badalona, Spain, 9Ferrer Advanced Biotherapeutics, Barcelona, Spain, 10IRB, Lleida, Spain, 11Health Value, Madrid, Spain, 12Medical Oncology Dpt, 12 de Octubre Hospital, Madrid, Spain, 13IDIBELL, Barcelona, Spain

**PMD72**  C6  **MODELING THE COST-EFFECTIVENESS OF A NEW COVERED STENT (WILLIS) VS. ENDOVASCULAR COIL OCCLUSION FOR THE TREATMENT OF INTRACRANIAL ANEURYSMS IN CHINA**

Li L1, Li M2, Liu J3, Wan J4, Xie Z5, Wang W6, Zhou Y7, Ding S8, Li B9, Li Z10, Xuan J11, Fujan University, Shanghai, China, 2Affiliated Sixth People's Hospital of Shanghai Jiao Tong University, Shanghai, China, 3Affiliated Shanghai Jiao Tong University Hospital, Shanghai, China, 4Affiliated Changhai Hospital of Second Military Medical University Shanghai, Shanghai, China, 5Affiliated Renji Hospital of Shanghai Jiaotong University, Shanghai, China, 6MicroPort Neurotech Company, Shanghai, China, 7Shanghai Centennial Scientific, Shanghai, China, 8Sun Yat-Sen University, Guangzhou, China

**PMD73**  C7  **COST-EFFECTIVENESS OF SCREENING FOR COLORECTAL CANCER IN ARGENTINA**

Maceira D, Espinola N, Palacios A, Center for the Study of State and Society (CEDES), Buenos Aires, Argentina

**PMD74**  C8  **A COST-EFFECTIVE ANALYSIS OF REVOLUTION CT FOR PATIENTS WITH ACUTE CHEST PAIN**

He L, Yang L, Peking University, Beijing, China

**PMD75**  C9  **COST-EFFECTIVENESS OF A LEFT ATRIAL APPENDAGE CLOSURE DEVICE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION UNABLE OR UNWILLING TO TOLERATE ORAL ANTIICOAGULANT THERAPY IN ITALY AND SPAIN**

Amin A1, Cruz González i2, Reddy V3, Holmes D4, Berti S5, Itíguez Romo A6, De Deppo L7, Priest V8, Simmonds M9, Lee C10, Wasserman M11, Margonato A12, Double Helix Consulting, London, UK, 13University Hospital of Salamanca, Salamanca, Spain, 14Mount Sinai, New York, NY, USA, 15Mayo Clinic College of Medicine, Rochester, MN, USA, 16Fondazione Toscana G. Monasterio, Massa, Italy, 17Complejo Hospitalario Universitario, Pontevedra, Spain, 18Boston Scientific Europe, Milano, Italy, 19Boston Scientific Asia Pacific, The Metropolis Tower One, Singapore, 20Boston Scientific Australasia, Sydney, Austria, 21Double Helix Consulting, New York, NY, USA, 22San Raffaele Hospital, Milano, Italy

**PMD76**  C10  **A COST-EFFECTIVE ANALYSIS OF THE OPTIMUM NUMBER OF BLOOD CULTURE FOR ADULT PATIENTS WITH INFECTION**

He L, Yang L, Peking University, Beijing, China

**PMD77**  C11  **VALUE OF ANTIDRUG ANTIBODY SCREENING IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS PATIENTS WHO FAILED INITIAL TUMOR NECROSIS FACTOR-ALPHA TREATMENT**

Dilokthornsakul P1, Campbell JD2, 1Naesruan University, Muang, Phitsanulok, Thailand, 2University of Colorado Anschutz Medical Campus, Denver, CO, USA

**PMD78**  C12  **COST-EFFECTIVENESS ANALYSIS FOR THE USE OF THE CCP SCORE IN THE MANAGEMENT OF EARLY LOW RISK PROSTATE CANCER IN THE FRENCH CONTEXT**

de Pouvourville G, ESSEC Business School, Cergy-Pontoise, France

**PMD79**  C13  **THE COST-EFFECTIVENESS ANALYSIS OF PHILIPS MOTIVA TELEHEALTH SYSTEM: A COMPARISON BETWEEN HOME TELEMONITORING, NURSE TELEPHONE SUPPORT AND USUAL CARE IN CHRONIC HEART FAILURE**

Grustam AS1, Severens JL2, de Massari D3, Koymans R4, Vrijhoef H5, Erasmus University, Rotterdam, The Netherlands, 2Philips Research, Eindhoven, The Netherlands, 3National University of Singapore, Singapore, Singapore

**PMD80**  C14  **COST EFFECTIVENESS ANALYSIS OF A DEVICE TO MONITOR LEVODOPA-INDUCED DYSKINESIA IN PARKINSON’S PATIENTS**


**PMD81**  C15  **EARLY STAGE ECONOMIC EVALUATION OF CARETOY SYSTEM FOR EARLY INTERVENTION IN PRETERM INFANTS AT RISK OF NEURODEVELOPMENTAL DISORDERS**

Manetti S1, Cecchi F2, Sgandurra G3, Cioni G4, Laschi C5, Dario P6, Turchetti G7, Scuola Superiore Sant'Anna, Pisa, Italy, 8IRCCS Fondazione Stella Maris, Pisa, Italy

**PMD82**  C16  **A FIVE-YEAR MODEL TO ASSESS THE COST-EFFECTIVENESS OF NEW DIAGNOSTIC TESTS IN THE EARLY DIAGNOSIS OF RHEUMATOID ARTHRITIS**

Buisman LR1, Luime JJ2, Oppe M3, Hazes JM4, Rutten-van Mölken MP5, Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus MC, Rotterdam, The Netherlands, 3EuroQol Group, Rotterdam, The Netherlands

**PMD83**  C17  **COST-EFFECTIVENESS OF PEN DEVICES FOR NPH INSULIN ADMINISTRATION COMPARED WITH SYRINGE AND VIAL IN ADULT PATIENTS WITH DIABETES MELLITUS IN COLOMBIA**

Lasalvia P1, Barahona J2, Romero D3, Gil S4, Castañeda-Cardona C5, Bayona JG6, Triana JJ7, Laserna A1, Restrepo P8, Mejía M9, Rosselli D10, Pontificia Universidad Javeriana, Bogota, Colombia, 11Pontificia Universidade Javeriana, Bogotá, Colombia
PMD84 C18 COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE REPLACEMENT: CURRENT DECISION-ANALYTIC MODELS AND FUTURE OPPORTUNITIES  
Busca R1, Geiser BP2, Pietzch JB3, Medtronic International Trading Sàrl, Tolochenaz, Switzerland, 4Wing Tech Inc., Irvine, CA, USA  

PMD85 C19 COST-UTILITY ANALYSIS OF SACRAL NERVE STIMULATION FOR THE TREATMENT OF FECAL INCONTINENCE REFRACTORY TO CONSERVATIVE TREATMENT: LOOKING FOR OPTIMAL TREATMENT PATH  
Pochoptien M1, Plisko R1, Drzal R1, Baran M1, Sekiewicz B1, Dudding T2, Knowles C2, Grifi M3, Valyi A3, HTA Consulting, Krakow, Poland, 2University Hospital Southampton NHS Foundation Trust, Southampton, UK, 3Queen Mary University of London, London, UK, 4Medtronic International Trading Sàrl, Tolochenaz, Switzerland, 5Medtronic Ltd UK & Ireland, Watford, UK  

PMD86 C20 EARLY ECONOMIC EVALUATION OF SHORT-TERM VARIABILITY OF QT INTERVALS AS A POTENTIAL TEST FOR PREDICTING THE EFFECTIVENESS OF ICD IMPLANTATION IN PATIENTS WITH HEART FAILURE  
Tomini F1, Prinzen F2, van Asselt TA3, Maastricht University Medical Center, Maastricht, The Netherlands, 4Maastricht University, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands, 5Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands  

PMD87 C21 A COST-EFFECTIVENESS MODEL EVALUATING COMPONENT-RESOLVED DIAGNOSIS (CRD) VERSUS STANDARD TESTING METHOD (SKIN PRICK TESTING (SPT)) IN THE DIAGNOSIS AND TREATMENT OF ALLERGIC RHINITIS IN THE NETHERLANDS  

PMD88 C22 EARLY ECONOMIC EVALUATION OF A HYPOTHETICAL PERFECT TEST FOR PREDICTING THE EFFECTIVENESS OF IMPLANTABLE PACEMAKER-DEFIBRILLATOR DEVICES (CRT-D) IN PATIENTS WITH HEART FAILURE  
Tomini F1, van Asselt TA2, Maastricht University Medical Center, Maastricht, The Netherlands, 4University of Groningen, Groningen, The Netherlands  

PMD89 C23 LONG-TERM COST-EFFECTIVENESS OF TRANSANAL IRRIGATION IN PATIENTS WITH NEUROGENIC BOWEL DYSFUNCTION WHO HAVE FAILED STANDARD BOWEL CARE  
Emmanuel A1, Christensen P2, Kumar G3, Passananti V1, Mealing S4, Stoerling ZM5, Andersen F6, Soerensen J6, Kirshblum S7, University College London Hospital, London, UK, 4Aarhus University Hospital, Aarhus, Denmark, 5ICON Health Economics, Oxford, UK, 6ICON Health Economics and Epidemiology, Oxford, UK, 7Coloplast A/S, Humlebaek, Denmark, 8Rutgers New Jersey Medical School, Newark, NJ, USA  

PMD90 C24 REDUCTION OF COMPLICATIONS AND ASSOCIATED COSTS FOR TYPE 2 DIABETIC PATIENTS USING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN THE UK  
Roze S1, Duteil E2, Hallas N3, de Portu S4, HEVA HEOR Sarl, Lyon, France, 5HEVA-HEOR, Lyon, France, 6Medtronic, Watford, UK, 7Medtronic International Sàrl, Tolochenaz, Switzerland  

PMD91 C25 COST-UTILITY ANALYSIS OF CONTINUOUS INFUSION PUMP WITH INTEGRATED MONITORING COMPARED WITH MULTIPLE DAILY INJECTION TREATMENT FOR PATIENTS 15-YEARS OR OLDER WITH TYPE 1 DIABETES MELLITUS IN COLOMBIA  
Quitian H1, Gomez AM2, Garcia Peña AA1, Arciniegas J1, Iragorri N1, Mantilla B1, Gomez-Restrepo C1, Rosselli D2, Pontificia Universidad Javeriana, Bogota, Colombia, 3Pontificia Universidade Javeriana, Bogota, Colombia  

PMD92 C26 COST-UTILITY OF HEXAMINOLEVULINIC BLUE LIGHT CYSTOSCOPY (HAL) ASSISTED TRANSCURETHRAL RESECTION OF THE BLADDER TUMOUR (TURB) COMPARED TO TURB WITH WHITE LIGHT CYSTOSCOPY (WLC) ALONE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NIMBC) IN POLAND  
Jablonowski Z1, Konecki T1, Ziobro M1, Haldas M1, Wolski Z2, Marteau F3, Sosnowski M1, Medical University of Lodz, Lodz, Poland, 4HTA Consulting, Cracow, Poland, 5Collegium Medicum Nicolaus Copernicus University, Bydgoszcz, Poland, 6IPSEN Pharma, Boulogne-Billancourt, France  

PMD93 C27 HEALTH-ECONOMIC ANALYSIS OF THE USE OF SENSOR-AUGMENTED PUMP (SAP) THERAPY IN THE NETHERLANDS COMPARED TO INSULIN PUMP THERAPY ALONE (CSI), IN TYPE 1 DIABETIC PATIENTS  
Roze S1, Duteil E2, de Brouwer BF3, de Portu S4, HEVA-HEOR Sarl, Lyon, France, 5HEVA-HEOR, Lyon, France, 6Medtronic Trading NL BV, Heerlen, The Netherlands, 7Medtronic International Sàrl, Tolochenaz, Switzerland  

PMD94 C28 DELAYED ENHANCEMENT CARDIAC MAGNETIC RESONANCE TO REFINE PATIENT SELECTION FOR IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY IN PRIMARY PREVENTION - AN EXPLORATORY COST-EFFECTIVENESS ANALYSIS  
Silva Miguel L1, 1Ferreira AM2, CISEP (Research Centre on the Portuguese Economy), Lisbon, Portugal, 2Hospital de Santa Cruz and Hospital da Luz, Camaxide and Lisbon, Portugal  

PMD95 C29 COST-EFFECTIVENESS ANALYSIS OF TESTING FOR BRCA1 AND BRCA2 MUTATIONS IN WOMEN DiAGNOSED WITH OVARian CANCER and THEIR FEMALE FIRST- and SECOND DEGREE RELATIVES USING A DISCRETE EVENT SIMULATION: A UK HEALTH SERVICE PERSPECTIVE  

PMD96 C30 IDENTIFYING THE MOST COST-EFFECTIVE WAY OF DIAGNOSING ASTHMA IN ADULTS USING MULTIPLE
TESTS – A COST-UTILITY ANALYSIS FROM THE NICE ASTHMA GUIDELINE
Haines A1, Davies E1, Higgins B2, Menzies-Gow A3, Thomas M4, Masoli M5, Gaillard E6, National Clinical Guideline Centre, London, UK, 1Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, 2Royal Brompton and Harefield NHS Foundation Trust, London, UK, 3University of Southampton, Southampton, UK, 4Plymouth Hospitals NHS Trust, Plymouth, UK, 5University of Leicester, Leicester, UK

PMD97 C31 RISK FACTORS FOR DEVELOPING DIABETES AS A DETERMINANT OF THE COST-EFFECTIVENESS OF USING CORONARY CALCIUM SCORE TO GUIDE PRIMARY PREVENTION WITH STATINS
Silva Miguel L1, Ferreira AM2, CISEP (Research Centre on the Portuguese Economy), Lisbon, Portugal, 1Hospital de Santa Cruz and Hospital da Luz, Carnaxide and Lisbon, Portugal

PMD98 C32 EXAMINING THE ECONOMIC IMPACT OF LABORATORY DEVELOPED TESTING IN FLOW CYTOMETRY IMMUNOPHENOTYPING FOR HEMATOLOGIC MALIGNANCIES: AN ANALYSIS OF HEALTH RESOURCE UTILIZATION
Smallwood C1, Galama L1, Apoll L1, Heinrich K2, Buchanan S3, Demers J4, Becton, Dickinson and Company, Mississauga, ON, Canada, 2Becton, Dickinson and Company, Franklin Lakes, NJ, USA, 3St. Michael's Hospital, Toronto, ON, Canada

PMD99 C33 ECONOMICAL AND ORGANIZATIONAL IMPACT OF ADOPTING DIFFERENT IN SITU HYBRIDIZATION TECHNOLOGIES TO ASSESS HER2 GENE AMPLIFICATION IN BREAST CANCER
Paolini D1, Rossoni R1, Guardione D1, Arena V1, Roche Diagnostics S.p.A., Monza, Italy, 1Policlinico Universitario, Rome, Italy

MEDICAL DEVICE/DIAGNOSTICS - Patient-Reported Outcomes & Patient Preference Studies
PMD100 D1 COPD ICS/LABA TREATMENT INHALERS AND THEIR IMPACT ON ADHERENCE
Sicras-Mainar A1, Ferrer V1, Navarro R2, Collar JM3, Badalona Serveis Assistencials, Badalona. Barcelona, Spain, 1EAP La Roca del Vallés, Barcelona, Spain, 2Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, 3Mundipharma Pharmaceuticals, S.L., Madrid, Spain

PMD101 D2 THE IMPORTANCE OF INHALER DEVICES: AN INCORRECT INHALER TECHNIQUE LEADS TO SUBOPTIMAL MEDICATION COMPLIANCE IN PATIENTS WITH COPD
Darba J1, Ramírez G2, Sicras-Mainar A3, Francoli-Martínez P4, Torvinen S5, Sánchez-de la Rosa R6, Universitat de Barcelona, Barcelona, Spain, 2BCN HEALTH ECONOMICS & OUTCOMES RESEARCH SL, Barcelona, Spain, 3Badalona Serveis Assistencials, Badalona. Barcelona, Spain, 4Teva Pharma Spain, Alcobendas-Madrid, Spain, 5Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, 6Teva Pharmaceuticals, Madrid, Spain

PMD102 D3 DEVICE INHALATORS IN ASTHMA AND THEIR IMPACT ON TREATMENT ADHERENCE
Sicras-Mainar A1, Collar JM2, Ferrer V2, Navarro R3, Badalona Serveis Assistencials, Badalona. Barcelona, Spain, 1Mundipharma Pharmaceuticals, S.L., Madrid, Spain, 2EAP La Roca del Vallés, Barcelona, Spain, 3Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

PMD103 D4 THERAPY ADHERENCE IN PATIENTS WITH MULTIPLE SCLEROSIS USING AN ELECTRONIC MULTIDOSE AUTO-INJECTION DEVICE
Krol M1, Osowski U2, Merck Serono, Schiphol-rijk, The Netherlands, 1Merck Serono, Darmstadt, Germany

PMD104 D5 IDENTIFICATION OF FACTORS INVOLVED IN MEDICATION COMPLIANCE: INCORRECT INHALER TECHNIQUE OF ASTHMA TREATMENT LEADS TO POOR COMPLIANCE
Darba J1, Ramírez G2, Sicras-Mainar A3, García-Bujalance L4, Torvinen S5, Sánchez-de la Rosa R6, Universitat de Barcelona, Barcelona, Spain, 2BCN HEALTH ECONOMICS & OUTCOMES RESEARCH SL, Barcelona, Spain, 3Badalona Serveis Assistencials, Badalona. Barcelona, Spain, 4Teva Pharma Spain, Alcobendas-Madrid, Spain, 5Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, 6Teva Pharmaceuticals, Madrid, Spain

PMD105 D6 EVALUATION OF INHALER TECHNIQUE MASTERY AND HANDLING ERRORS WITH SPIROMAX®, EASYHALER®, AND TURBUHALER® DEVICES (FINHALER)
Sandler N1, Holländer J1, Långström D2, Santitla A1, Saukkonen A2, Torvinen S3, Åbo Akademi University, Turku, Finland, 1Teva Pharmaceuticals Finland, Espoo, Finland, 2Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands

PMD106 D7 EVALUATION OF INHALER PERCEPTION AND PREFERENCE OF SPIROMAX®, EASYHALER®, AND TURBUHALER® DEVICES (FINHALER)
Sandler N1, Holländer J1, Långström D2, Santitla P1, Saukkonen A2, Torvinen S3, Åbo Akademi University, Turku, Finland, 1Teva Pharmaceuticals Finland, Espoo, Finland, 2Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands

PMD107 D8 PEN DEVICES FOR INSULIN ADMINISTRATION COMPARED TO NEEDLE AND VIAL: SYSTEMATIC REVIEW OF LITERATURE AND META-ANALYSIS
Lasalvia P1, Barahona J2, Romero D3, Gil S4, Castañeda-Cardona C5, Bayona JG6, Triana JJ1, Lasema A1, Restrepo P1, Mejia M1, Rosselli D2, Pontificia Universidad Javeriana, Bogota, Colombia, 1Pontificia Universidad Javeriana, Bogotá, Colombia

PMD108 D9 HEALTH STATE UTILITIES ASSOCIATED WITH ATTRIBUTES OF WEEKLY INJECTION DEVICES FOR TREATMENT OF TYPE 2 DIABETES
Matza LS1, Stewart KD1, Davies EW2, Paczkowski R3, Boye KS4, Evidera, Bethesda, MD, USA, 1Evidera, London,
**PMD109** D10 HEALTH STATE UTILITIES ASSOCIATED WITH GLUCOSE MONITORING DEVICES

Matza LS1, Stewart KD1, Davies EW1, Hellmünd R2, Polonsky WK4, Kerr D3, Evidera, Bethesda, MD, USA, 2Evidera, London, UK, 3Abbott Diabetes Care, Alameda, CA, USA, 4University of California San Diego, San Diego, CA, USA, 5William Sansum Diabetes Center, Santa Barbara, CA, USA

**PMD110** D11 THE IMPACT OF ROBOTIC TECHNOLOGY ON NEURO-REHABILITATION: PRELIMINARY RESULTS ON ACCEPTABILITY AND EFFECTIVENESS

Turchetti G1, Mazzoleni S2, Dario P3, Saldi D1, Guglielmelli E4, 1Scuola Superiore Sant'Anna, Pisa, Italy, 2Scuola Superiore Sant'Anna, Pontedera (PI), Italy, 3Università Campus Bio-Medico, Roma, Italy

**PMD111** D12 PREFERENCES FOR DRY POWDER INHALER ATTRIBUTES AMONG PATIENTS WITH ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM FIVE EUROPEAN COUNTRIES

Hawken NA1, Amri i1, Elmocat Neine M2, Aballéa S1, Torvinen S1, Pilch A1, 1Creativ- Ceutical, Luxembourg, Luxembourg, 2Creativ-Ceutical, Tunis, Tunisia, 3Creativ-Ceutical, Paris, France, 4Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands

**PMD112** D13 SUBJECTIVE OUTCOMES WITH BONE CONDUCTION AND MIDDLE EAR IMPLANTS FOR PATIENTS WITH CONDUCTIVE OR MIXED HEARING LOSS


**MEDICAL DEVICE/DIAGNOSTICS - Health Care Use & Policy Studies**

**PMD113** D14 REFERENCE PRICING FOR LABORATORY TESTS IN THE UNITED STATES: IMPACT ON PRICES AND SPENDING

Robinson J, Brown T, Whaley C, University of California, Berkeley, Berkeley, CA, USA

**PMD114** D15 THE ASSESSMENT OF VALUE FOR MEDICAL DEVICES: A CASE STUDY ON INJECTION TECHNIQUE EDUCATION IN INSULIN DELIVERY

Charter R1, Hopley C2, Su T3, Grima D3, Strauss K4, Becton Dickinson AG, Allschwil, Switzerland, 2Becton Dickinson, Oxford, Switzerland, 3Cornerstone Research Group, Burlington, ON, Canada, 4Becton Dickinson, Erembodegem, Belgium

**PMD115** D16 HEALTHCARE ASSOCIATED INFECTIONS. IMPACT AND COSTS OF DIAGNOSIS AND MANAGEMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS (CDI). THE EXPERIENCE OF A UNIVERSITY HOSPITAL IN ROME

Capozzi C1, Fontana C2, Volpi A1, Lombardi G3, Lisena FP1, Paulon L1, Maurici M2, Visconti G3, Tor Vergata University, Rome, Italy, 1Tor Vergata University Hospital, Rome, Italy, 2Rarreg, Cesano Maderno, Italy

**PMD116** D17 REVIEW OF US MEDICARE SYSTEM FOR REIMBURSEMENT OF NEW MEDICAL DEVICES

Battaglia S1, Fattore G2, Busca R1, Medtronic International Trading Sàrl, Tolochenaz, Switzerland, 2SDA-Bocconi School of Management, Centre for Research in Healthcare Management (CERGAS), Milano, Italy

**PMD117** D18 PATTERNS OF USE OF TESTS TO MONITOR DISEASE ACTIVITY AMONG PATIENTS CURRENTLY TREATED FOR RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) IN EUROPE

Narayanan S3, O'Meara PA1, White JL3, Chan JN3, Hooper RL3, Baynton EJ2, 1Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA, 3Ipsos Healthcare, London, UK

**PMD118** D19 COMPARISON OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TESTED AND NOT-TESTED METASTATIC NON-SMALL CELL LUNG CANCER (MNSCL) PATIENT COHORTS IN EUROPE

Narayanan S1, Gallo F1, Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA, 3Ipsos Healthcare, New York, NY, USA

**PMD119** D20 COMPARISON OF KRAS TESTED AND NOT-TESTED METASTATIC COLORECTAL CANCER (MCRC) PATIENT COHORTS IN EUROPE

Narayanan S1, Gallo F1, Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA, 3Ipsos Healthcare, New York, NY, USA

**PMD120** D21 KNOWLEDGE ON THE APPROPRIATE TECHNIQUE OF BLOOD PRESSURE MONITORING AND LIMITS OF THE OSCILLOMETRIC BLOOD PRESSURE MEASUREMENT

Oláh A1, Horváth A1, Pakai A2, Boncz I1, Fullér N1, Knisz J1, Müller A1, Szébeni-Kovács G1, 1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary

**PMD121** D22 VIRTUAL CONSULTATION SYSTEM TO ENABLE RARE DISEASES DIAGNOSIS

De Rosa M1, Rinaldi E, Ortall M, Cooezzoli A, CINECA Interuniversity Consortium, Casalecchio di Reno, Italy

**PMD122** D23 MODELING OF CLINICAL PATHWAYS IN THE IMPLANTATION OF CARDIOVERTER DEFIbrILLATORS FROM 2006 TO 2013 USING THE FRENCH HOSPITAL P.M.S.I. DATABASE

Prodel M1, Augusto V2, Jouaneton B1, Lamarsalle L1, Xie X2, HEVA, LYON, France, 2Ecole des Mines Saint-Etienne, Saint-Etienne, France

**PMD123** D24 HOW TO CAPTURE AND REWARD THE BENEFITS ASSOCIATED WITH COMPANION DIAGNOSTICS?

Doutriaux A1, Cognet M1, Paubel P2, Levy P3, Amaris, London, UK, 2Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France; Health Law Institute, Inserm, UMR S 1145, Paris Descartes Université, Sorbonne Paris Cité, Paris, France, 3University Paris-Dauphine, Paris, France

**PMD125** D25 NEW NHI REIMBURSEMENT COVERAGE PARADIGM CALLED ‘SELECTIVE REIMBURSEMENT SCHEME’ ON THE FOUR MAJOR DISEASES IN KOREA
THE IMPACT OF NEW ENDOVASCULAR THERAPIES FOR FEMOROPOPITEAL ARTERIAL DISEASE ON THERAPY UTILIZATION AND CASE VOLUMES IN GERMANY, 2009-2013

PMD126 D26


MEDICAL DEVICES: INNOVATIVE MODELS TO ACCESS THE MARKET LEVERAGING ON SHARED INFRASTRUCTURE AMONG PAYERS AND PHARMACEUTICAL COMPANIES

PMD127 D27

M. Ortali, A. Roncadori, A. Covezzoli, A. De Rosa, M. CINECA Interuniversity Consortium, Casalecchio di Reno, Italy

WHAT IS CE Marking? How Technologies are Classified, and How to Navigate the System

PMD128 D28


WHEN IS A BONE FRACTURE NO LONGER “FRESH”?

PMD129 D29

R. Scott, J. Jones, R. G. Bioventus LLC, Durham, NC, USA

THE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME (MTEP): AN ANALYSIS OF NOTIFICATIONS, DECISION-MAKING AND THE INTERPRETATION OF CLAIMED HEALTHCARE SYSTEM BENEFITS

PMD130 D30

G. Murray, L. Crowe, R. Howells, 1Abacus International, Manchester, UK, 2Abacus International, Bicester, UK

THE IMPACT OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) ON PRESCRIPTION COSTS IN NEWLY TREATED TYPE 2 DIABETES MELITUS (T2DM): A RETROSPECTIVE COHORT ANALYSIS

PMD131 D31

G. Grimes, B. Bennett, H. Henman, M. Trinity College Dublin, Dublin, Ireland

ACCESSING THE MEDICAL DEVICES MARKET IN EGYPT AND SAUDI ARABIA: A SYSTEMATIC REVIEW OF POLICIES AND REGULATIONS

PMD132 D32

M. Gad, C. Kriza, P. Kolominsky-Rabas, Centre for Health Technology Assessment (HTA) and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg; National Leading-Edge Cluster Medical Technologies ‘Medical Valley EMM’, Erlangen, Germany

IDENTIFYING OPPORTUNITIES FOR VALUE-BASED CONTRACTING FOR MOLECULAR DIAGNOSTICS AS A MEANS TO IMPROVE OUTCOMES OF HOSPITAL ACQUIRED INFECTIONS

PMD133 D33

A. DiPaolo, A. Marcarelli, M. Girardi, G. GfK, WAYLAND, MA, USA

BUDGET IMPACT ANALYSIS OF BIOABSORBABLE DRUG-ELUTING SINUS IMPLANTS FOR ENDOSCOPIC SINUS SURGERY

PMD134 E1

N. Rudimk, J. Mallow, J. Pali, J. Rizzo, 1University of Calgary, Calgary, AB, Canada, 2CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, 3Stony Brook University, Stony Brook, NY, USA

RE-USE OF INSULIN SYRINGE NEEDLES AND ITS EXTRA DISEASE BURDEN FOR DIABETIC PATIENTS IN BEIJING

PMD135 E2

B. Cui, Z. Zhao, J. Zhong, T. Liu, L. Tao, 1Peking University, Beijing, China, 2Beijing TianTian Hospital, Beijing, China, 3Beijing Medical Economics Research Association, Beijing, China

COST-EFFECTIVENESS OF LOCAL INSUFFLATION OF WARM HUMIDIFIED CO2 DURING OPEN AND LAPAROSCOPIC COLORECTAL SURGERY

PMD136 E3


ECONOMIC ANALYSIS OF EVARREST® SEALANT MATRIX COMPARED WITH STANDARD OF CARE IN SEVERE SOFT TISSUE SURGICAL BLEEDING: A UNITED KINGDOM HOSPITAL PERSPECTIVE

PMD137 E4

N. Jamous, S. Carter, N. Ferko, A. Hogan, M. Corrail, J. Batiller, J. Ethicon Biosurgery, Berkshire, UK, 2Johnson & Johnson, Wokingham, UK, 3Cornerstone Research Group Inc., Burlington, ON, Canada, 4Ethicon Biosurgery, USA, Somerville, NJ, USA

MEDICAL DEVICES: WHY DO SOME PAY MORE THAN OTHERS DO? ANALYSIS OF PRICE VARIATION IN FRENCH PUBLIC HOSPITAL IN 2013

PMD138 E5

M. Grande, A. Le Louette, M. Henn, L. Bertrand, P. Paubel, 1Assistance Publique-Hôpitaux de Paris (AP-HP), PARIS, France, 2Centre Hospitalier de Saint Denis, SAINT DENIS, France, 3Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France; Health Law Institute, Inserm, UMR S 1145, Paris Descartes Université, Sorbonne Paris Cité, Paris, France

USING REAL-WORLD HOSPITAL PURCHASING AND CONSUMPTION DATA TO IMPROVE HEALTHCARE SYSTEMS EFFICIENCIES

PMD139 E6

D. Carlow, D. Dua, D. Erickson, S. Garfield, G. GfK Custom Research, Wayland, MA, USA

ECONOMIC ANALYSIS OF EVICEL® COMPARED WITH STANDARD OF CARE FOR DURAL CLOSURE IN ELECTRIC CRANIAL SURGERY: A UNITED KINGDOM HOSPITAL PERSPECTIVE

PMD140 E7

S. Lim, N. Ferko, B. Tibensky, W. Danker, M. Jamous, J. Batiller, R. Kocharian, 1Ethicon, Inc., Somerville, NJ, USA, 2Cornerstone Research Group Inc., Burlington, ON, Canada, 3Cornerstone Research Group, Burlington, ON, Canada, 4Ethicon Biosurgery, USA, Somerville, NJ, USA, 5Ethicon Biosurgery, Berkshire, UK, 6Ethicon Inc., Somerville, NJ, USA

EVALUATION OF THE HEALTH ECONOMIC IMPACT OF ADOPTING SHERLOCK 3CG® TIP CONFIRMATION SYSTEM FOR PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT: U.S. AND U.K. HEALTHCARE
IMPLICATIONS FOR THE GERMAN SETTING
THE USE OF REAL WORLD EVIDENCE TO SUPPORT MARKET ACCESS OF MEDICAL DEVICES – IMPLICATIONS FOR THE GERMAN SETTING
PCV 1  F16  THE LINK BETWEEN PROTON PUMP INHIBITORS AND ISCHEMIC HEART DISEASE COULD BE EXPLAINED BY PROTopathic BIAS: A PHARMACOVIGILANCE ANALYSIS
Ali AK, Eli Lilly and Company, Indianapolis, IN, USA

PCV 2  F17  ADVERSE DRUG REACTIONS, MEDICATION ADHERENCE AND PHYSICIANS’ PRESCRIBING BEHAVIOR: WHICH RELATIONSHIP? A DATABASE ANALYSIS ON STATIN USE
Leporini C1, Degli Esposti L2, Sangiorgi D3, Ursini F4, Scicchitano F1, Russo E1, University of Catanzaro, Catanzaro, Italy, 3CilCon S.r.l., Ravenna, Italy

PCV 3  G1  LEAD DAMAGE IN THE FIRST-YEAR FOLLOWING CARDIAC IMPLANTABLE ELECTRONIC DEVICE (CIED) REPLACEMENT: INCIDENTS AND COSTS BASED ON DEVICE TYPE
Nichols CI1, Vose JG1, Mittal S2, Medtronic Advanced Energy, Portsmouth, NH, USA, 2Valley Health System of New York and New Jersey, New York, NY, USA

PCV 4  G2  NETWORK META-ANALYSIS OF ORAL ANTICOAGULANTS FOR PRIMARY PREVENTION, TREATMENT AND SECONDARY PREVENTION OF VENOUS THROMBOEMBOLIC DISEASE, AND FOR PREVENTION OF STROKE IN ATRIAL FIBRILLATION
Lopez-Lopez JA1, Sterne J1, Bodalia PN2, Bryden PA1, Davies P3, Okoli GN3, Thom H3, Caldwell DM3, Dias S1, Eaton D1, Higgins J1, Hollingworth W1, Salisbury C1, Savovic J1, Sofat R3, Stephens-Boal A3, Welton NJ3, Hingorani A3, University of Bristol, Bristol, UK, 2University College London Hospitals, London, UK, 3Anticoagulation Europe, Kent, UK, 4University of Bristol, BRISTOL, UK, 5University College London, London, UK, 6Thrombosis UK, LLANWRDA, UK

PCV 5  G3  ASSESSMENT OF A VENOUS RISK MODEL FOR CLASSIFYING PATIENTS WITH MULTIMORBIDITY IN THE BASQUE COUNTRY
Millán E1, Lopez Arbeloa G1, Samper R2, Carneiro M1, Pocheville E1, Aurrekoetxea J2, de Pablos I2, Oroeta J1, Osakidetza, Basque Health Service, Vitoria-Gasteiz, Spain, 2Basque Health Department, Vitoria-Gasteiz, Spain

PCV 6  G4  CLINICAL AND ECONOMIC IMPACT OF CHRONIC HEART FAILURE IN GENERAL PRACTICE: ANALYSIS OF 13,633 PATIENTS
Lapi F1, Cricelli I1, Simonetti M1, Colombo D2, Nica M2, Health Search, Italian College of General Practitioners and Primary Care., Firenze, Italy, 2Novartis Farma, Origgio, Italy

PCV 7  G5  SYSTEMATIC LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN HYPERTRIGLYCERIDEMIA
Martin AL1, Travers KU1, Burns MD1, Palmer M2, Henriksson KM3, Rikner K3, Evidera, Lexington, MA,
PCV8  G6  PATIENT PROFILE OF NEW USERS OF NOVEL ORAL ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION (NVAF): REAL-WORLD EVIDENCE FROM PRIMARY CARE DATA IN GERMANY
Lefevre C1, Johnson M2, Maguire A2, Collings S2, Kloss S3, Evans D1,1 Bristol-Myers Squibb, Rueil-Malmaison, France, 2 Oxon Epidemiology, London, UK, 3 Pfizer Deutschland GmbH, Berlin, Germany

PCV10  G7  TRENDS AND CORRELATES OF PULMONARY EMBOLISM IN HOSPITALIZED SPANISH PATIENTS
Ayodele OA, Zhang N, Decision Resources Group, Burlington, MA, USA

PCV11  G8  COMPARATIVE EFFECTIVENESS OF TRIPLE ANTIHYPERTENSIVE COMBINATION THERAPY FOR PATIENTS WITH RESISTANT HYPERTENSION IN TAIWAN
Lin C1, Tsai M2, Chen W3, Chuang P4, Tang C5,1 Taipei Medical University, Taipei, Taiwan, 2 National Taiwan University Medical College and Hospital, Taipei, Taiwan

PCV12  G9  NETWORK META-ANALYSIS TO ASSESS COMPARATIVE EFFECTIVENESS OF BETA-BLOCKERS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
Aggarwal S1, Topaloglu H2, Kumar S2,1 NOVEL Health Strategies, Chevy Chase, MD, USA, 2 GLOBAL ACCESS Monitor, Bethesda, MD, USA

PCV13  G10  COST-EFFECTIVENESS OF APIXABAN COMPARED TO LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN FOR TREATMENT AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM
Lanitis T1, Hamilton M2, Quon P3, Brown C1, Masseria C4, Cohen AT5,1 Evidera, London, UK, 2 BMS, Princeton, NJ, USA, 3 Evidera, Bethesda, MD, USA, 4 Pfizer Inc., New York, NY, USA, 5 Guy's and St Thomas' NHS Foundation Trust, London, UK

PCV14  G11  REAL-WORLD EFFECTIVENESS OF AMLODIPINE/VALSARTAN/HYDROCHLOROTHIAZIDE SINGLE-PILL COMBINATION IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION
Viriato O1, Antunes M2, Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo, Portugal, 2 Faculdade de Ciências da Universidade de Lisboa, Lisboa, Portugal

PCV15  G12  A MIXED TREATMENT COMPARISON (MTC) TO COMPARE THE EFFICACY OF ANTI-THROMBOTIC AGENTS IN TREATMENT AND SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH DEEP VEIN THROMBOSIS (DVT)

PCV16  G13  COMPARATIVE EFFECTIVENESS OF TICAGRELOR VS. PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME
Kim K1, Lee TA, Arditi AK, Didomenico RJ, Touchette D, Walton SM, University of Illinois at Chicago, Chicago, IL, USA

PCV17  G14  CAN DATA SIMULATION HELP EVALUATE HTA OUTCOMES OVER TIME AND FACILITATE EARLY DECISION-MAKING? A CASE STUDY OF TICAGRELOR IN ACUTE CORONARY SYNDROME IN THE UK
Dequen P1, Cooper NJ, Abrams K, University of Leicester, Leicester, UK

PCV18  G15  ASPIRIN VERSUS CLOPIDOGREL IN PATIENTS WITH ISCHEMIC STROKE: A COST AND EFFECTIVENESS COMPARISON FROM BEIJING MEDICAL INSURANCE DATABASE
Wen L1, Wu J1, Yang L1,1 Peking University, Beijing, China, 2 Bayer, Beijing, China

PCV19  G16  A MIXED TREATMENT COMPARISON (MTC) TO COMPARE THE EFFICACY OF ANTI-THROMBOTIC AGENTS IN THE ACUTE TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH ACTIVE CANCER

PCV20  G17  ASSOCIATION BETWEEN ADHERENCE TO EVIDENCE-BASED HEART FAILURE DRUG TREATMENT AND ONE-YEAR ALL-CAUSE HOSPITALIZATION AND ALL-CAUSE MORTALITY
Moisan J1, Girouard C2, Demers E2, Perez-Herrera N2, Zaour N3, Grégoire J4,1 Laval University, Quebec, QC, Canada, 2 Centre de recherche du CHU de Québec, Quebec, QC, Canada, 3 Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PCV21  G18  SYSTEMATIC REVIEW AND META-ANALYSIS OF SELF-MONITORING AND SELF-MANAGEMENT OF ANTICOAGULATION THERAPY WITH VITAMIN K ANTAGONISTS
Locatelli I1, Marjanovic I1, Janzic A1, University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia

PCV22  G19  NETWORK META-ANALYSIS OF VARIOUS TREATMENT STRATEGIES IN RESISTANT HYPERTENSION

PCV23  G20  ASPIRIN VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: A COST AND EFFECTIVENESS COMPARISON FROM BEIJING MEDICAL INSURANCE DATABASE
Wen L1, Wu J1, Yang L1,1 Peking University, Beijing, China, 2 Bayer, Beijing, China

PCV24  G21  LONG-TERM INCREASED INPATIENT AND OUTPATIENT VISITS ASSOCIATED WITH CARDIOVASCULAR EVENTS: A LARGE UNITED STATES REAL WORLD STUDY
Fox KM1, Wang L2, Quek RG3, Gandra SR1, Li L2, Baser O1, Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 2 STATinMED Research, Plano, TX, USA, 3 Amgen, Inc., Thousand Oaks, CA, USA, 4 STATinMED Research, Columbia University, New York, NY, USA

PCV25  G22  EFFECTIVENESS AND SAFETY OF NEW AND TRADITIONAL ORAL ANTICOAGULANTS IN A POPULATION-BASED COHORT OF NEW USERS WITH ATRIAL FIBRILLATION
PCV40 H4 A RETROSPECTIVE, CROSS SECTIONAL STUDY ON THE PREVALENCE OF HYPERTENSION AND TREATMENT STATUS IN OBESE PATIENTS USING A HEALTHCARE DATABASE IN JAPAN
Tanabe K1, Takahashi S1, Iy I2, Kitazaki S2, Yamamoto Y3, Fujimoto Y1, Pfizer Japan Inc, Tokyo, Japan, 2MinaCare co.ltd, Tokyo, Japan

PCV41 H5 EPIDEMIOLOGY OF STATIN-TREATED PATIENTS WITH UNCONTROLLED LDL LEVELS FROM ITALIAN ADMINISTRATIVE OFFICIAL DATABASES
Degli Esposti L1, Sangiorgi D1, Crovato E2, Buda S3, CliCon S.r.l., Ravenna, Italy

PCV42 H6 ASSESSING RETROSPECTIVE DATA ON THE MANAGEMENT OF ISCHEMIC STROKE
Zulkifly PA1, Othman PN2, Shaharuddin S2, Long CM3, Universiti Teknologi MARA, Bandar Puncak Alam, Malaysia, 2Universiti Teknologi MARA, Selangor, Malaysia

PCV43 H7 EPIDEMIOLOGICAL BURDEN AND MANAGEMENT OF HYPERCHOLESTEROLEMIA IN HIGH CARDIOVASCULAR RISK PATIENTS IN SPAIN: A COMPREHENSIVE PICTURE FROM A SYSTEMATIC REVIEW OF THE LITERATURE
Callejo D1, Cuervo J2, Rubio M3, Subirá R4, de la Sierra A5, Pintó X6, Guijarro C6, López Miranda J1, BAP Health Outcomes Research SL, Oviedo, Spain, 2LASER ANALYTICA, Oviedo, Spain, 3Sanofi, Barcelona, Spain, 4University Hospital Mutua Terrassa, Terrassa, Spain, 5University Hospital Mutua Bellvitge, L'Hospitalet de Llobregat, Spain, 6University Hospital Alcorcón Foundation, Alcorcón, Spain, 7Reina Sofia Hospital, Córdoba, Spain

PCV44 H8 BENEFIT-RISK OF VKA FOR ATRIAL FIBRILLATION BEFORE DOAC: A COHORT STUDY IN A CLAIMS AND HOSPITALIZATION DATABASE
Blin P1, Dureau-Pourmin C1, Lassalle R1, Abouelfath A1, Droz-Perreuteau C1, Moore N2, INSERM CIC1401, ADERA, Bordeaux University, Bordeaux, France, 2INSERM CIC1401, Bordeaux University, Bordeaux, France

PCV45 H9 IMPACT OF GENETIC FACTORS ON GASTROINTESTINAL BLEEDING IN A PROSPECTIVE COHORT OF NEW WARFARIN USERS
Dumas S1, Perreault S2, Côté R3, Shahabi P4, Mongrain I5, Gaulin M5, Provost S6, Tardif J7, Dubé M8, Université de Montréal, Montréal, QC, Canada, 2Montreal General Hospital, Montreal, QC, Canada, 3Montreal Heart Institute, Montréal, Montreal, QC, Canada

PCV47 H10 HOSPITAL READMISSIONS AND MORTALITY PATTERNS IN A COHORT WITH HEART FAILURE: 1 YEAR FOLLOW-UP FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM DATABASE
Asano EW1, Teich V1, Amaral LM2, Fernandes RA2, Fahham L3, Sense Company, São Paulo, Brazil, 2Sense Company, Rio de Janeiro, Brazil

PCV48 H11 HEART FAILURE IN A HEALTH AREA OF MADRID, SPAIN. DESCRIPTION AND MANAGEMENT FROM ELECTRONIC MEDICAL RECORDS
Parrondo J1, Sarria A2, University of Alcalá, Coslada - Madrid, Spain, 2Agencia de Evaluación de Tecnologías Sanitarias - Instituto Carlos III, Madrid, Spain

PCV49 H12 INCIDENCE OF CARDIOVASCULAR EVENTS FOLLOWING MYOCARDIAL INFARCTION IN FRANCE: AN OBSERVATIONAL ANALYSIS USING A CLAIMS DATABASE
Philippe F1, Blin P2, Laurendeau C3, Bouée S4, Gourmelen J5, Levy Bachelot L6, Leproust S7, Steg PG8, Département de Pathologie Cardiaque, Paris, France, 2INSERM CIC1401, ADERA, Bordeaux University, Bordeaux, France, 3Cemka-Eval, Bourg La Reine, France, 4CEMKA, Bourg La Reine, France, 5INSERM UMS 011, Villejuif, France, 6MSD France, COURBEVOIE, France, 7Département de Cardiologie, Paris, France

PCV50 H13 COMPARATIVE EFFECTIVENESS ON CARDIOVASCULAR OUTCOMES OF METFORMIN INITIAL THERAPY AND ADD-ON SECOND-LINE DRUGS AMONG PATIENTS WITH TYPE 2 DIABETES
Kim Y1, Ko M1, Jo A1, Kang S1, Tchoe H2, Park C2, Kim H1, Choi J1, Park D1, Lee W1, National Evidence based Health-care Collaborating Agency, Seoul, South Korea, 2National Evidence-based Health-care Collaborating Agency, Seoul, South Korea, 3Asan Medical Center, Seoul, South Korea

PCV51 H14 STATIN USE AND RISK OF NEW-ONSET TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE: A NATIONWIDE POPULATION-BASED OBSERVATIONAL STUDY USING NATIONAL CLAIM DATA
Jo A1, Ko M1, Kim Y1, Kang S1, Cho S1, Park D2, National Evidence based Health-care Collaborating Agency, Seoul, South Korea, 2Asan Medical Center, Seoul, South Korea

PCV52 H15 CORRELATION OF TRIGLYCERIDES AND ACUTE PANCREATITIS: A SYSTEMATIC EVIDENCE REVIEW
Bardia A1, Garg G1, Invaluesys Research, Hyderabad, India, 2Invaluesys Research, Burgdorf, Germany

PCV53 H16 CARDIOVASCULAR EVENT RATES IN A HIGH-RISK GENERAL POPULATION COHORT OF 340,000 INDIVIDUALS IN THE UNITED KINGDOM
Ansell D1, Khan I1, Proudfoot C2, Gbenedio T2, Joulain F3, Pockett RD4, Catterick D5, Gooch K6, IMS Health, London, UK, 2Sanofi, Bridgewater, NJ, USA, 3Sanofi, Guildford, UK, 4Sanofi, Chilly-Mazarin, France, 5Swansea Centre for Health Economics, Swansea, UK

PCV55 H18 PREDICTION MODEL FOR FUNCTIONAL STATUS AT DISCHARGE FOLLOWING RHABILITATION AFTER INTRACREREBRAL HEMORRHAGE
Kim S1, Shin J2, Kim S3, Hahn S1, Seoul National University College of Medicine, Seoul, South Korea, 2National Rehabilitation Center, Ministry of Health and Welfare, Seoul, South Korea, 3Systems Biomedical Informatics National
Core Research Center, Seoul, South Korea

PCV56  H19  PCV72
Bezard F, Iudem, Montreal, QC, Canada

PCV57  H20  MORTALITY TRENDS IN CARDIOVASCULAR DISEASE: A NEW MODEL TO VISUALISE THE CONTRIBUTION OF SPECIFIC DISEASES, COHORT EFFECTS AND CODING CHANGES TO OVERALL MORTALITY IMPROVEMENT
Martin C, Martin A, Crystallise Ltd., London, UK

PCV58  H21  SIMPSON'S PARADOX: WHY SMOKING REDUCES THE RISK OF DYING OF CARDIOVASCULAR DISEASE
Martin A, Martin C, Crystallise Ltd., London, UK

CARDIOVASCULAR DISORDERS - Cost Studies

PCV59  H22  BUDGET IMPACT MODEL (BIM) OF RIVAROXABAN IN COMPARISON WITH ENOXAPARIN PLUS WARFARIN IN THE TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) UNDER THE PERSPECTIVE OF THE PRIVATE HEALTH SYSTEM
Piedade A, 1 Paladini L, 2 Tobaruela F, 2 Nakada C, 2 Evidências - Kantar Health, Campinas, Brazil, 2Bayer Healthcare, São Paulo, Brazil

PCV60  H23  IMPACT ON ITALIAN NATIONAL HEALTH SERVICE EXPENDITURE FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM WITH RIVAROXABAN
Roggeri A, 1 Roggeri DP, 1 Pengo V, 1ProCure Solutions, Nembro (BG), Italy, 1University Hospital Padova, Padova, Italy

PCV61  H24  BUDGET IMPACT ANALYSIS OF TRIPLIAM FOR THE TREATMENT OF HYPERTENSION IN ITALY
Lanati EP, 1 Orlando VL, MA Provider Srl, Milano, Italy

PCV62  H25  BUDGET-Impact-Analysis of Iron Treatment Using Intravenous Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Austria
Ressl S, Walter E, Bauer M, Institute for Pharmacoeconomic Research, Vienna, Austria

PCV63  H26  AN ASSESSMENT OF ENOXAPARINE BENEFIT ON HEALTHCARE BUDGET IN SPAIN
Delgado M, 1 Restovic G, 1 Planellas L, 2 Rubio M, 1 Miñarro C, 1 Sanofi, Barcelona, Spain, 1IMS Health, Barcelona, Spain, 1IMS Health, Madrid, Spain

PCV64  H27  COST SAVINGS BY THE USE OF BEMIPARIN IN THE TREATMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM IN SPAIN
Pinyol C, 1 Navarro B, 2 Fernández-Lomana JM, 2 Gutiérrez C, 1 INNOVA Strategic Consulting, Terrassa (Barcelona), Spain, 1Laboratorios Farmacéuticos Rovi S.A., Madrid, Spain

PCV65  H28  PRESCRIPTION ALGORITHMS: IMPACT ON STATINS
Buigues-Pastor L, 1 Sánchez-Chorro JL, 2 Méndez-Valera P, 3 Muñoz-Fernández JI, 1 Valencia Regional Government - Spain, Valencia, Spain, 2Extremadura's Regional Government - Spain, Mérida, Spain

PCV66  H29  DEVELOPMENT OF PRESCRIPTION E-PROTOCOLS FOR MEDICINES AND INTEGRATION ON THE GREEK NATIONAL E-PRESCRIPTION SYSTEM
Karanikas H, Papadakis M, Thireos E, Athens Medical Society, Athens, Greece

PCV67  H30  MEDICAL COST OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF) AND TREATED WITH VITAMIN K ANTAGONISTS (VKAS) ACCORDING TO INR CONTROL STATUS IN SPAIN
Postema R, 1 Bardoulat I, 2 Roset M, 3 Maurel F, 2 Lefevre C, 2 Evans D, 2 Bristol-Myers Squibb, Braine-l'Alleud, Belgium, 2IMS Health, Paris, France, 3IMS Health, Barcelona, Spain, 4IMS Health, La Défense, France, 5Bristol-Myers Squibb, Rueil-Malmaison, France

PCV68  H31  HOSPITAL COST ANALYSIS OF PATIENTS WITH CARDIOVASCULAR EVENTS AND REVASCULARISATION PROCEDURES IN SPAIN
Cots F, 1 Chiarello P, 1 Kaskens L, 2 Arrabal N, 1 Instituto Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain, 2Ferreras internacional, Barcelona, Spain

PCV69  H32  HOSPITALIZATION EXPENSES ANALYSIS OF CHINESE STROKE PATIENTS WITH URBAN EMPLOYEE BASIC MEDICAL INSURANCE
Xie X, Pfizer China, Beijing, China

PCV70  H33  PHARMACOECONOMIC ANALYSIS OF TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION IN UKRAINE
Makarov O, 1 Sur S, Solobiukova N, Arterium Corporation, Kyiv, Ukraine

PCV71  H3  RESOURCE UTILISATION AND COSTS IN PATIENTS WITH POST-STROKE SPASTICITY IN THE UNITED KINGDOM
Raluy-Callado M, 1 Cox A, 1 MacLachlan S, 2 Gabriel S, 2 Dinet J, 1 Evidera, London, UK, 2IPSEN Pharma, Boulogne-Billancourt, France

PCV72  H2  INCREASED COSTS DUE TO MYOCARDIAL INFARCTION (MI) IN FRANCE: AN OBSERVATIONAL ANALYSIS USING A CLAIMS DATABASE
Blin P, 1 Philippe F, 1 Laurendeau C, 2 Bouee S, 1 Gourmelen J, 6 Levy Bachelot L, 6 Leproust S, 6 Steg PG, 1INSERM CIC1401, ADERA, Bordeaux University, Bordeaux, France, 2Département de Pathologie Cardiaque, Paris, France, 6CEMKa, Bourg La Reine, France, 6CEMKa, Bourg La Reine, France, 5INSERM UMS 011, Villejuif,
PCV73 13 HEALTHCARE COSTS ASSOCIATED WITH NON-VALVULAR ATRIAL FIBRILLATION IN ITALY
Cammarota S1, Citarella A1, Creazzola S1, De Marino C1, Izzo P2, La Bella G2, Piscitelli R1, Romagnuolo F2, Esposito E2, Guida A1, LinkHealth s.r.l., Naples, Italy, 1Local Health Authority, Naples, Italy

PCV74 14 COST OF ILLNESS IN AORTIC STENOSIS PATIENTS
Veronesi C1, Beccaguti G2, Corbo M1, Blini V1, Degli Esposti L3, CitiCon S.r.l., RAVENNA, Italy, 1Medtronic Italia Spa, Milano, Italy, 2CitiCon S.r.l., Ravenna, Italy

PCV75 15 TRENDS IN EMERGENCY ROOM VISITS DUE TO HYPERKALEMIA IN THE UNITED STATES
Aggarwal S1, Topaloglu H1, Kumar S2, NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PCV76 16 ECONOMIC BURDEN IN DIRECT COSTS OF OBESITY AND OVERWEIGHT IN RUSSIA
Krysanova V1, Zhiruleva M.I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCV77 17 MEDICAL COSTS AND RESOURCES CONSUMPTION IN PATIENTS WITH ATRIAL FIBRILLATION: AN ITALIAN OBSERVATIONAL STUDY
Conti S1, Fornari C1, Botto G1, Inama G1, Tondo C1, Ciampichini R1, Chiodini V1, Mantovani LG1, Madotto F1, Cesana G1, University of Milano - Bicocca, Monza, Italy, 1Ospedale S.Anna, Como, Italy, 2Istituto Clinico F. S. Camillo, Cremona, Italy, 3Centro Cardiologico Monzino, Milano, Italy

PCV78 18 COSTS OF CARDIOVASCULAR (CV) EVENTS IN THE UNITED KINGDOM (UK) USING REAL-WORLD DATA
Danese M1, Gleeson M1, Kutikova L1, Griffiths R1, Azough A2, Khunti K2, Konpapally Seshasai SR2, Ray KK1,1Outcomes Insights Inc., Westlake Village, CA, USA, 1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen Ltd., Uxbridge, UK, 3University of Leicester, Leicester, UK, 4St George’s, University of London, London, UK, 5School of Public Health, Imperial College London, London, UK

PCV79 19 ESTIMATING THE ECONOMIC BURDEN OF STROKE IN SOUTH INDIA: A COST-OF-ILLNESS STUDY
Mounica B1, Chalapathi, Guntur, India

PCV80 10 SYSTEMATIC LITERATURA REVIEW OF DIRECT HEALTH CARE COSTS FOR CARDIOVASCULAR EVENTS AMONG EUROPEAN PATIENTS WITH DYSLIPIDEMIA OR HIGH CARDIOVASCULAR RISK
Nicholson G1, Paoli C2, Gandra SR2,1ICON, plc., El Segundo, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA

PCV81 11 ESTIMATING THE BURDEN OF DIABETES TO THE FRENCH NATIONAL HEALTH INSURANCE
Aguade A1, De Lagasnerie G1, Denis P1, Gastaldi-Menager C1, Fagot-Campagna A1, Gissot C2, Polton D3,1CNAMTS (National Health Insurance), Paris Cedex 20, France, 2CNAMTS (National Health Insurance), Paris, France

PCV82 12 REAL WORLD EVIDENCE AND COSTS OF CHRONIC HEART FAILURE: FINDINGS FROM 41,413 PATIENTS OF THE ARNO DATABASE
Rossi E1, Ciconzio E1, Nica M1, Colombo D2, Maggioni AP3,1CINEA Interuniversity Consortium, Casalecchio di Reno, Italy, 2Novartis Farma, Origgio, Italy, 3ANIICO Research Center, Florence, Italy

PCV83 13 RESOURCE UTILIZATION AND TREATMENT COSTS OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
Lefevere C1, Benhaddi H1, Lacoin L1, Diaz Cuervo H1, Lee Y1, Evans D1, Budd D1, Bristol-Myers Squibb, Rueil-Malmaison, France, 2Bristol-Myers Squibb, Braine-l’Alleud, Belgium, 3Bristol-Myers Squibb, Uxbridge, UK, 4Laser Outcomes, Oviedo, Spain, 5Laser Outcomes, New York, NY, USA

PCV84 14 ANALYSIS OF IN-HOSPITAL RESOURCE USE AFTER AN ISCHEMIC STROKE
Dewilde S1, Annemans L2, Thijs V2,15HE & UGent, Brussel, Belgium, 2University of Ghent, Ghent, Belgium, 3KULeuven, Leuven, Belgium

PCV85 15 AN EPIDEMIOLOGICAL EVALUATION OF THE INCIDENCE OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN PATIENTS WITH HIP OR KNEE REPLACEMENT SURGERY AND OF ITS IMPACT ON THE AVERAGE LENGTH OF STAY AND HOSPITALIZATION COST
Chevalier P1, Lamotte MJ, IMS Health, Vilvoorde, Belgium

PCV86 16 DIRECT TREATMENT COSTS OF STROKE IN TURKEY
Tatar M1, Senturk A2, Tuna E1, Karabulut E1, Caliskan Z1, Arsava EM1, Topcuoglu MA1, Hacettepe University, Ankara, Turkey, 1Polar Health Economics and Policy Consultancy, Ankara, Turkey

PCV87 17 LOCAL COST STUDY OF TREATMENT OF VENOUS THROMBOEMBOLISM IN TURKEY
Tatar M1, Senturk A2, Tuna E1, Bilginer B1, Ulus AT1, Buyuktuna N2, Hacibedel B3, Saritas G3, Poyraz MB2, Hacettepe University, Ankara, Turkey, 1Polar Health Economics and Policy Consultancy, Ankara, Turkey, 2Bristol Myers Squibb, Istanbul, Turkey, 3Pfizer Pharmaceuticals, Department of Health Economics and Outcomes Research, Istanbul, Turkey, 4TOBB ETU University, Ankara, Turkey

PCV88 18 ECONOMIC BURDEN OF ACUTE MYOCARDIAL INFARCTION IN VIETNAM
Nguyen TD1, Nguyen T2, Postma M3,1Groningen University, Groningen, The Netherlands, 2Thai Nguyen General Hospital, Thai Nguyen, The Netherlands, 3University of Groningen, Groningen, The Netherlands

PCV89 19 A COMPARISON OF TWO LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS) IN TERMS OF COST PER PATIENT Planellas L1, Mifjarro C2, Restovic G1, Delgado M3, Rubio M1,1IMS Health, Barcelona, Spain, 2IMS Health, Madrid,
PCV90  I20 THE COST OF ACUTE CARE HOSPITALIZATIONS ASSOCIATED WITH CHRONIC HEART FAILURE IN CANADA
Fischer AA1, Liu N1, Borelli R1, Barbeau M1, Zaurer N1, IMS Brogan, Mississauga, ON, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PCV91  I21 AN EPIDEMIOLOGICAL EVALUATION OF THE IMPACT OF PERCUTANEOUS CORONARY INTERVENTIONS ON THE HOSPITALIZATION COST, LENGTH OF STAY AND MORTALITY OF PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROMES
Chevalier P, Lamotte M, IMS Health, Vilvoorde, Belgium

PCV92  I22 COST-BENEFIT ANALYSIS OF YINDANXINTAI DROPPING PILLS IN THE TREATMENT OF ANGINA PECTORIS CAUSED BY CORONARY HEART DISEASE
Wu H, Shi Q, Guizhou Medical University, Guiyang, China

PCV93  I23 COST BENEFITS OF INCORPORATING LEVOSIMENDAN INTO CARDIAC SURGERY PRACTICE: GERMAN BASE CASE
Hendrich J1, Mardiguian S1, Smare C1, Bertranou E1, Kivivko M2, Lättiä T2, HERON Commercialization, LONDON, UK, 3Orion Pharma, ESPOO, Finland

PCV94  I24 COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE STRATEGIES OF MONITORING FOR AMIODARONE-RELATED THYROID TOXICITY IN UK PRIMARY CARE
Berdunov V, Avery AJ, Elliott RA, University of Nottingham, Nottingham, UK

PCV95  I25 A COST-EFFECTIVENESS ANALYSIS OF NOVEL ORAL ANTICOAGULANTS FOR ACUTE TREATMENT AND SECONDARY PREVENTION OF VENOUS THROMBOEMBOLIC DISEASE
Bryden P1, Welton NJ1, Thom H1, Sterne J1, Bodalia P1, Davies P1, López-López J1, Okoli GN1, Caldwell DM1, Dias S1, Eaton D1, Higgins J1, Salisbury C1, Savovic J1, Sofat R2, Stephens-Boal A3, Hingorani A4, Hollingworth W1, 1University of Bristol, BRISTOL, UK, 2University College London, London, UK, 3Anticoagulation Europe, Kent, UK, 4Thrombosis UK, Llanwrda, UK

PCV96  I26 COST-EFFECTIVENESS OF COMBINED TREATMENT WITH ALTEPLASE (RT-PA) AND CEREBROLYSIN IN ACUTE ISCHEMIC HEMISPHERIC STROKE IN AUSTRIA
Walter E, Bauer M, Ressl S, Institute for Pharmacoconomic Research, Vienna, Austria

PCV97  I27 COST-EFFECTIVENESS OF A NOVEL PHARMACIST GUIDED WARFARIN PHARMACOGENETIC SERVICE
Gor D1, Kim K1, Chumnumwat S1, Galanter WL1, You J1, Walton SM1, Garofalo J1, Duarte J1, Krishnan JA1, Bauman JL1, Nutescu EA1, 1University of Illinois at Chicago, Chicago, IL, USA, 2The Chinese University of Hong Kong, Shatin, Hong Kong

PCV98  I28 IS EDOXABAN A COST-EFFECTIVE ALTERNATIVE TO VENOUS THROMBOEMBOLIC PATIENTS TREATED WITH VITAMIN K ANTAGONISTS IN SPAIN?
Jiménez D1, Suárez C2, Barja P3, Rodríguez JM4, Pérez-Alcántara F4, 1Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Hospital Universitario de La Princesa, Madrid, Spain, 3Daichi Sankyo España, S.A., Madrid, Spain, 4Obiluke Consulting, S.L., Barcelona, Spain

PCV99  I29 OPPORTUNISTIC SCREENING FOR ATRIAL FIBRILLATION IN PRIMARY CARE – A CLINICAL AND COST-EFFECTIVENESS ANALYSIS
Moran P1, Teljeur C1, Harrington P1, Smith S2, Normand C2, Ryan M1, 1Health Information and Quality Authority (HIQA), Dublin, Ireland, 2Royal College of Surgeons in Ireland, Dublin, Ireland, 3Trinity College Dublin, Dublin, Ireland

PCV100 I30 ECONOMIC EVALUATION OF TRIMETAZIDINE IN THE MANAGEMENT OF CHRONIC STABLE ANGINA IN GREECE
Kourlaba G1, Gourzoulidis G2, Tsiefis K2, Andrikopoulos G2, Beletsi A3, Maniakas N1, 1Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, 2National School Of Public Health, Athens, Greece, 3University Hospital “Hippokration”, Athens, Greece, 4Henry Dunant Hospital Center, Athens, Greece, 5Servier Hellas, Athens, Greece

PCV101 I31 THE COST-EFFECTIVENESS OF TREATMENT FOR CHRONIC HEART FAILURE: A SYSTEMATIC REVIEW

PCV102 I32 DEVELOPMENT OF A MODEL TO PROVIDE INSIGHT IN THE VALUE OF FIBRINOGEN CONCENTRATE FOR TREATING EXCESSIVE BLEEDINGS DURING COMPLEX CARDIOVASCULAR SURGERY
Van der Maas M1, Lepage-Nefkens I2, de Graaf G3, Panaxea B.V., Enschede, The Netherlands, 2Panaxea BV, Enschede, The Netherlands

PCV103 I33 THE COST-EFFECTIVENESS OF NOVEL ORAL ANTICOAGULANTS FOR THE PREVENTION OF STROKE IN ATRIAL FIBRILLATION IN ENGLAND AND WALES
Thom H1, Hollingworth W1, Bryden PA1, Sterne J1, Bodalia PN1, Davies P1, Lopez-Lopez JA1, Okoli GN1, Caldwell DM1, Dias S1, Eaton D1, Higgins J1, Salisbury C1, Savovic J1, Sofat R2, Stephens-Boal A3, Hingorani A4, Welton NJ1, 1University of Bristol, Bristol, UK, 2University College London Hospitals, London, UK, 3Anticoagulation Europe, Kent, UK, 4University College London, London, UK, 5Thrombosis UK, Llanwrda, UK
PCV104 J1 IS EDOXABAN COST-EFFECTIVE FOR NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH VITAMIN K ANTAGONISTS IN SPAIN?  
Lekuona I1, Anguita M2, Zamorano JL3, Barja P4, Rodriguez JM5, Pérez-Alcántara F2, Hospital de Galdakao, Usansolo, Bizkaia, Spain, 1Sociedad Española de Cardiología, Madrid, Spain, 3University Hospital Ramón y Cajal, Madrid, Spain, 2Daichi Sankyo España, S.A., Madrid, Spain, 5Oblikue Consulting, S.L., Barcelona, Spain

PCV105 J2 COST-EFFECTIVENESS ANALYSIS OF BEMIPARIN USED AS ACUTE TREATMENT FOR DEEP VENOUS THROMBOSIS WITHOUT PULMONARY EMBOLISM  
Aguirre A1, Carlos F2, Naranjo M1, Fernandez C1, UCB, Mexico, Mexico, 2R A C Salud Consultores S.A. de C.V, Mexico City, Mexico

PCV106 J3 ECONOMIC EVALUATIONS OF NEW ORAL ANTICOAGULANTS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP OR TOTAL KNEE REPLACEMENT  
Brockbank J, Wolowacz S, RTI Health Solutions, Manchester, UK

PCV107 J4 COST-EFFECTIVENESS OF FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY AND CHRONIC HEART FAILURE IN AUSTRIA  
Walter E, Bauer M, Reissl S, Institute for Pharmacoconomic Research, Vienna, Austria

PCV108 J5 COMPARISON OF OVERALL COSTS BETWEEN ALPROSTADIL AND LIMB AMPUTATION IN PATIENTS AFFECTED BY PERIPHERAL ARTERIAL DISEASE STAGES III AND IV IN MEXICO  
Aguirre A1, Carlos F2, Gasca R3, Naranjo M1, Fernandez C1, UCB, Mexico, Mexico, 2R A C Salud Consultores S.A. de C.V, Mexico City, Mexico

PCV109 J6 PHARMACOECONOMIC ANALYSIS OF VARIOUS TREATMENT STRATEGIES FOR PATIENTS WITH CHRONIC VENOUS INSUFFICIENCY OF THE LOWER LIMITS  
Ryazhnenov VV1, Gorokhova SG2, Gorokhov V2, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Research Clinical Center of JSC Russian Railways, Moscow, Russia

PCV110 J7 CLINICAL AND ECONOMIC ANALYSIS OF EFFECTIVENESS OF FONDAPARINUX SODIUM IN THE TREATMENT OF ACUTE CORONARY SYNDROME  
Krasnova L1, Vorobiev P2, Tyurina I3, Shiganov S1, Russian Society for Pharmacoconomics and Outcomes Research, Moscow, Russia, 2First Sechenov Moscow State Medical University, Moscow, Russia

PCV111 J8 THE COST-EFFECTIVENESS OF BARIATRIC SURGERY IN GERMANY  
Belarbi S1, Kusel J1, Maruszczak M1, Slater D2, Thomas MG2, Martini O2, Ethicon SAS, Issy-Les-Moulineaux, France, 1Costello Medical Consulting Ltd, Cambridge, UK, 2Ethicon, part of Johnson & Johnson Medical GmbH, Norderstedt, Germany

PCV112 J9 COST-EFFECTIVENESS OF THE NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR ATRIAL FIBRILLATION IN PORTUGAL  
Costa J1, Fiorentino F2, Caldeira D3, Inês M4, Pereira C5, Pinheiro L6, Vaz Carneiro A6, Gouveia M7, Borges M2, Institute of Molecular Medicine, Lisbon, Portugal, 2Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 3Laboratórios Pfizer Lda., Lisbon, Portugal, 4Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 5Católica Lisbon School of Business and Economics, Lisbon, Portugal

PCV113 J10 DABIGATRAN FOR THE TREATMENT AND SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM  
Stevanovic J1, Kappelhoff B2, Voorhaar M3, Postma MJ4, University of Groningen, Groningen, The Netherlands, 2Boehringer Ingelheim GmbH, Ingelheim, Germany, 3Boehringer Ingelheim, Alkmaar, The Netherlands

PCV114 J11 A POLYPILL INTERVENTION TO IMPROVE ADHERENCE FOR SECONDARY CARDIOVASCULAR DISEASE PREVENTION IN SPAIN: A COST-EFFECTIVENESS STUDY  
Arrabal N1, Kaskens L, Garcia-Alonso F, Gracia A, Ferrer internacional, Barcelona, Spain

PCV115 J12 DEVELOPMENT OF A CONCEPTUAL MODEL FOR EARLY HEALTH TECHNOLOGY ASSESSMENT OF TISSUE-ENGINEERED HEART VALVES  
Huygens SA1, Rutten-van Mölken MP2, Bekkers JA1, Bogers AJ4, Boutron CV3, Chemuleau SA3, de Jaegere PP3, Kappetein AP1, Kluin J2, van Mieghem NM3, Versteegh MI1, Witsenburg M1, Takkenberg JJ2, Erasmus Medical Centre, Rotterdam, The Netherlands, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3Eindhoven University of Technology, Eindhoven, The Netherlands, 4University Medical Centre Utrecht, Utrecht, The Netherlands, 5Academic Medical Centre Amsterdam, Amsterdam, The Netherlands, 6Leiden University Medical Centre, Leiden, The Netherlands

PCV116 J13 A COST-EFFECTIVENESS STUDY ON THE INCREASED INTAKE OF POTASSIUM AND VITAMIN B2 AMONG ADULTS IN CHINA  
Lara C, Detzel P, Nestlé Research Center, Lausanne, Switzerland

PCV117 J14 CLINICAL AND ECONOMIC IMPACTS OF THE USE OF A PRESCRIPTION ASSISTANCE SOFTWARE FOR VITAMIN K ANTAGONIST TREATMENT IN FRENCH MANAGEMENT OF ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLIC EVENTS  
Sivignon M1, Roze S2, Murphy C3, Tissieu A4, HEVA HEOR Sarl, Lyon, France, 2Merck Serono Sas, Lyon, France

PCV118 J15 A NEW COST-EFFECTIVENESS MODELLING APPROACH IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION  
McMurray JJ1, Cowie MR2, Cohen AA3, Briggs A4, de Pouvourville G5, Taylor M5, Hancock E6, Trueman D7, Mumby-Croft J8, Deschaseaux C9, University of Glasgow, Glasgow, UK, 1Imperial College London, London,
PCV119 J16 COST-MINIMIZATION ANALYSIS OF RIVAROXABAN IN COMPARISON TO ENOXAPARIN PLUS WARFARIN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) UNDER THE PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

Piedade A¹, Paladini L³, Tobaruel F², Nakada C², Evidências - Kantar Health, Campinas, Brazil, ²Bayer Healthcare, São Paulo, Brazil

PCV120 J17 COST-EFFECTIVENESS OF EDOXABAN COMPARED WITH WARFARIN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLIC EVENTS IN THE UK

Taylor M¹, Claxton L², Lewis L¹, Harrington AE³, Alexandre AF², Bakhai A², Brueggenjuergen B³, ¹York Health Economics Consortium, York, UK, ²York Health Economics Consortium, University of York, York, UK, ³Daiichi Sankyo Europe, Munich, Germany, ⁴Royal Free, Barnet and Chase Farm Hospitals, London, UK, ⁵Steinbeis-University-Berlin, Berlin, Germany

PCV121 J18 COST-UTILITY ANALYSIS OF CHOCOLATE CONSUMPTION FOR PREVENTION OF CARDIOMETABOLIC DISEASE

O’Day K, Campbell DJ, Xcenda, Palm Harbor, FL, USA

PCV122 J19 COST-UTILITY ANALYSIS OF RNALONE FOR THE SYMPTOMATIC TREATMENT OF PATIENTS WITH CHRONIC ANGINA PECTORIS IN GREECE

Kourlaba G¹, Vlachopoulos C², Parissis J³, Kanakakis J⁴, Gourzoulidis G⁵, Maniadakis N⁶, ¹Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, ²University Hospital “Ippokrateio”, Athens, Greece, ³University Hospital “Attikon”, Athens, Greece, ⁴Alexandra” Hospital, Athens, Greece, ⁵National School Of Public Health, Athens, Greece

PCV123 J20 COST-UTILITY ANALYSIS OF APIXABAN IN THE ACUTE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM IN FRANCE

Stern S¹, Cotte E², Minacori R³, Gosden T⁴, Hamilton M⁵, Phatak H⁶, Quon P¹, Evidera, Bethesda, MD, USA, ²BMS, Rueil-Malmaison, France, ³Pfizer, Tadworth, Surrey, UK, ⁴BMS, Princeton, NJ, USA, ⁵Bristol-Myers Squibb, Princeton, NJ, USA

PCV124 J21 A LITERATURE REVIEW TO EVALUATE THE PHARMACOECONOMIC VALUE OF RANOLAZINE FOR THE TREATMENT OF SYMPTOMATIC CHRONIC STABLE ANGINA

Vellopoulos K¹, Kourlaba G², Maniadakis N³, Vardas P³, ¹Department of Health Services Organization, National School of Public Health, Athens, Greece, ²Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, ³Department of Cardiology, Heraklion University Hospital, Heraklion, Greece

PCV125 J22 COST-UTILITY OF STATIN IN SECONDARY PREVENTION: A PROPENSITY SCORE METHOD OF ADMINISTRATIVE DATABASE

Luque A, Nobre MR, Abrahão MT, São Paulo University, São Paulo, Brazil

PCV126 J23 COST-EFFECTIVENESS OF EDOXABAN COMPARED WITH OTHER LICENSED NOACS FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLIC EVENTS IN THE UK

Claxton L¹, Taylor M¹, Lewis L¹, Alexandre AF², Harrington AE³, Bakhai A², Brueggenjuergen B³, ¹York Health Economics Consortium, University of York, York, UK, ²York Health Economics Consortium, York, UK, ³Daiichi Sankyo Europe, Munich, Germany, ⁴Royal Free, Barnet and Chase Farm Hospitals, London, UK, ⁵Steinbeis-University-Berlin, Berlin, Germany

PCV127 J24 ECONOMIC EVALUATION OF A PHARMACOGENOMIC TEST FOR STATIN-INDUCED MYOPATHY IN CARDIOVASCULAR HIGH-RISK PATIENTS INITIATING A STATIN

Mitchell D¹, Guertin JR², Iliza AC¹, LeLorier J¹, ¹University of Montreal, Montreal, QC, Canada, ²St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada

PCV128 J25 SYSTEMATIC REVIEW OF PRODUCTIVITY LOSSES ASSOCIATED WITH CARDIOVASCULAR DISEASE IN EUROPE

Gordois AL¹, Proudfoot EM¹, Paoli CJ, Gandra SR², Covance Market Access Services Inc., Sydney, Australia, ²Amgen, Inc., Thousand Oaks, CA, USA

PCV129 J26 SYSTEMATIC REVIEW OF HYPERKALEMIA DUE TO ANGIOTENSIN ENZYME CONVERTING INHIBITORS

Aggarwal S¹, Topaloglu H¹, Kumar S¹, NOVEL Health Strategies, Chevy Chase, MD, USA, ²GLOBAL ACCESS Monitor, Bethesda, MD, USA

PCV130 J27 RESOURCE UTILISATION AND BLEEDING EVENTS DURING ANTICOAGULATION TREATMENT: REAL-WORLD FINDINGS FROM ENGLAND

Lister S¹, Lefevre C², Menown I³, Alikhan R², Lacoin L¹, Bird A², You M², Ridha E³, Evans D², ¹Bristol-Myers Squibb, Uxbridge, UK, ²Bristol-Myers Squibb, Rueil-Malmaison, France, ³Craigavon Cardiac Centre, Craigavon, UK, ⁴University Hospital of Wales, Cardiff, UK, ⁵Pfizer, Surrey, UK, ⁶Bristol-Myers Squibb, Plainsboro, NJ, USA

PCV131 J28 BELIEFS ABOUT MEDICINES IN AN URBAN COMMUNITY HEALTH CENTER HYPERTENSION POPULATION

Barr JT, Conley M, Sluboski K, Griffith J, Northeastern University, Boston, MA, USA
PCV132 J29 QUALITY OF LIFE AND EMOTIONAL IMPACT OF A FIXED DOSE COMBINATION OF ANTIHYPERTENSIVE DRUGS IN PATIENTS WITH UNCONTROLLED HYPERTENSION
Schmieder RE1, Fronk E2, Alexandre AF3, Bramlage P4, Universitätsklinikum Erlangen, Erlangen, Germany, 1Daiichi Sankyo Europe, Munich, Germany, 2IPPMed, Cloppenburg, Germany

PCV133 J30 COMPARISON BETWEEN THE INTERIM EQ-5D-5L SCORE AND THE NEW JAPANESE SCORING IN STROKE PATIENTS
Noto S1, Izumi R2, Shiroiwa T3, Igarashi A4, Ikeda S5, Fukuda T6, Saito S7, Shimozuma K8, Kobayashi M9, Moriwaki K10, Ishida H11, Niigata University of Health and Welfare, Niigata, Japan, 1National Institute of Public Health, Wako, Japan, 2University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, 3International University of Health and Welfare, Otawara, Japan, 4National Institute of Public Health, Wako, Saitama, Japan, 5Okayama University, Okayama, Japan, 6Ritsumeikan University, Kusatsu, Japan, 7CRECON Medical Assessment Inc., Tokyo, Japan, 8Kobe Pharmaceutical University, Kobe, Japan, 9Yamaguchi University, Ube, Japan

PCV134 J31 A SYSTEMATIC REVIEW OF CARDIOVASCULAR EVENT UTILITIES IN EUROPE
Blieden M1, Smith D2, Becker BT3, Paoli CJ4, Gandra SR5, Evidera, Lexington, MA, USA, 1Amgen, Inc., Thousand Oaks, CA, USA

PCV135 J32 HEALTH-RELATED QUALITY OF LIFE IN HEART FAILURE PATIENTS: HEALTH UTILITIES AND PREDICTIVE DETERMINANTS
Gorostiza I1, Escobar A2, Bilbao A3, Garcia-Perez L4, Navarro G5, Quirós R6, Basurto University Hospital (Osakidetza) - REDISSEC, Bilbao, Spain, 1Dirección del Servicio Canario de la Salud - REDISSEC, Santa Cruz de Tenerife, Spain, 2Corporació Parc Taulí Clinic, Sabadell. Barcelona, Spain, 3Costa del Sol Hospital, Marbella, Spain

PCV136 J33 QUALITY OF LIFE EXPERIENCING CANCER-ASSOCIATED THROMBOSIS
Dewilde S1, Lloyd AJ2, Holm MV3, Lee AY4, 1SHE & UGent, Brussel, Belgium, 2Bladon Associates, Oxford, UK, 3LEO Pharma A/S, Ballerup, Denmark, 4University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada

PCV137 K1 STUDY OF KNOWLEDGE, ATTITUDE AND PRACTICE OF GENERAL POPULATION OF GUNTUR TOWARDS SILENT KILLER DISEASES : HYPERTENSION AND DIABETES
Mounica B, chalapath, guntur, India

PCV138 K2 DESIGN OF THREE NEW CONDITION-SPECIFIC QUESTIONNAIRES TO ASSESS QUALITY OF LIFE, SYMPTOMS AND TREATMENT SATISFACTION OF PATIENTS WITH ABDOMINAL AORTIC ANEURYSM: THE ANEURYSM-DQOL, ANEURYSM-SRQ AND ANEURYSM-TSQ
Peach G1, Wilson A2, Plowright R2, Romaine J3, Thompson M4, Hinchliffe RJ5, Bradley C6, 1St George's Vascular Institute, London, UK, 2Health Psychology Research Ltd, Surrey, UK

PCV139 K3 PATIENT UTILITY ESTIMATES IN PATIENTS AT HIGH CARDIOVASCULAR RISK
Joulain F1, Bechet M, Valcheva V, Gorczyca K, Gooch K, Sanofi, Chilly-Mazarin, France, 1Sanofi, Gentilly cedex, France

PCV140 K4 ASSESSMENT OF PATIENT-REPORTED HEALTH STATUS IN PULMONARY ARTERIAL HYPERTENSION PATIENTS TREATED WITH RIOCIGUAT: 2-YEAR RESULTS FROM THE PATENT-2 EXTENSION STUDY
Mathai SC1, Bonner N2, Minai OA3, Busse D4, Brockmann B5, Teal S6, Gater A7, de la Orden Abad M8, Johns Hopkins School of Medicine, Baltimore, MD, USA, 2Adelphi Values Ltd, Bollington, UK, 3Cleveland Clinic, Cleveland, OH, USA, 4Chrestos Concept, Ratingen, Germany, 5Bayer Pharma AG, Berlin, Germany

PCV141 K5 ASSESSMENT OF PATIENT-REPORTED HEALTH STATUS IN CHRONIC THROMBOEMBOLIC PULMONARY ARTERIAL HYPERTENSION PATIENTS TREATED WITH RIOCIGUAT: 2-YEAR RESULTS FROM THE CHEST-2 EXTENSION STUDY
Minai OA1, Bonner N2, Mathai SC3, Busse D4, Brockmann B5, Teal S6, Gater A7, de la Orden Abad M8, 1Cleveland Clinic, Cleveland, OH, USA, 2Adelphi Values Ltd, Bollington, UK, 3Johns Hopkins School of Medicine, Baltimore, MD, USA, 4Chrestos Concept, Ratingen, Germany, 5Bayer Pharma AG, Berlin, Germany

PCV142 K6 EFFECT OF INTERVENTION BY COMMUNITY PHARMACISTS ON AWARENESS OF CONTINUING TREATMENT AMONG PATIENTS WITH HYPERTENSION
Shoji M, Okada H, Onda M, Sakane N, Nakayama T, Osaka University of Pharmaceutical Sciences, Osaka, Japan, 1National Hospital Organization Kyoto Medical Center, Kyoto, Japan, 2Kyoto University, Kyoto, Japan

PCV143 K7 THE QUALITY OF LIFE IN PATIENTS 12 MONTHS AFTER AN ACUTE CORONARY SYNDROM: RESULTS FROM THE PGRX-3 REAL WORLD DATASET
Nordon C1, Abenhaim L2, Worsfold A3, Amzal B4, Rossignol M5, Grimaldi-Bensouda L6, 1LASER Research, Paris, France, 2LASER Analytica, London, UK, 3Decision Analytics, LASER Analytica, London, UK and, Paris, France, 4McGill University, Montreal, QC, Canada

PCV144 K8 A SYSTEMATIC LITERATURE REVIEW ON THE IMPACT OF THERAPEUTIC INTERVENTIONS ON QUALITY OF LIFE IN SYSTOLIC HF RANDOMIZED CLINICAL TRIALS
George A, Deschaseaux C, Agrawal R, Heinrich L, Ghosh P, 1Novartis Healthcare Pvt Ltd, Hyderabad, India, 2Novartis Pharma AG, Basel, Switzerland

PCV145 K9 APHERESIS TREATMENT IN GERMAN PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA - A PSYCHODRAMA MARKET RESEARCH
**Schmid T**, Michailov G, Amgen GmbH, Munich, Germany, Amgen GmbH, München, Germany

**Bereza BG**†, Pechilavanoglou P, Coyle D, Wells G, So D, Grootendorst P, Papadimitropoulos M, University of Toronto, Toronto, ON, Canada, THETA (Toronto Health Economics and Technology Assessment Collaborative), Toronto, ON, Canada, University of Ottawa Faculty of Medicine, Ottawa, ON, Canada, University of Ottawa Heart Institute, Ottawa, ON, Canada

**CARDIOVASCULAR DISORDERS - Health Care Use & Policy Studies**

**PCV147** Impact of Heart Failure on Hospital Admissions and Mortality in Spain in the Period 2009-2013

Obradors M, Figueras M, Villoro R, González-Domínguez A, Merino M, Hidalgo A, Novartis Farmaceutica S.A., Barcelona, Spain, Weber, Economía y Salud, Majadahonda, Spain, University of Castilla-La Mancha, Toledo, Spain

**PCV148** Analysis of Primary and Secondary APR-DRG Codes of an Ischemic Stroke Admission

Dewilde S, Annemans L, Thijs V, SHE & UGent, Brussel, Belgium, University of Ghent, Ghent, Belgium, KULeuven, Leuven, Belgium

**PCV149** Simulating the Impact of a Cardiovascular Prevention Program

Leleu H†, Limbe M‡, Femery V, Blachier M, PUBLIC HEALTH EXPERTISE, Paris, France, MGEN, Paris, France

**PCV150** A Triple Aim Framework for the Performance Assessment of Disease Management Programs


**PCV151** Atrial Fibrillation and Anti-Coagulation Service Run by a Clinical Nurse Specialist

Daacke I†, Hau N†, Williams J‡, Natarajan I§, Boehringer Ingelheim, Bracknell, UK, University Hospital of North Midlands NHS Trust, Stoke-on-Trent, UK

**PCV152** Novel Oral Anticoagulant Use in the EU5: How Are Payer Policies and Physician Preferences Shaping the Prescribing Landscape?

O’Connor E†, Cox J‡, Fletcher-Louis M§, Ribeiro A¶, Decision Resources Group, London, UK, Decision Resources Group, Exton, PA, USA

**PCV153** Real-World Identification of European Patients with Statin-Associated Symptoms: Clinical Practice Compared with Clinical Guidelines

Hovingh GK†, Gandra SR‡, McKendrick J§, Dent R¶, Wieffer HM¶, Catapano AL¶, Oh P¶, Rosenson RS¶, Stroes ES¶, Academic Medical Center, Amsterdam, The Netherlands, Amgen, Inc., Thousand Oaks, CA, USA, PRMA Consulting, Hampshire, UK, PRMA Consulting, Fleet, UK, University of Milan, Milan, Italy, Toronto Rehabilitation Institute, Toronto, ON, Canada, Mount Sinai Icahn School of Medicine, New York, NY, USA, Academic Medical Center, the Netherlands, Amsterdam, The Netherlands

**PCV154** Managing Patients with Statin-Associated Symptoms: Does Real-World Clinical Practice Align with Clinical Guidelines and HTA Recommendations in Europe?

Hovingh GK†, Gandra SR‡, McKendrick J§, Dent R¶, Wieffer HM¶, Catapano AL¶, Oh P¶, Rosenson RS¶, Stroes ES¶, Academic Medical Center, Amsterdam, The Netherlands, Amgen, Inc., Thousand Oaks, CA, USA, PRMA Consulting, Hampshire, UK, PRMA Consulting, Fleet, UK, University of Milan, Milan, Italy, Toronto Rehabilitation Institute, Toronto, ON, Canada, Mount Sinai Icahn School of Medicine, New York, NY, USA, Academic Medical Center, the Netherlands, Amsterdam, The Netherlands

**PCV155** Effectiveness of the ST2 for Prognosis in Heart Failure: Systematic Reviews

Kim SY*, Bang HY†, Sul AR, National Evidence-based Collaborating Agency, Seoul, South Korea

**PCV156** The Effect of a Telephone Counseling Intervention by Pharmacist on Patients’ Beliefs About Medicines and Blood Pressure Control

Daniela Scala D†, Caruso Domenico D†, D’avino Maria M†, Valeria Marina Monetti V*, Valentina Orlando V*, Francesca Guerriero P†, Enrica Menditto E‡, AORN Cardarelli, Naples, Italy, University of Naples Federico II, Naples, Italy

**PCV157** Factors Associated with the Duration of Anticoagulation Therapy Following Acute VTE in England in General Practice: An Observational Study Using CPRD-HES Databases

Lacoin L†, Ridha E†, Lefevre C‡, Moorthy V*, Vasudev M*, Lister S‡, Bird A†, Minns I*, Evans D*, Alkhan R*, Bakhai A*, Bristol-Myers Squibb, Uxbridge, UK, Bristol-Myers Squibb, Rueil-Malmaison, France, Sigma, Northbrook, IL, USA, Pfizer, Surrey, UK, University Hospital of Wales, Cardiff, UK, Barnet and Chase Farm Hospitals NHS Trust, Barnet, UK

**PCV158** What Factors Influence Survival in Stroke: Turkey Case

Ozturk Y, Demir C, Gursoy K, Koselerli R, Turkish Social Security Institution, Ankara, Turkey

**PCV159** Analysis of Stroke Statistics in Turkey

Ozturk Y, Demir C, Gursoy K, Koselerli R, Turkish Social Security Institution, Ankara, Turkey

**PCV160** The Atlantic Divide in Coronary Heart Disease: Health Technologies Use in the US and Portugal
THE ECONOMIC ASPECT OF WARFARIN PHARMACOGENETICS INTRODUCTION INTO HEALTH SYSTEM
Janzic A, Kos M, University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia
K25

DATA FRAMEWORK TO IMPROVE RELATIONSHIP IN DRUGS THERAPIES BETWEEN GPS AND HOSPITAL PHYSICIANS
Voci C, Cavana M, Vecchi E, Francini F, Borsari M, Castanò C, Frigeri F, Azienda Ospedaliero-Universitària Policlinico di Modena, Modena, Italy
K26

ANGIOTENSIN CONVERTING ENZYME INHIBITORS PRESCRIBING PATTERN FOR DIFFERENT INDICATIONS: A POPULATION BASED STUDY
Mahmoudpour SH, Asselbergs FW³, Souverein PC¹, de Boer A¹, Maitland-van der Zee A¹, Utrecht University, UTRECHT, The Netherlands, ²University Medical Centre Utrecht, UTRECHT, The Netherlands
K27

TRANSITIONING FROM GENERIC TO PROTECTED BRAND DRUG IN PATIENTS WITH DM, HYPERTENSION AND HYPERLIPIDEMIA
Shimizu S, Institute for Health Economics and Policy, minato-ku Tokyo, Japan
K28

PRESCRIPTION PATTERN OF ANTIHYPERTENSIVE AGENTS IN A TERTIARY CARE TEACHING HOSPITAL IN CENTRAL NEPAL
Paudel Subedi S, College of Medical Sciences, Chitwan, Nepal
K29

ADHERENCE WITH THERAPEUTIC GUIDELINES IN THE TREATMENT OF VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM IN CLINICAL PRACTICE. FINDINGS FROM THE VICTOR STUDY
Degli Esposti L, Sangiorgi D, Crovato E, Buda S, CiCon S.R.L., Ravenna, Italy
K30

ANTICOAGULANT TREATMENT AFTER VTE IN THE NETHERLANDS
Bezemier ID¹, Folkerts K², van den Berg E¹, Bamber L², Penning-van Beest FJ¹, Herings RM¹, Coppens M¹, PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, ²Bayer Pharma AG, Wuppertal, Germany, ³Academic Medical Center, Amsterdam, The Netherlands
K31

PERSISTENCE TO VITAMIN-K ANTAGONISTS (VKA) AND NOVEL ORAL ANTICOAGULANTS (NOACS) IN NON-VALVULAR ATRIAL FIBRILLATION (NVAF): AN OBSERVATIONAL STUDY USING A COMPREHENSIVE REGIONAL DATABASE IN CATALONIA, SPAIN
Lefevre C¹, Benhaddi H¹, Lacoín L¹, Diaz Cuervo H¹, Lee Y², Evans D¹, Budd D¹, Bristol-Myers Squibb, Rueil-Malmaison, France, ²Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ³Bristol-Myers Squibb, Uxbridge, UK, ⁴Laser Outcomes, Oviendo, Spain, ⁵Laser Outcomes, New York, NY, USA
K32

THE ECONOMIC BURDEN OF POOR ADHERENCE TO STATINS IN BELGIUM
Ramos M, Caekenbergh K, Lamotte M, IMS Health, Vilvoorde, Belgium
K33

CLINICAL PATHWAY AND HEALTH CARE RESOURCES UTILIZATION OF A PATIENTS COHORT AT HIGH RISK OF CARDIOVASCULAR DISEASE OF LOCAL HEALTHCARE UNIT (ASLN¹) OF MILAN: A RESULTS OF INTERVENTION ON SECONDARY PREVENTION
Valentino MC¹, Di Matteo S¹, Colombo GL², Malnis D², Bruno GM¹, S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy, ²University of Pavia, Milan, Italy, ³DIPARTIMENTO GOVERNANZA asl Milano1, Rho, Italy
L1

DISEASE MAPPING AND TEMPORAL-SPATIAL TRANSITION OF HOSPITAL ADMISSIONS DUE TO HEART FAILURE IN PORTUGAL
Viriato D¹, Antunes M², Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo, Portugal, ²Faculdade de Ciências da Universidade de Lisboa, Lisboa, Portugal
L2

PHARMAECONOMIC ANALYSIS OF THE COMBINED HOMOCYSTEINE-LOWERING AND STANDARD THERAPY VERSUS STANDARD THERAPY OF PATIENTS WITH CHD, POSTPERCUTANEOUS CORONARY INTERVENTION (PCI) AND B12 DEFICIENCY
Mishchenko O, Jakovleva L, Kyrchenko O, Gerasymova O, Bezditko N, Tkachova O, National University of Pharmacy, Kharkiv, Ukraine
L3

ARE SPANISH REGIONS IMPLEMENTING THE NATIONAL THERAPEUTIC POSITIONING REPORT (TPR) REGARDING NEW ORAL ANTICOAGULANTS (NOAC) IN THE SAME WAY? A CASE OF REGIONAL VARIABILITY IN DRUG ACCESS
Rodriguez Barrios JM¹, Pérez-Álcántara F¹, Gonzalez-Juantey JR², Avendano C³, Suarez C², López-Bastida J³, Barja de Soroa P³, Daichi-Sankyo, Madrid, Spain, ²OBLIKUE Consulting, Barcelona, Spain, ³Santiago University Hospital, Santiago de Compostela, Spain, ⁴Puerta de Hierro University Hospital, Madrid, Spain, ⁵La Princesa University Hospital, Madrid, Spain, ⁶Castilla La Mancha University, Talavera de la Reina, Spain
L4

RELATIONSHIP BETWEEN ADHERENCE TO POST PERCUTANEOUS CORONARY INTERVENTION (PCI) GUIDELINES AND CLINICAL OUTCOMES OF POST-PCI PATIENTS IN HONG KONG - A 5-YEAR RETROSPECTIVE COHORT STUDY
Hui KC¹, Tang SC¹, Yan BP², Lee VW¹, The Chinese University of Hong Kong, Shatin, Hong Kong, ²Chinese University of Hong Kong, Shatin, Hong Kong
PCV175 L6  A MANAGEMENT VIEW ON HEALTH ECONOMICS - CASE STUDY ON NETWORK META ANALYSES (NMA) FOR PULMONARY ARTERIAL HYPERTENSION (PAH)
Danesa D, Migliore A, Jegers M, Vrije Universiteit Brussel, Brussels, Belgium

PCV176 L7  DEVELOPMENT OF MEDICAL AND TECHNOLOGICAL DOCUMENTS ON STANDARDIZATION OF MEDICAL CARE IN CARDIOVASCULAR DISEASES IN UKRAINE
Melnyk Y, Lishchynshyna O, Netyazhenko N, State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine

PCV177 L8  HEART FAILURE MANAGEMENT: A NATIONWIDE POPULATION-BASED COHORT STUDY USING THE FRENCH EGB DATABASE

PCV178 L9  INVESTIGATING THE RELATIONSHIP BETWEEN “SEVERITY OF ILLNESS” AND THE “MODIFIED RANKIN SCALE” IN ISCHEMIC STROKE PATIENTS WITH RESPONSE MAPPING
Dewilde S, Annemans L, Thijs V, SHE & UGent, Brussel, Belgium, University of Ghent, Ghent, Belgium, KU Leuven, Leuven, Belgium

PCV179 L10 IRON DEFICIENCY IN PATIENTS WITH CHRONIC HEART FAILURE: A SYSTEMATIC LITERATURE REVIEW
Bauer M, Ressl S, Walter E, Institute for Pharmaceutical Research, Vienna, Austria

PCV180 L11 TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) LEVELS IN PATIENTS WITH HYPERTENSION (HT), DIABETES (DM), BOTH (HT AND DM) AND CHRONIC KIDNEY DISEASE (CKD)
Acuña L, Sanchez P, Soler L, Alvis LF, Cuenta de Alto Costo, Bogotá, Colombia, Cuenta de alto costo, bogota, Colombia

PCV181 L12 PILOT ASSESSMENT OF PHARMACEUTICALS BASED ON THE EUNETHA CORE MODEL FOR RAPID RELATIVE EFFECTIVENESS ASSESSMENT
Sacarreu D, Tesar T, D’Andon A, HAS (French National Authority for Health), SAINT-DENIS LA PLAINE, France, Working group for Pharmacoconomics, Clinical Outcomes and HTA, Slovak Ministry of Health, Bratislava, Slovak Republic

PCV182 L13 REVEALED OPPORTUNISM: HOW PHYSICIANS GAME PRIOR AUTHORIZATION PROTOCOLS UNTIL THEY ARE RESCINDED
Kahan NR, Chinitz D, Waitman D, Leumit Health Services, Tel-Aviv, Israel, Hebrew University, Jerusalem, Israel

PCV183 L14 LIPID MODIFYING THERAPY TREATMENT PATTERNS AND CHOLESTEROL CONTROL AFTER CARdioVASCULAR EVENTS IN THE UNITED KINGDOM

MENTAL HEALTH - Clinical Outcomes Studies

PMH1 L15 DOES USE OF ANTIPSYCHOTICS INCREASE THE RISK OF DEATH: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES
Hsu W, Rego LS, Esmaily-Fard A, Lee C, National Taiwan University Hospital, Taipei City, Taiwan, Zeus Química, Lda., Porto, Portugal, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, National Taiwan University Hospital, Yunlin Branch, Douliou, Taiwan

PMH2 L16 RISK FACTORS FOR DEMENTIA DIAGNOSIS IN GERMAN PRIMARY CARE PRACTICES
Wendschlag A, Jacob L, Kostev K, Bohiken J, Rapp MA, IMS Health, Frankfurt/Main, Germany, Ecole Normale Superieure de Lyon, Lyon, France, IMS Health, Frankfurt am Main, Germany, Praxis Bohiken, Berlin, Germany, University of Potsdam, Potsdam, Germany

PMH3 L17 COGNITIVE SYMPTOMS IN MAJOR DEPRESSIVE DISORDER AND THEIR ITALIAN PSYCHIATRISTS’ PERCEPTION
Pegoraro V, Cataldo N, Albert U, Brugnoli R, Caraci F, Dell’Osso BM, Di Sciscio G, Tortorella A, Vampini C, IMS Health Information Solutions Medical Research srl, Milan, Italy, University of Turin, Turin, Italy, Azienda Ospedaliera Sant’Andrea, Rome, Italy, University of Catania, Catania, Italy, University of Milan - Ospedale Policlinico, Milan, Italy, Policlinico Hospital, Bari, Italy, University of Naples SUN, Naples, Italy, Ospedale Civile Maggiore, Verona, Italy

PMH4 L18 COMPARATIVE EFFICACY OF PHARMACOLOGICAL AND SOMATIC INTERVENTIONS IN ADULT PATIENTS WITH TREATMENT-RESISTANT DEPRESSION: A NETWORK META-ANALYSIS

PMH5 L19 LONGITUDINAL MODELING OF THE RELATIONSHIP BETWEEN LISDEXAMFETAMINE DIMESYLATE AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH MODERATE TO SEVERE BINGE EATING DISORDER
Pawaskar M, Agh T, Radenouk J, Vokó Z, McElroy SL, Herman BK, Gasior M, Shire, Wayne, PA, USA, Syreon Research Institute, Budapest, Hungary, Lindner Center of HOPE, Mason, OH, USA
PMH6 L20 LONGITUDINAL MODELING THE EFFECT OF LISDEXAMFETAMINE DIMESYLATE AND CHANGES IN BINGE EATING FREQUENCY ON DISABILITY IN PATIENTS WITH BINGE EATING DISORDER
Pawaskar M1, Vokó Z1, Ağh T1, Sheehan DV1, McElroy SL2, Radenouk J3, Merész G3, Herman BK3, Gasior M3, Shire, Wayne, PA, USA, 4Syreon Research Institute, Budapest, Hungary, 5University of South Florida, Tampa, FL, USA, 6Lindner Center of HOPE, Mason, OH, USA

PMH7 L21 TREATMENT CONTINUATION AND TREATMENT CHARACTERISTICS OF FOUR LONG ACTING ANTIPSYCHOTIC MEDICATIONS (PALIPERIDONE PALMITATE, RISPERIDONE MICROSPHERES, OLANZAPINE PAMOATE AND HALOPERIDOL DECANOATE) IN THE NETHERLANDS
Denee TR1, Geerts P2, Sermon J3, Decuyper F4, Widrich C5, Rijnjies R6, Mulder CL7, Janssen-Cilag BV, Tilburg, The Netherlands, 2Janssen-Cilag NV, Beerse, Belgium, 3IMS Health, Vilvoorde, Belgium, 4IMS Health, The Netherlands, Capelle aan den IJssel, The Netherlands, 5Erasmus MC, Rotterdam, The Netherlands

PMH8 L22 EFFECTIVENESS OF SUPPORTING INFORMAL CAREGIVERS OF PEOPLE WITH DEMENTIA: A SYSTEMATIC REVIEW
Vandepitte S1, Van Den Noortgate N1, Putman K2, Verhaeghe S1, Faes K2, Annemans L3, 4University of Gent, Ghent, Belgium, 5University of Brussels, Brussels, Belgium

PMH10 L23 PRESCRIPTION PATTERNS OF DRUGS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDERS IN JAPANESE CHILDREN AND ADOLESCENTS
Inagaki A1, Endo Y2, Yoshizumi A3, Yamazumi J4, Hashimoto K5, Watanabe K6, Ito T7, Tsukada K8, Aoyama Gakuin University, Tokyo, Japan, 2Institute of Neuropsychiatry, Tokyo, Japan, 3Hizen Psychiatric Center, Yoshinogari, Saga, Japan, 4Kohnodai Hospital, National Center of Global Health and Medicine, Ichikawa, Japan

PMH11 L24 PREVALENCE OF SLEEPING PILLS CONSUMPTION AND ITS ASSOCIATION WITH DEPRESSIVE SYMPTOMS
Kodaira K, Okuyama JH, Silva M, University of Sorocaba, Sorocaba, Brazil

PMH12 L25 MENTAL HEALTH DISORDER PREVALENT TRENDS IN GERMANY: A LONGITUDINAL ANALYSIS
Schlander M1, Schwarz O2, Trott E3, Banaschewski T4, University of Heidelberg, Wiesbaden, Germany, 1University of Heilbronn, Wiesbaden, Germany, 2University of Würzburg, Wiesbaden, Germany, 4Central Institute of Mental Health, Mannheim, Germany

MENTAL HEALTH - Cost Studies

PMH13 L26 BUDGET IMPACT ANALYSIS OF INTRODUCING LISDEXAMFETAMINE DIMESYLATE FOR THE TREATMENT OF BINGE EATING DISORDER IN THE UNITED STATES
Ağh T1, Pawaskar M1, Nagy B2, Szilberhorn L1, Vokó Z1, Syreon Research Institute, Budapest, Hungary, 2Shire, Wayne, PA, USA

PMH14 L27 LURASIDONE IN ADULTS WITH SCHIZOPHRENIA IN THE UK: A COST CONSEQUENCE ANALYSIS CONSIDERING COST IMPLICATIONS OF IMPROVED EFFICACY AND SAFETY
Rajagopalan K1, Trueeman D2,Crowe L3, Patel P4, Loebel A5, Sunovion Pharmaceuticals, Inc, Marlborough, MA, USA, 1Abacus International, Bicester, UK, 2Sunovion Pharmaceuticals, Inc, Fort Lee, NJ, USA

PMH15 L28 COST-UTILITY AND BUDGET IMPACT ANALYSES COMPARING LURASIDONE WITH ARIPIPRAZOLE IN ADULTS WITH SCHIZOPHRENIA IN SCOTLAND
Rajagopalan K1, Trueeman D2, Crowe L3, Patel P4, Loebel A5, Sunovion Pharmaceuticals, Inc, Marlborough, MA, USA, 1Abacus International, Bicester, UK, 2Sunovion Pharmaceuticals, Inc, Fort Lee, NJ, USA

PMH16 L29 PERCENTAGE PRICE VARIATION AMONG ANTIDEPRESSANT DRUGS IN INDIAN MARKET: AN ECONOMIC PERSPECTIVE
Hussain S, Kumari S, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India

PMH17 L30 THE ACTUAL COST OF A “FORCED SWITCH” OF PSYCHIATRIC PATIENTS TO A NEW THERAPY: A MARKOV CHAIN – MONTE CARLO SIMULATION
Anelli M, Puglisi R, Keypharma srl - Product Life Group, Milano, Italy

PMH18 L31 OBSERVATIONAL STUDY OF RESOURCE USE AND COST OF ALZHEIMER’S DISEASE IN EUROPE (GERAS) - 18-MONTH RESULTS FROM THE FRENCH COHORT
Rapp T1, Vellas B2, Andrieu S3, Chartier F4, Baraille L5, Belger M6, University of Paris Descartes, Paris, France, 2Toulouse University Hospital, Toulouse, France, 3Eli and Lilly, Neuilly-sur-Seine Cedex, France, 4Eli Lilly and Company Ltd, Windlesham, UK

PMH19 L32 THE ECONOMIC BURDEN OF MENTAL DISORDERS IN KOREA
Kim HJ, Lee S, Ho SH, Korea National Rehabilitation Center, National Rehabilitation Research Institute, Seoul, South Korea

PMH20 L33 COSTS OF MENTAL DISORDERS IN POLAND AND THEIR COMPLICATIONS
Lesniowska J, Kozminski University, Warsaw, Poland

PMH21 M1 THE ECONOMIC BURDEN OF PHARMACEUTICALS IN PEOPLE DIAGNOSED WITH DEPRESSION, ANXIETY-RELATED DISORDER AND SUBSTANCE USE IN AUSTRALIA
Lee Y1, Magnus A2, Chatterton ML3, Mihalopoulos C3, 4Deakin University, Burwood, Australia, 2Deakin University, Geelong, Australia, 4Deakin University, Melbourne, Australia

PMH22 M2 COST EFFECTIVENESS ANALYSIS OF ARIPIPRAZOLE ONCE-MONTHLY VERSUS PALIPERIDONE PALMITATE
IN SPAIN
Sapin C, Gimeno de la Fuente V, Blancher P, Beillat M, Lundbeck SAS, Issy les Moulineaux, France, Lundbeck España SA, Barcelona, Spain, Otsuka Pharmaceutical SA, Barcelona, Spain, Lundbeck SAS, Issy-les-Moulineaux, France

PMH23 M3 COST-EFFECTIVENESS ANALYSIS OF THE INFORMATION TECHNOLOGY AIDED RELAPS PREVENTION PROGRAMME IN SCHIZOPHRENIA (ITAREPS) IN THE CZECH REPUBLIC
Micloch T, Kruntoradova K, Mandelikova M, Dolezal T, Institute of Health and Technology Assessment, iHETA, Prague, Czech Republic

PMH24 M4 STUDY ON COST-EFFECTIVENESS ANALYSIS FOR TREATMENT OF MAJOR DEPRESSION DISEASE: A SYSTEMATIC REVIEW OF LITERATURE FROM 2004-2014
Hiroi S, Yamabe K, Inoue S, Kobayashi M, Takeda Pharmaceutical Company Ltd., Tokyo, Japan, CRECON Medical Assessment Inc., Tokyo, Japan

PMH25 M5 ECONOMIC ANALYSIS OF PALIPERIDONE LONG-ACTING ACTING INJECTABLE FOR CHRONIC SCHIZOPHRENIA IN PORTUGAL
Maia-Lopes S, Van Impe K, Goswami P, Einarson TR, Janssen Cilag Portugal, Barcarena, Portugal, CRECON GmbH, Neuss, Germany, University of Toronto, Toronto, ON, Canada

PMH26 M6 PHARMACOECONOMIC EVALUATION OF ARIPIPRAZOLE ONCE-MONTHLY VERSUS PALIPERIDONE PALMITE IN THE UK: FINDINGS FROM QUALIFY

PMH27 M7 COST-EFFECTIVENESS ANALYSIS OF OPIOID SUBSTITUTION TREATMENT IN SLOVENIA
Hren R, University of Ljubljana, Ljubljana, Slovenia

PMH28 M8 A SYSTEMATIC REVIEW OF MODEL-BASED ECONOMIC EVALUATIONS OF DRUG SUBSTITUTION THERAPIES IN MAINTENANCE TREATMENT OF NON-PRESCRIPTION OPIOID DEPENDENCE

PMH29 M9 THE COST EFFECTIVENESS OF AGOMELATINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
Ignatyeva V, Axventyeva M, Frolov M, The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, Volgograd State Medical University, Volgograd, Russia

PMH30 M10 PRIMARY CARE DEMENTIA CLINIC REDUCES SOCIETAL COST OF DEMENTIA: A COST-UTILITY ANALYSIS
Teo WK, National Healthcare Group, Singapore, Singapore

PMH31 M11 EVALUATION OF THE BURDEN OF OPIOID ABUSE AMONG US VETERAN PATIENTS
Baser O, Ogboro A, Tan H, Du J, Xie L, STATinMED Research, Columbia University, New York, NY, USA, The University of Michigan, Ann Arbor, MI, USA, STATinMED Research, Ann Arbor, MI, USA

PMH32 M12 ECONOMIC BURDEN IN STUDIES PUBLISHED IN 2014: WHAT TYPE OF MENTAL HEALTH DISORDERS AND OUTCOMES HAVE BEEN MOST COMMONLY ASSESSED?
Martin A, Crystallise Ltd., London, UK

MENTAL HEALTH - Patient-Reported Outcomes & Patient Preference Studies

PMH33 M13 ESTIMATING THE IMPACTS OF MEDICATION ADHERENCE AND PERSISTENCE ON COSTS AND HOSPITALIZATION: THE CASE OF ATYPICAL ANTIPSYCHOTICS
Ni W, Jiang Y, University of Southern California, Los Angeles, CA, USA

PMH34 M14 EFFECT OF ANTIDEPRESSANT-BASE TREATMENT OF DEPRESSED PATIENTS: AN OBSERVATION AMONG PATIENTS WITH COMPLETE ADHERENCE WITH THAI DEPRESSION INVENTORY AND LAM EMPLOYMENT ABSENCE AND PRODUCTIVITY SCALE IN PSYCHIATRIC HOSPITALS
Pumpaisalchai W, Dulchuprapsa W, Werawattanachai C, Kunacaroensup A, Pumpaisalchai W, Udombhornprapha A, Suan Prung Psychiatric Hospital, Chiang Mai, Thailand, Prasrimahabhodi Psychiatric Hospital, Ubonradchatani, Thailand, Dararassamee, Royal Thai Police Hospital, Chiang Mai, Thailand, Eastern Asia University, Pathum Thani, Thailand

PMH37 M15 PRO SELF-ASSESSMENT AND PATIENT RETENTION IN MAJOR DEPRESSION STUDIES: EFFICIENCY OF A DIRECT-TO-PATIENT CONTACT APPROACH
Wiederkehr S, Michel J, Fournie X, Mapi, Lyon, France

PMH38 M16 DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED OUTCOME MEASURE OF THE PSYCHOLOGICAL IMPACT OF SUBMENTAL FAT
Gross TM, Burgess SM, Somogyi C, Lizzul PF, Beddingfield FC, KYTHERA Biopharmaceuticals, Inc, Westlake Village, CA and Department of Statistics, University of California Santa Barbara, Santa Barbara, CA, USA, Strategic Outcomes Services, Mission Viejo, CA, USA, KYTHERA Biopharmaceuticals, Inc., Westlake Village, CA, USA, KYTHERA Biopharmaceuticals, Inc., Westlake Village, CA and David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

PMH39 M17 HUMANISTIC BURDEN IN DEMENTIA: WHICH TOOLS WERE MOST COMMONLY USED IN STUDIES PUBLISHED
IN PUBMED IN 2014?

**Martin A**, Crystallise Ltd., London, UK

**PMH40 M18**  **PATIENT, CAREGIVER AND TREATMENT FACTORS ASSOCIATED WITH MEDICATION SATISFACTION AMONG TREATED PATIENTS IN THE CAREGIVER PERSPECTIVE ON PEDIATRIC ADHD (CAPPA) STUDY IN EUROPE**

Fridman M¹, Banaschewski T², Harpin V³, Quintero J⁴, Chen K⁵, AMF Consulting, Inc., Los Angeles, CA, USA, ²Central Institute of Mental Health, Mannheim, Germany, ³Ryegate Children’s Centre, Sheffield, UK, ⁴Hosp. Univ. Infanta Leonor, Madrid, Spain, ⁵Shire, Lexington, MA, USA

**PMH41 M19**  **OCCUPATIONAL DISABILITY AND ECONOMIC DEPRIVATION OF INDIVIDUALS SUFFERING FROM TREATED MENTAL HEALTH DISORDERS**

Pignot M¹, Pisa G¹, Potthoff P², Kantar Health, Munich, Germany, ²Kantar Health Germany, Munich, Germany

**MENTAL HEALTH - Health Care Use & Policy Studies**

**PMH42 M20**  **OPIOID ADDICTION TREATMENT IN THE EU: MARKET ACCESS LEVERS FOR EMERGING BRANDS ENTERING A GENERIC MARKET**

Taylor N¹, Cox J², Fletcher-Louis M³, Ribeiro A⁴, Decision Resources Group, Burlington, MA, USA, ⁴Decision Resources Group, London, UK, ²Decision Resources Group, Exton, PA, USA

**PMH43 M21**  **REDUCING CONSUMPTION VERSUS MAINTAINING ABSTINENCE: MARKET ACCESS CHALLENGES FACING A NOVEL TREATMENT PATHWAY FOR ALCOHOL ADDICTION IN THE EU**

Kiernon B¹, Cox J², Fletcher-Louis M³, Ribeiro A⁴, Decision Resources Group, Burlington, MA, USA, ⁴Decision Resources Group, London, UK, ²Decision Resources Group, Exton, PA, USA

**PMH44 M22**  **INEQUITY IN ACCESS TO ALZHEIMER DISEASE INDICATED TREATMENT ACROSS DIFFERENT GEOGRAPHIC AREAS OF TURKEY**

Dokuyucu Ö¹, Saylan M¹, Ozdemir Ö², Keskinaslan A³, Novartis, Istanbul, Turkey, ²Yorum Consulting Ltd., Istanbul, Turkey, ³Novartis AG, Istanbul, Turkey

**PMH45 M23**  **DRUG UTILIZATION PATTERN OF LISDEXAMFETAMINE DIMESYLATE IN EUROPE**

Cook MN¹, Varughese S¹, Maxwell T¹, Thun B², Ehlken B², von Bredow D², Keja J³, Shire, Wayne, PA, USA, ²IMS Health GmbH & Co OHG, RWES, Munich, Germany, ³RWES, IMS Health, Rotterdam, The Netherlands

**PMH46 M24**  **ANTIDEPRESSANT USE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A COMPARISON OF TREATMENT RESISTANT AND NON-TREATMENT RESISTANT EPISODES IN THE UNITED KINGDOM USING THE CPRD DATABASE**

Kubitz N¹, Potluri R², Mehra M³, Janssen-Cilag GmbH, Neuss, Germany, ²SmartAnalyst Inc., New York, NY, USA, ³Global Market Access & Commercial Strategy Organization, Raritan, NJ, USA

**PMH47 M25**  **CHARACTERISTICS AND HEALTHCARE RESOURCE USE OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER INITIATED ON SNRI COMPARED TO SSRI IN BEIJING CHINA**

Chen Y¹, Yue L¹, Shi Q¹, Liu Q¹, Montgomery W³, Lilly Suzhou Pharmaceutical Company, Ltd., Shanghai, China, ²Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China, ³Eli Lilly Australia, West Ryde, Australia

**PMH48 M26**  **THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIDEPRESSANTS IN BELGIUM: PRESCRIBING BEHAVIOR AND MISUSE OF ANTIDEPRESSANTS**

Ramos M¹, Brouyère S², Caekelbergh K³, Lamotte M¹, IMS Health, Vilvoorde, Belgium, ²IMS Health, Drogenbos, Belgium

**PMH49 M27**  **THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIDEPRESSANTS IN BELGIUM**

Caekelbergh K, Ramos M, Lamotte M, IMS Health, Vilvoorde, Belgium

**PMH50 M28**  **DEPRESSION: HIGHLIGHT MOLECULES USED IN PATIENTS FROM SUPPLEMENTARY HEALTH IN BRAZIL**

Marra FC, Montezani E, Dapx Intelligence for Healthcare, São Paulo, Brazil

**PMH51 M29**  **INTEGRATED CLINICAL PATHWAY IN SCHIZOPHRENIA**

Colombo GL¹, Valentino MC², Di Matteo S¹, Bruno GM³, ¹University of Pavia, Milan, Italy, ²S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy

**SENSORY SYSTEMS DISORDERS - Clinical Outcomes Studies**

**PSS1 M30**  **A PROSPECTIVE STUDY TO COMPARE SAFETY AND EFFICACY OF VARIOUS ANTI-GLAUCOMA AGENTS AND EVALUATE THE EFFECT OF AEROBIC EXERCISE ON INTRA-OCULAR PRESSURE IN NEWLY DIAGNOSED PRIMARY OPEN ANGLE GLAUCOMA PATIENTS IN A TERTIARY CARE HOSPITAL**

Agrawal A, MUHS, NASHIK, KALYAN, MUMBAI, India

**PSS3 M32**  **BURDEN OF DISEASE IN PATIENTS WITH GLAUCOMA IN BRAZIL**

Ferreira CN¹, Sanders KN², Clark OA³, Pomerantz D⁴, Chapnick J⁵, Hatanaka M⁶, Pfizer, São Paulo, Brazil, ⁶Pfizer, Inc., New York, NY, USA, ²Evidencias - Kantar Health, Campinas, Brazil, ³Kantar Health, Horsham, PA, USA, ⁴University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁵Sao Paulo, Brazil

**PSS4 M33**  **EFFICACY AND SAFETY OF SURGICAL TREATMENT OPTIONS FOR PRIMARY ANGLE CLOSURE GLAUCOMA: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS**

Verma J¹, John D², Nair SR³, Oonman S¹, Mishra R¹, Shah P¹, Jha D², Shaikh S¹, ¹Capita Ind Pvt. Ltd., Mumbai, India, ²Capita India Pvt. Ltd., Mumbai, India
PSS5 N1 SKIN WHITENING MULTIPLE EMULSIONS LOADED WITH GREEN TEA AND LOTUS EXTRACTS: AN EFFICACY STUDY
Mahmood T, Akhtar N, University of Central Punjab, Lahore, Pakistan, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

PSS6 N2 OUTCOME OF HARKÁNY THERMAL WATER COMPLETED PUVA THERAPY VERSUS TRADITIONAL PUVA THERAPY OF PSORIATIC PATIENTS

PSS7 N3 EFFICACY COMPARISON OF ANTI-VEGF AND LASER PHOTOCOAGULATION IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Regnier SA, Malcolm WA, Novartis Pharma, Basel, Switzerland, Novartis UK, Frimley, UK

PSS9 N5 DRUG SURVIVAL RATES IN PATIENTS WITH PSORIASIS UTILIZING ETANERCEPT COMPARED TO ADALIMUMAB – A NATIONWIDE POPULATION-BASED COHORT STUDY IN SWEDEN
Berglund A, Dorange A, Ljungberg A, Niklason A, Biogen AB, Upplands Vasby, Sweden, Pfizer AB, Sollevntuna, Sweden

PSS10 N6 HEALTHCARE PATHWAYS AND BURDEN OF DISEASE OF PATIENTS WITH SKIN AND SOFT TISSUE INFECTIONS (SSTIS)
Calabria S, Cinconze E, Martini N, Rossi E, Esposito I, De Rosa M, CORE, Collaborative Outcome Research, Bologna, Italy, CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, Accademia Nazionale di Medicina, Roma, Italy

PSS11 N7 PREVALENCE OF ACNE VULGARIS IN EUROPE AND IMPACT OF LIFESTYLE FACTORS
Delarue A, Zzik A, Berdeaux G, Pierre Fabre DermatoCosmétique, Lavaur, France, Pierre Fabre, Boulogne Billancourt, France

PSS12 N8 SUN EXPOSURE IN MEXICO: AN OBSERVATIONAL STUDY ON POPULATION HABITS AND KNOWLEDGE OF RISKS ASSOCIATED WITH SUCH EXPOSURE
Zzik A, Berdeaux G, Pierre Fabre, Boulogne Billancourt, France

SENSORY SYSTEMS DISORDERS - Cost Studies

PSS13 N9 BUDGET IMPACT MODEL OF OMALIZUMAB IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA IN ITALY
Ravasio R, Caowson MR, McBride D, Balp M, Roccia A, Health Publishing & Services Srl, Milan, Italy, RTI Health Solutions, Manchester, UK, Novartis Pharma AG, Basel, Switzerland, Novartis Farma SpA, Origgio, Italy

PSS14 N10 BIOLOGIC TREATMENTS FOR MODERATE-SEVERE PSORIASIS. WHAT EFFICACY GIVES YOU, COST SHOULD NOT TAKE IT AWAY
Blanch C, Prades M, Lázán L, Figueras M, Novartis Farmacéutica, Barcelona, Spain, Outcomes'10, Castellon, Spain, Novartis Farmacéutica S.A., Barcelona, Spain

PSS15 N11 ECONOMIC BURDEN OF PNEUMOCOCCAL INFECTIONS IN CHILDREN UNDER FIVE YEARS OLD
Ceyhan M, Ozsurekci Y, Aykac K, Hacettepe University Faculty of Medicine, Department of Pediatric Infectious Diseases, Ankara, Turkey

PSS16 N12 COMPARABLE ANALYSIS OF PRICES FOR FIRST STAGE OF DENTAL IMPLANTATION IN UKRAINE
Got S, Barylyak A, Uhrny M, Fal O, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PSS17 N13 SUGAR FREE GUM IN THE PREVENTION OF CARIES: A COMPARISON OF GERMANY AND FINLAND
Kreimendahl F, Institute of Empirical Health Economics, Burscheid, Germany

PSS18 N14 COSTS ASSOCIATED WITH THE MANAGEMENT AND MORBIDITY OF DIABETIC MACULAR ODEMA AND MACULAR ODEMA SECONDARY TO RETINAL VEIN OCCLUSION
Balaña M, Abraldes M, Pareja A, Roura M, from the OBSERVAR Study Group, Novartis Farmacéutica S.A., Barcelona, Spain, Complexo Hospitalario Universitario de Santiago de Compostela, Universidade de Santiago de Compostela, Santiago de Compostela, Spain, Red Temática de Investigación Cooperativa en Salud (RETICS), Instituto de Salud Carlos III, Santiago de Compostela, Spain, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain

PSS19 N15 THE COST-OF-DISEASE (COD) IN DIABETIC MACULAR EDEMA (DME) IN TURKEY: AN EXPERT PANEL APPROACH FOR ESTIMATION OF COSTS
Deger C, Ozdemir O, Eldem B, Unlu N, Alp MN, Saatci AO, Ozmert E, Altintas AK, Sermet F, Erdal E, Sar C, Asan S, Sumer F, Parali E, Ozel O, Bayer Turk Kimya San. Ltd. St., Istanbul, Turkey, Yorum Consulting Ltd., Istanbul, Turkey, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara Training & Research Hospital, Ankara, Turkey, Ankara Numune Training & Research Hospital, Ankara, Turkey, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, Ankara University, Faculty of Medicine, Ankara, Turkey, Ankara Ulucanlar Eye Training & Research Hospital, Ankara, Turkey

PSS20 N16 DIRECT AND INDIRECT COSTS ASSOCIATED TO RETINAL VASCULAR DISEASES IN ITALY. A PROBABILISTIC COST OF ILLNESS STUDY
**PSS21 N17** THE COST-OF-DISEASE (COD) IN CENTRAL RETINAL VEIN OCCLUSION (CRVO) IN TURKEY: AN EXPERT PANEL APPROACH FOR ESTIMATION OF COSTS

Deger C1, Ozdemir O2, Eldem B3, Unlu N4, Alp MN5, Saacti AO6, Ozmert E1, Erdal E1, Sar C1, Asan S1, Sumer F1, Parali E1, Ozel O1, Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey, 2Yorum Consulting Ltd. Istanbul, Turkey, 3Hacettepe University Faculty of Medicine, Ankara, Turkey, 4Ankara Training & Research Hospital, Ankara, Turkey, 5Ankara Numune Training & Research Hospital, Ankara, Turkey, 6Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, 7Ankara University, Faculty of Medicine, Ankara, Turkey

**PSS22 N18** THE COST-OF-DISEASE (COD) IN WET AGE-RELATED MACULAR DEGENERATION (WAMD) IN TURKEY: AN EXPERT PANEL APPROACH FOR ESTIMATION OF COSTS

Deger C1, Ozdemir O2, Eldem B3, Unlu N4, Alp MN5, Saacti AO6, Ozmert E1, Erdal E1, Sar C1, Asan S1, Sumer F1, Parali E1, Ozel O1, Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey, 2Yorum Consulting Ltd. Istanbul, Turkey, 3Hacettepe University Faculty of Medicine, Ankara, Turkey, 4Ankara Training & Research Hospital, Ankara, Turkey, 5Ankara Numune Training & Research Hospital, Ankara, Turkey, 6Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, 7Ankara University, Faculty of Medicine, Ankara, Turkey

**PSS23 N19** ESTIMATION OF INDIRECT (WORK-RELATED PRODUCTIVITY) COSTS ASSOCIATED WITH MODERATE-TO-SEVERE PLACQUE PSORIASIS IN GERMANY

Graham CN1, McBride D2, Miles L3, Kneidj J4, Mollon P2, RTI Health Solutions, NC, NC, USA, 2RTI Health Solutions, Manchester, UK, 3RTI Health Solutions, Research Triangle Park, NC, USA, 4Novartis Pharma GmbH, Nuernberg, Germany, 5Novartis Pharma AG, Basel, Switzerland

**PSS24 N20** NATIONAL STUDY TO ASSESS THE COSTS OF PATIENTS WITH HIGH MYOPIA WITH AND WITHOUT CHOROIDAL NEOVASCULARISATION

Balaná M1, Ruiz-Moreno JM2, Roura M3, on Behalf Of The Study Group of Mypathway, 1Novartis Farmacéutica S.A., Barcelona, Spain, 2Universidad Castilla La Mancha, Albacete, Spain

**PSS25 N21** COST EFFECTIVENESS ANALYSIS OF RANIBIZUMAB COMPARED TO AFLIBERCEPT AND LASER INTERVENTION IN TREATMENT OF DIABETIC MACULAR EDEMA (DME) IN THE CZECH REPUBLIC

Klimes J1, Regnier SA2, Mahon R3, Budek T4, Dostal F1, Skalkicky D1, Depta J2, Novartis, s.r.o., Prague, Czech Republic, 2Novartis Pharma, Basel, Switzerland, 3Novartis Global Business Services, Dublin, Ireland, 4Novartis Pharma AG, Basel, Switzerland

**PSS26 N22** INTRAVITREAL AFLIBERCEPT INJECTION FOR THE TREATMENT OF VISUAL IMPAIRMENT DUE TO MACULAR OEDema SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: COST-EFFECTIVENESS VERSUS RANIBIZUMAB


**PSS27 N23** COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PLACQUE PSORIASIS IN THE ITALIAN SETTING

Barbieri M1, Capri S2, Oskar B1, Centre for Health Economics, University of York, York, UK, 2School of Economics and Management Cattaneo - LIU University, Castellanza, Italy, 3Celgene Corporation, Milan, Italy

**PSS28 N24** RANIBIZUMAB VS. VERTEPORFIN PHOTODYNAMIC THERAPY FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION: COST EFFECTIVENESS STUDY IN PORTUGAL

Montóia B1, Guerreiro T1, Viraio D1, Novartis Farma – Produtos Farmaceuticos S.A., Porto Salvo, Portugal, 2Novartis Farma – Produtos Farmaceuticos S.A., Porto Salvo, Portugal

**PSS29 N25** COST-EFFECTIVENESS OF APREMILAST TO MODERATE TO SEVERE PSORIASIS IN SCOTLAND


**PSS30 N26** COST-EFFECTIVENESS OF TREATMENTS FOR WET AGE-RELATED MACULAR DEGENERATION (WAMD) IN THE NETHERLANDS, THE CASE OF INTRAVITREAL AFLIBERCEPT (IVT-AFL) AND RANIBIZUMAB

Tempelaar S1, de Meijer C1, Stephens S1, Pharmerit International, York, UK, 2Bayer B.V., Mijdrecht, The Netherlands

**PSS31 N27** COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN SPAIN

Carrascosa JM1, Vianacllocha F2, Caloto T3, Echave M4, Oyagüez I5, Tencer T1, Department of Dermatology, Germans Trias i Pujol University Hospital, Barcelona, Spain, 2Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain, 3Department of Health Economics, Celgene Corporation, Madrid, Spain, 4Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 5Celgene Corporation, Warren, NJ, USA

**PSS32 N28** COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN DIABETIC MACULAR OEDEMA IN SWEDEN

Castelo Branco A1, Eriksson M2, Nilsson J1, Mapi Group, Stockholm, Sweden, 2Bayer AB, Solna, Sweden

**PSS33 N29** COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN GREECE

Kourlaba G1, Tzanetakos C2, Datseris J3, Rouvas A4, Arzoumanidou D5, Maniadakis N6, Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, 2National School of Public Health, Athens,
PSS34 N30 COST-EFFECTIVENESS ANALYSIS OF CONCOMBENT VERSUS RANIBIZUMAB FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN CHINA
Zhao M1,2, Feng W1,3, Zhang L4, Ke X5,6, Zhang W5,6, Xuan J7,8, Peking University People's Hospital, Beijing, China. 1First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China, 2Shanghai Centennial Scientific Company, Shanghai, China, 3Kanghong Pharmaceutical Company, Chengdu, China, 4Sun Yat-Sen University, Guangzhou, China

PSS35 N31 BUDGET IMPACT ANALYSIS OF APRILIMIST ON MODERATE TO SEVERE PSORIASIS IN SPAIN
Vanaclocha F1, Carrascosa JM2, Caloto T3, Elias I4, Echave M5, Tencer T6, 1Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain, 2Department of Dermatology, Germans Trias i Pujol University Hospital, Barcelona, Spain, 3Department of Health Economics, Celgene Corporation, Madrid, Spain, 4Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 5Celgene Corporation, Warren, NJ, USA

PSS36 N32 BUDGET IMPACT ANALYSIS OF APRILIMIST IN PATIENTS WITH PSORIASIS IN THE ITALIAN SETTING
Barbieri M1, Capri S2, Oskar B3, Centre for Health Economics, University of York, York, UK, 1School of Economics and Management Cattaneo - LIUC University, Castellanza, Italy, 2Celgene Corporation, Milan, Italy

PSS37 N33 COST-EFFECTIVENESS OF IKERVIS® IN SEVERE DRY EYE DISEASE IN THE UK [UPDATE]
Morton TD1, Ernst F2, Mealing S3, Eaton J4, Hawkins NS5, Thompson JC6, Amrane M7, ICON plc, Oxford, UK, 1Santen Pharmaceutical, Munich, Germany, 2ICON Health Economics and Epidemiology, Oxford, UK, 3Icon, Dublin, Germany, 4ICON Health Economics, Oxford, UK

PSS38 O1 DRUG UTILISATION AND HEALTHCARE RESOURCES USE IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS
Degli Esposti L, Sangiorgi D, Buda S, Crovato E, ClicCon S.r.l., Ravenna, Italy

PSS39 O2 SUGAR FREE GUM: IMPACT ON ORAL HEALTH AND COPAYMENT IN GERMANY
Spyra A, Institute of Empirical Health Economics, Burscheid, Germany

PSS40 O3 COST-EFFECTIVENESS ANALYSIS OF TOPICAL FILED TREATMENT THERAPIES FOR THE TREATMENT OF ACTINIC KERATOSIS IN GREECE
Athanasakis K1, Boubouchaipoupolou N2, Tarantilis F3, Tsiantou V4, Kontodimas S5, Kyriopoulos J6, National School of Public Health, Athens, Greece, 1LEO Pharmaceutical Hellas S.A, Athens, Greece

PSS41 O4 COST-EFFECTIVENESS OF RANIBIZUMAB VS. DEXAMETHASONE IMPLANT IN DIABETIC MACULAR EDEMA
Cavusoglu Sezen S1, Dokuyucu O2, Saylan M3, Burke C4, Mahon R5, Keskinaslan A6, Novartis, Istanbul, Turkey, 1Novartis Global Business Services, Dublin, Ireland, 2Novartis AG, Istanbul, Turkey

PSS42 O5 COST-EFFECTIVENESS OF SECUKINUMAB COMPARED TO USTEKINUMAB IN PATIENTS WITH PSORIASIS FROM A SWEDISH HEALTH CARE PERSPECTIVE
Costa-Scharplatz M1, Lang A2, Gustavsson A3, Fasth A4, Novartis Sweden AB, Täby, Sweden, 1Quantify Research, Stockholm, Sweden

PSS43 O6 ADAPALENE 0.1% / BENZOYL PEROXIDE 2.5% + DOXYCYCLINE 200MG IS A LESS EXPENSIVE ALTERNATIVE COMPARED TO ORAL ISOTRETINOIN FOR THE MANAGEMENT OF SEVERE NODULAR ACNE IN SWEDEN
Selva-Hammer C1, Boval M2, Patel S3, Amaris UK, London, UK, 1Galermer, La Defense, France

PSS44 O7 COST-UTILITY OF RANIBIZUMAB VS ABLISTERCEPT FOR TREATING VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN GREECE
Kourlaba G1, Relakis J2, Mahon R3, Kalogeropoulos M4, Pantelopoulos G5, Kousidou O6, Maniadakis N7, Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, 1Department Of Health Services Organization, National School Of Public Health, Athens, Greece, 2Novartis Ireland Limited, Dublin, Ireland, 3Novartis Hellas, Metamorfosis, Greece, 4Department of Health Services Organization, National School of Public Health, Athens, Greece

PSS45 O8 COST-UTILITY ANALYSIS OF INGENUM MEBUTATE VERSUS IMIQUIMOD 5% FOR ACTINIC KERATOSIS TREATMENT IN SPAIN
Ortega-Joquin N1, Elias I2, de la Cueva P3, Del Pozo LJ4, Boada A5, Moreno D6, Aguilar M7, Mosquera E8, Mirada A9, Gibbons C10, Ovargüez I11, Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 1Infanta Leonor University Hospital, Madrid, Spain, 2Son Espases University Hospital, Palma de Mallorca, Spain, 3Germans Trias i Pujol University Hospital, Barcelona, Spain, 4Virgen Macarena University Hospital, Sevilla, Spain, 5Costa del Sol Hospital, Malaga, Spain, 6LEO SPAIN, Barcelona, Spain, 7LEO U.K, Berkshire, UK

PSS46 O9 HEALTH AND ECONOMIC OUTCOMES RELATED TO DELAY BETWEEN MEDICAL INDICATION AND TREATMENT WITH RANIBIZUMAB IN AGE-RELATED MACULAR DEGENERATION IN GREECE
Kourlaba G1, Chatzikou M2, Pantelopoulos G3, Maniadakis N4, Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, 1Novartis (Hellas) S.A.C.I., Athens, Greece, 2Department of Health Services Organization, National School of Public Health, Athens, Greece

PSS47 O10 COST-UTILITY OF OMALIZUMAB COMPARED WITH STANDARD OF CARE FOR THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA (CSU)
Graham J1, McBride D2, Stull D3, Halliday A4, Alexopoulos ST5, Balip M6, Griffiths M7, Agirrezabal I8, Brennan A9, RTI
COST-EFFECTIVENESS OF OMALIZUMAB IN CHRONIC SPONTANEOUS URTICARIA IN THE NETHERLANDS
Kanters TA, Gertsen K, Hakkaart L, Erasmus University Rotterdam, Rotterdam, The Netherlands, Novartis pharma, Arnhem, The Netherlands

COST-UTILITY ANALYSIS OF INGENOL MEBUTATE VERSUS DICLOFENAC 3% FOR ACTINIC KERATOSIS TREATMENT IN SPAIN
Elias I, Ortega-Joquin N, Aguilar M, Moreno D, Boada A, Del Pozo Li, de la Cueva P, Mirada A, Mosquera E, Gibbons C, Ovagiez I, Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, Costa del Sol Hospital, Malaga, Spain, Virgen Macarena University Hospital, Seville, Spain, Germans Trias i Pujol University Hospital, Barcelona, Spain, Son Espases University Hospital, Palma de Mallorca, Spain, Infanta Leonor University Hospital, Madrid, Spain, LEO SPAIn, Barcelona, Spain, LEU U.K, Berkshire, UK

A COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB 300 MG VS CURRENT THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PLAPEAURISIAS IN ITALY
D'Ausilio A, Aiello A, Daniel F, Graham C, Roccia A, Toumi M, Creativ Ceutical, Milano, Italy, RTI Health Solutions, NC, NC, USA, Novartis Farma SpA, Origgio, Italy, Aix-Marseille University, Marseille, France

COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE CZECH REPUBLIC
Klimes J, Mollon P, Graham C, Rajnoch J, Dostal F, Skalicky D, Jordan P, Novartis, s.r.o., Prague, Czech Republic, Novartis Pharma AG, Basel, Switzerland, RTI Health Solutions, NC, NC, USA

HEALTHCARE RESOURCE UTILISATION AMONG CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA PATIENTS– FINDINGS FROM THE FIRST INTERNATIONAL BURDEN OF ILLNESS STUDY (ASSURE-CSU)
PSS57  O20  ASSESSMENT OF DENTAL STATUS AND PERCEPTION TOWARDS ORAL HEALTH AMONG PHARMACY STUDENTS IN QUETTA, PAKISTAN
ul Haq N, Iqbal Q, Nasim A, Riaz S, Haque N, Akram A, University of Balochistan, Quetta, Pakistan

PSS58  O21  CHARACTERISTICS OF ACNE VULGARIS IN EUROPEAN ADOLESCENTS AND PATIENTS PERCEPTIONS
Delarue A, Zik A, Berdeaux G,1 Pierre Fabre DermatoCosmétique, Lavaur, France, 2Pierre Fabre, Boulogne Billancourt, France

PSS59  P1  IMPACT OF ALEXITHYMA AND DISEASE CHARACTERISTICS ON WORK PRODUCTIVITY AND ACTIVITY IN PSORIASIS PATIENTS WITH SHORT DISEASE DURATION: EPIDESP MULTICENTRE STUDY
Paul C,1 Girolomoni G,2 Radtke MA,2 Sampogna F,3 Spuls P,4 Kirby B,5 Brunoni M,5 Smirnov P,5 Bergmans P,5 Rundle J,5 Lavie F,5 Puig L,1,15 Paul Sabatier University, Toulouse, France, 2Université de Verona, Verona, Italy, 3Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany, 4Istituto Dermopatico dell'Immacolata, Rome, Italy, 5Academic Medical Centre, University of Amsterdam, Amsterdam Zuid-Oost, The Netherlands, 6St Vincent's University Hospital, Dublin, Ireland, 7Janssen, Issy les Moulineaux, France, 8Janssen Pharmaceutica NV, Moscow, Russia, 9Janssen-Cilag B.V., LT Tilburg, The Netherlands, 10Janssen-Cilag Ltd, High Wycombe, Buckinghamshire, UK, 11Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain

PSS60  P2  VALIDATION OF THE SPANISH VERSION OF THE URTICARIA ACTIVITY SCORE (UAS) AND ITS USE OVER ONE WEEK (UAS7)
Balaná M,1 Valero A,1 Giménez-Arnau A,2 Ferrer M,2 Jauregui I,1 Ballesteros C,1 on behalf of the study group of EVALUAS,1 Novartis Farmacéutica S.A., Barcelona, Spain, 2Hospital Clinic, Barcelona, Spain, 3Hospital Mar, Barcelona, Spain, 4Clínica Universitaria de Navarra, Pamplona, Spain, 5Hospital de Basurto, Bilbao, Spain

PSS61  P3  SOCIAL IMPACT OF PSORIASIS IN SPAIN: A RASCH ANALYSIS FROM A SURVEY
Gonzalez-de Paz L,1 Ribera M,2 Gracitacos-Masmijia J,2 Ros S,2 Blanch-Mur C,2 Alfonzo-Zamora S,9 Universitat Internacional de Catalunya, Sant Cugat del Vallés (Barcelona), Spain, 2Hospital Universitari de Sabadell-Corporació Parc Taulí, Sabadell, (Barcelona), Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Novartis Farmacéutica, Barcelona, Spain, 5Acción Psoriasis, Barcelona, Spain

PSS62  P4  IMPROVED VISUAL FUNCTION IS ASSOCIATED WITH INFLAMMATION REDUCTION IN SUBJECTS WITH NON-INFECTIONOUS UVEITIS (NIU) OF THE POSTERIOR SEGMENT TREATED WITH INTRAVITREAL SIROLIMUS: RESULTS FROM SAKURA STUDY 1
Lescaauwaet B,1 Duchateau L,1 Verstraeten T,1 Therau S,1 Xintera Ltd., London, UK, 2Ghent University, Merelbeke, Belgium, 3P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium, 4Ludwig-Maximilians-Universität München, Munich, Germany

PSS63  P5  REVIEW OF PATIENT REPORTED OUTCOMES IN GLAUCOMA
Aggarwal S,1 Kumar S,2 Topaloglu H,1 NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PSS64  P6  BURDEN OF INFANTILE HEMANGIOMA ON FAMILY: AN INTERNATIONAL CROSS-SECTIONAL STUDY
Delarue A,1 Zik A,2 Berdeaux G,2 Pierre Fabre DermatoCosmétique, Lavaur, France, 2Pierre Fabre, Boulogne Billancourt, France

PSS65  P7  QUALITY OF LIFE AND PERSPECTIVES OF HAPPINESS IN MIDDLE-AGED AND OLDER PEOPLE WITH DYSPHAGIA
Naito M,1 Suzukamo Y,2 Fuji W,2 Seto H,3 Murata K,3 Naito T,4 Kikutani T,5 Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Tohoku University, Sendai, Japan, 3Kyushu Dental University, Kitakyushu, Japan, 4South Miyagi Medical Center, Shibata-gun, Japan, 5Iizuka City Hospital, Iizuka, Japan, 6Fukuoka Dental College, Fukuoka, Japan, 7Nippon Dental University Graduate School of Life Dentistry at Tokyo, Tokyo, Japan

PSS66  P8  THE VALUE OF ACHIEVING COMPLETE OR NEAR COMPLETE RESOLUTION OF PSORIASIS
Edson-Heredia E,1 Barrows S,2 Masaquel C,2 Nikai E,2 Mallbris L,1 Puig L,3 Eli Lilly and Company, Indianapolis, IN, USA, 2RTI Health Solutions, Ann Arbor, MI, USA, 3Eli Lilly and Company, Brussels, Belgium, 4Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain

PSS67  P9  DOES HEALTH-RELATED QUALITY OF LIFE EVALUATION IN PSORIASIS MATTER? A REVIEW OF LABELS OF PSORIASIS PRODUCTS APPROVED BY THE FDA AND THE EMA
Acquando C,1 Perret C,2 Arnould B,3 Mapi Research Trust, Lyon, France, 2Patient-Centered Outcomes - Mapi, Lyon, France

PSS68  P10  WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA PATIENTS: RESULTS FROM THE FIRST INTERNATIONAL BURDEN OF ILLNESS STUDY (ASSURE-CSU)
Bap M,1 Chambenoit O,2 Chiva-Razavi S,2 Lynde C,3 Sussman G,1 Chapman-Rothe N,2 Weller K,6 Maurer M,6 Koenders J,7 Knust AC,8 Halliday A,7 Alexopoulos ST,9 Nakonechna A,10 Grattan C,11 Abouzakouk M,10 Sweeney C,12 Radder C,12 Wolin D,13 McBride D,14 Hollis K,12 Tian H,15 Elberink J,16 Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Lynxmed Research Inc., Toronto, ON, Canada, 4St Michael's Hospital, University of Toronto, Toronto, ON, Canada, 5Novartis Pharma GmbH, Nuernberg, Germany, 6Charité - Universitätsmedizin Berlin, Berlin, Germany, 7Novartis Pharma B.V., Arnhem, The Netherlands, 8University Medical Center Utrecht, Utrecht, The Netherlands, 9Novartis Pharmaceuticals UK Limited, Surrey, UK, 10Hull and East Yorkshire NHS Hospital Trust, Hull, UK, 11Norfolk and Norwich University Hospital, Norwich, UK, 12RTI Health Solutions, Research Triangle Park, NC, USA, 13RTI Health Solutions, Ann Arbor, MI, USA, 14RTI Health
SENSORY SYSTEMS DISORDERS - Health Care Use & Policy Studies

**PSS69 P11** PATIENT DIAGNOSTIC THERAPEUTIC PATHWAY FOR PATIENTS WITH PSORIASIS: THE ORGANISATIONAL ANALYSIS OF 13 EXCELLENCE CENTRES OF THE TUSCANY REGION (ITALY)
Cannizzo S, Palla I, Turchetti G, Scuola Superiore Sant'Anna, Pisa, Italy

**PSS70 P12** REAL-WORLD TREATMENT PATTERNS OF RANIBIZUMAB AMONG PATIENTS WITH RETINAL DISEASES IN CANADA: 5 YEARS OF DATA
Rousseau C, Saad R, Davies B, Zaour N, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

**PSS71 P13** NATIONWIDE TREND ANALYSIS OF TARGETED THERAPIES FOR TREATMENT OF MALIGNANT NEOPLASMS OF THE EYE IN TAIWAN (2009-2016)
Hsu JC¹, Gonzalez-Gonzalez L², Lu V³, Lu CY⁴, National Cheng Kung University, Tainan, Taiwan, ²Harvard Medical School, Boston, MA, USA, ³Sydney Eye Hospital, Chatswood, Australia

**PSS73 P14** PRICE FLUCTUATIONS ACROSS LIFECYCLE: INSIGHTS FROM THE ANTI-VEGF MARKET
Chriv E, Carr DR, Anastasaki E, Bradshaw SE, Market Access Solutions Ltd, London, UK

**PSS74 P15** GLAUCOMA: HIGHLIGHT MOLECULES USED IN PATIENTS FROM SUPPLEMENTARY HEALTH IN BRAZIL
Marra FC, Montezani E, Dapx Intelligence for Healthcare, São Paulo, Brazil

**PSS75 P16** TREATMENT OF MACULAR EDEMA: WHAT'S NEW? EVIDENCE FROM AN HTA STUDY COMPARING RANIBIZUMAB AND DEXAMETHASONE IMPLANT
Ferrario L¹, Foglia E¹, Bandello F¹, Ferri C¹, Figini î, Franzin M², Gambaro G³, Introini U⁴, Medaglia M⁵, Staurenghi G⁶, Tadini P⁷, Croce D⁸, LIUC University, Castellanza, Italy, ²Scientific Institute San Raffaele, Milano, Italy, ³Valduce Hospital Como, Como, Italy, ⁴Hospital Authority L. Sacco, Milano, Italy, ⁵University of the Witwatersrand, Johannesburg, South Africa

**PSS76 P17** SELECTIVE RETINA THERAPY
MO J, National Evidence-based Healthcare Collaborating Agency, SEOUL, South Korea

**PSS77 P18** REAL WORLD SKIN CLEARANCE RATES FOR BIOLOGIC TREATMENTS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: INTERIM RESULTS FROM A LARGE PROSPECTIVE, OBSERVATIONAL STUDY
Paul C¹, Bewley A², Girolomoni G³, Reich K⁴, Puig L⁵, Lacour JP⁶, Augustin M⁷, Naldi L⁸, Menter AM⁹, Wade S¹⁰, Viswanathan HN¹¹, Palmer K¹², Klekotka P¹¹, Woolley JM¹², Paul Sabatier University, Toulouse, France, ²Whipps Cross University Hospital & the Royal London Hospital, London, UK, ³Università di Verona, Verona, Italy, ⁴Dermatologikum Hamburg, Hamburg, Germany, ⁵Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain, ⁶CHU de Nice - Hôpital l'Archet 2, NICE CEDEX 3, France, ⁷University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁸Centro Studi GISED, Bergamo, Italy, ⁹Texas Dermatology Associates, Dallas, TX, USA, ¹⁰Wade Outcomes and Research Consulting, Salt Lake City, UT, USA, ¹¹Amgen Inc., Thousand Oaks, CA, CA, USA, ¹²Amgen Inc., South San Francisco, CA, USA
RESEARCH POSTER PRESENTATIONS - SESSION II

CANCER - Clinical Outcomes Studies

PCN1 A1 PROSPECTIVE STUDY OF RADIATION RELATED ADVERSE EVENTS AND ITS MANAGEMENT IN CANCER PATIENTS— A PILOT STUDY
Himanshu Patel 1, Acsahe Annie P1, Rajesh H1, Baharul l1, Madhavi Y2, Parthasarathi G3, JSS College of Pharmacy, Mysore, JSS University, Mysore, India, Mysore, India, 2Bharath Hospital & Institute of Oncology, Mysore, India

PCN2 A2 ADVERSE EVENTS COSTS ASSOCIATED WITH ERLOTINIB OR AFATINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR MUTATION POSITIVE TUMOURS
Isla D1, De Castro J2, Juan Vidal O3, Grau S4, Orofino J5, Gordo R6, Rubio-Terrés C7, Rubio-Rodriguez D8, 1Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 2Hospital Universitario La Paz, MADRID, Spain, 3Hospital Universitari i Politècnic La Fe, VALENCIA, Spain, 4Hospital del Mar (IMIM), Barcelona, Spain, 5Roche Farma, Madrid, Spain, 6Health Value, Madrid, Spain

PCN3 A3 PHARMACOVIGILANCE OF ANTI-NEOPLASTIC AGENTS IN A DEVELOPING COUNTRY---A REPORT THROUGH A SPONTANEOUS REPORTING & CONTINUOUS MONITORING SYSTEM
Himanshu Patel , Parthasarathi G, Ramesh M, JSS College of Pharmacy, Mysore, JSS University, Mysore, India, Mysore, India

PCN4 A4 ASSESSMENT OF SERIOUS ADVERSE REACTIONS AMONG PATIENTS ON TYROSINE KINASE INHIBITORS: IDENTIFICATION OF SIGNIFICANT SIGNALS FOR GASTROINTESTINAL HEMORRHAGE AND PULMONARY REACTIONS
Raisch DW1, Chen C2, Arabyat R2, Rafi JA3, Bennett CL4, University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 2University of South Carolina College of Pharmacy, Columbia, SC, USA

PCN5 A5 FACTORS INFLUENCING TREATMENT DURATION IN METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH ZIV-AFLIBERCEPT: A REAL WORLD VIEW
Craver CW1, Belk K1, Blanchette CM2, MedAssets, Mooresville, NC, USA, 2University of North Carolina at Charlotte, Charlotte, NC, USA

PCN6 A6 EFFICACY AND SAFETY PROFILE OF COMBINED TARGETED THERAPY AGAINST EGFR AND VEGF IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON–SMALL-CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Rai MK1, Goyal R, Bhutani MK, Kaneria J, Mahendru K, Sharma N, Tata Consultancy Services, Mumbai, India

PCN7 A7 A SYSTEMATIC REVIEW TO ASSESS THE ASSOCIATION BETWEEN THE USE OF ANTIDEPRESSANTS AND MALE-ONLY CANCERS
Gupta J1, Sehgal M2, PAREXEL International, New Delhi, India, 2PAREXEL International, Chandigarh, India

PCN8 A8 SERIOUS POST-OPERATIVE INFECTIONS INCREASE RESOURCE UTILIZATION, LENGTH OF STAY, AND INPATIENT MORTALITY IN PEDIATRIC PATIENTS UNDERGOING BRAIN TUMOR RESECTION
Van Doren BA1, Noone J2, Odum SM, Huet YM, University of North Carolina at Charlotte, Charlotte, NC, USA

PCN9 A9 CHANGES IN THE MORTALITY RATE DURING THE LAST DECADE IN THE FIELDS OF ONCOLOGY IN HUNGARY
Balázs T1, Rakonczai P, Frigyesy R, Bacskaı M, Healthcare Consulting Ltd., Budapest, Hungary

PCN10 A10 PREVALENCE OF DEPRESSION AND ANXIETY AND THEIR RISK FACTORS IN WOMEN WITH BREAST CANCER IN GERMAN PRIMARY CARE
Engelhard J1, Bleicher L2, Kostev K1, 1IMS Health, Frankfurt am Main, Germany, 2University Clinic of Marburg, Marburg, Germany

PCN11 A11 THE EFFECT OF GLUCOSE LOWERING DRUG USE ON OVERALL MORTALITY AMONG BREAST CANCER PATIENTS
Vissers PA1, Zanders MM2, Voogd AC3, van Herk-Sukel MP4, Ruiter R5, Hollestein LM6, Herings RM7, Stricker BH8, van de Poll-Franse LV9, Tilburg University, Tilburg, The Netherlands, 2Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 3Maastricht University, Maastricht, The Netherlands, 4PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 5Erasmus Medical Center, Rotterdam, The Netherlands

PCN12 A12 MORTALITY REDUCTION FROM GASTRIC CANCER BY ENDOSCOPIC SCREENING: 6-YEARS FOLLOW-UP OF A POPULATION-BASED COHORT STUDY
Hamashima C1, Shabana M2, Okada K3, Okamoto M4, Osaki Y5, National Cancer Center, Tokyo, Japan, 2San-in Rosai Hospital, Yonago, Japan, 3Tottori East Medical Association, Tottori, Japan, 4Tottori University, Yonago, Japan

PCN13 A13 THERAPY OF DEPRESSION IN CANCER AND NON-CANCER PATIENTS IN GERMAN NEUROPSYCHIATRIC PRACTICES
Ziegelbauer K, Engelhard J, Kostev K,IMS Health, Frankfurt am Main, Germany

PCN14 A14 LONG-TERM TRENDS IN DESCRIPTIVE EPIDEMIOLOGY OF MALIGNANT MELANOMA IN THE SLOVAK REPUBLIC
Ondrusova M, Psenkova M, Suchansky M, Pharm-In Ltd, Bratislava, Slovak Republic
PCN15 A15 PATTERNS OF METACHRONOUS METASTASES AFTER CURATIVE TREATMENT OF BREAST CANCER

Kuiper JG1, van Herk-Sukel MP1, van Gestel YR2, Voogd AC1, Lemmens VE1, Siesling S3, PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Comprehensive Cancer Centre the Netherlands (IKNL), Eindhoven, The Netherlands, 3Maastricht University, Maastricht, The Netherlands, 4Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 5Comprehensive Cancer Centre the Netherlands (IKNL), Enschede, The Netherlands

PCN16 A16 TREATMENT STRATEGIES FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A META-ANALYSIS AND INDIRECT TREATMENT COMPARISON

Buchberger M1, Roachu U2, Vukicevic D1, Willenbacher W1, Siebert U1, UMIT - University for Health Sciences, Medical Informatics and Technology, Dept. of Public Health & HTA, Hall in Tyrol, Austria, 2UMIT - University for Health Sciences, Medical Informatics and Technology, Dept. of Public Health & HTA/ ONCOTYROL - Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria, 3ONCOTYROL - Center for Personalized Cancer Medicine/ Medical University Innsbruck, Innsbruck, Austria, 4Department of Health Policy & Management, Harvard Medical School, Institute for Technology Assessment & Department of Radiology, Hall i.T., Austria

PCN17 A17 BAYESIAN NETWORK META-ANALYSIS TO ASSESS RELATIVE EFFICACY OF IBRUTINIB VERSUS IDEALISI+OFATUMUMAB AND PHYSICIAN’S CHOICE IN RELAPSED/REFRACTORY CLL PATIENTS

Diels J1, van Sanden S2, Janssen Research & Development, Beersel, Belgium, 2Janssen EMEA, Beersel, Belgium

PCN18 A18 ASSESSMENT OF MAJOR MOLECULAR RESPONSE (MMR) AND COMPLETE CYTOGENETIC RESPONSE (CCyR) AS SURROGATE OUTCOMES OF SURVIVAL IN CHRONIC MYELOID LEUKEMIA CHRONIC PHASE (CML-CP) PATIENTS

Kwon H1, Park J1, Shin M1, Shin S1, National Evidence based Health-care Collaborating Agency, Seoul, South Korea

PCN19 A19 COMPARISON OF TREATMENT DURATION AMONG TARGETED AGENTS IN RENAL CELL CARCINOMA (RCC)

Feinberg BA1, Bohr M1, Drenning J2, Garofalo DF1, Montgomery J2, 1Cardinal Health, Dublin, OH, USA, 2Cardinal Health, Dallas, TX, USA

PCN20 A20 EVALUATION OF PATTERNS OF CARE IN RENAL CELL CARCINOMA (RCC): HIGH UNMET NEED PERSISTS

Feinberg BA1, Bohr M1, Drenning J2, Garofalo DF1, Montgomery J2, 1Cardinal Health, Dublin, OH, USA, 2Cardinal Health, Dallas, TX, USA

PCN21 A21 OVERALL SURVIVAL (OS), QUALITY OF LIFE (QOL), AND NEUROCOGNITIVE FUNCTION (NF) IN RECURRENT GlioBlastoma Multiforme (GBM): A SYSTEMATIC LITERATURE REVIEW

Signorovitch J1, Li N1, Ohashi E1, Dastani H5, Shaw J1, Orsini L2, 1Analysis Group, Inc., Boston, MA, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA

PCN22 A22 COMPARATIVE EFFICACY OF IMATINIB, DASATINIB AND Nilotinib FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): A META-ANALYSIS AND INDIRECT COMPARISON

Park J1, Kwon H1, Shin M1, Shin S1, Lee JY1, National Evidence based Health-care Collaborating Agency, Seoul, South Korea

PCN23 A23 EFFECTS OF LIFESTYLE INTERVENTIONS ON BODY MASS INDEX IN BREAST CANCER PATIENTS

Ghavami H1, Akyolcu N1, Nursing Faculty of Urmia Medical Sciences University, Urmia, Iran, 2Florence Nightingale Nursing Faculty of Istanbul University, Istanbul, Turkey

PCN24 A24 CLINICAL EFFECTIVENESS AND SAFETY OF ROBOT-ASSISTED LAPAROSCOPIC HYSTERECTOMY VERSUS TRADITIONAL LAPAROTOMY FOR ENDOMETRIAL CANCER: A SYSTEMATIC REVIEW

Park D1, National Evidence-based Collaborating Agency, Seoul, South Korea

PCN25 A25 OVERALL SURVIVAL (OS) AND QUALITY-OF-LIFE (QOL) OUTCOMES IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): A SYSTEMATIC LITERATURE REVIEW

Signorovitch J1, Li N1, Zhong Y1, Shaw J1, Dastani H5, Orsini L2, 1Analysis Group, Inc., Boston, MA, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA

PCN26 A26 LIPEGFILGRASTIM FOR REDUCTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA RELATED EVENTS: A META-ANALYSIS

Bond TC1, Mueller U2, Barnes G3, Gennaro R3, Tang B3, Schwartzberg L5, 1Covance Market Access, Gaithersburg, MD, USA, 2Teva Pharmaceutical, Ulm, Germany, 3Teva Pharmaceutical, Frazer, PA, USA, 4Global Health Economics and Outcomes Research – Growth Markets, Miami, FL, USA, 5The West Clinic, Memphis, TN, USA

PCN27 A27 COMPARATIVE EFFECTIVENESS OF GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF) FOR REDUCING INCIDENCE OF FEBRILE NEUTROPENIA (FN) –RELATED HOSPITALIZATION: A RETROSPECTIVE COHORT STUDY USING GERMAN CLAIMS DATA

Wetten S1, Li X2, Haas J1, Worth G2, Jacob C2, Braun S3, Tzivelekis S2, 1Amgen Ltd, Uxbridge, UK, 2Amgen Inc, Thousand Oaks, CA, USA, 3Xcenda GmbH, Hannover, Germany, 4Amgen Ltd, Zug, Switzerland

PCN28 A28 ANALYSIS OF ERIFULIN MESYLATE DOSING MODIFICATIONS IMPACT ON ADMINISTRATION PERSISTENCE IN PATIENTS WITH METASTATIC BREAST CANCER (MBC)

Feinberg BA1, Drenning J2, Garofalo DF1, Lal L3, Montgomery J2, 1Cardinal Health, Dublin, OH, USA, 2Cardinal Health, Dallas, TX, USA, 3Cardinal Health, Missouri City, TX, USA

PCN29 A29 A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY AND COMPARE CLINICAL TRIALS EVALUATING NOVEL THERAPEUTIC AGENTS IN POST-GEMCITABINE ADVANCED PanCREATIC CANCER
A REAL-WORLD ANALYSIS OF KOREAN NATION-WIDE DATABASE: PATTERN, ADHERENCE, AND ASSOCIATED HEALTHCARE COSTS OF IMATINIB AMONG PATIENTS WITH CHRONIC MYELOID LEUKEMIA
Shin S, Lee J, Kim J, Shin M, Kwon H, National Evidence based Health-care Collaborating Agency, Seoul, South Korea, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea

ERLOTINIB PLUS GEMCITABINE COMPARED WITH GEMCITABINE MONOTHERAPY IN PATIENTS WITH PANCREATIC CANCER: A REAL-WORLD ANALYSIS OF KOREAN NATION-WIDE DATABASE

THE RELATIVE EFFICACY AND SAFETY OF TREATMENTS IN SECOND-LINE MANAGEMENT OF CHRONIC MYELOID LEUKAEMLIA: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS FEASIBILITY STUDY

MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON AND SURVIVAL EXTRAPOLATION IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-REFRACTORY DTC): UPDATED ANALYSIS

A DESCRIPTION OF REAL-WORLD TREATMENT WITH ABRIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN THE POST-CHEMOTHERAPY SETTING IN FRANCE AND THE NETHERLANDS

REAL-WORLD ANALYSIS OF TYROSIN KINASE INHIBITOR TREATEMENT PATTERNS AMONG PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN KOREA

NEW DRUGS IN ADVANCED MELANOMA: DISPARITIES IN REQUIREMENTS FOR POST-LAUNCH REAL-WORLD EVIDENCE IN EUROPE
Langham J, Floyd D, PHMR Ltd, London, UK

NEW DRUGS IN NON-SMALL CELL LUNG CANCER: DISPARITIES IN REQUIREMENTS FOR POST-LAUNCH REAL-WORLD EVIDENCE IN EUROPE
Floyd D, Langham J, PHMR Ltd, London, UK

SYMPTOMS, CONCOMITANT CONDITIONS AND CARDIAC RISK IN EUROPEAN HYDROXYUREA TREATED POLYCYTHEMIA VERA PATIENTS

ASSESSING THE LEVEL OF RESISTANCE/INTOLERANCE TO HYDROXYUREA THERAPY AMONGST PATIENTS WITH POLYCYTHEMIA VERA IN EUROPE

THE IMPACT OF FIRST-LINE TYROSINE KINASE INHIBITORS (TKIS) ON OVERALL SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS: META-ANALYSIS OF MAJOR RANDOMIZED TRIALS BY MUTATION TYPE
Kato T, De Marinis F, Spicer J, Sebastian M, Griebsch I, Märtén A, Lungenhaus J, Shah R, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan, European Institute of Oncology, Milan, Italy, King’s College London, London, UK, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany, Boehringer Ingelheim GmbH, Ingelheim, Germany, Maidstone and Tunbridge Wells NHS Trust, Kent, UK

COMPARATIVE EFFICACY OF TREATMENTS FOR PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A NETWORK META-ANALYSIS
Zhang J, Zhou Z, Cai X, Signorovitch J, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Analysis Group, New York, NY, USA, Analysis Group, Boston, MA, USA

SURVIVAL AND COST AMONG PHOTODYNAMIC THERAPY PATIENTS WITH NON-SMALL CELL LUNG CANCER
Jayadevappa R, Chhatre S, University of Pennsylvania, Philadelphia, PA, USA

EFFECTS OF NUTRITIONAL SUPPLEMENT USAGE ON MORTALITY IN COLORECTAL CANCER PATIENT WITH ABDOMINAL RESECTION SURGERY
Gulkan S1, Berktaš M2, Tezcan ES3, Dogukan MN1, Ozkan O1, Koksal I1, Social Security Institute, Ankara, Turkey, 1Yeditepe University, Istanbul, Turkey

PCN44 B11 A CROSS-SECTIONAL EPIDEMIOLOGICAL CANCER REGISTRY IN EGYPT
Elshikh EA1, Anan I2, Ebaid AA1, Al Gamal DA1, Hamed MM2, Mouein EA2, Metry AB1, Tanta Cancer Center, Tanta, Egypt, 2Accsight, Cairo, Egypt

PCN45 B12 IMPACT OF CANCER DIAGNOSIS AND TREATMENT ON GLYCAEMIC CONTROL AMONG INDIVIDUALS WITH COLORECTAL CANCER USING GLUCOSE LOWERING DRUGS
Zanders MM1, van Herk-Sukel MP2, Herings RM1, van de Poll-Franse LV1, Haak H1, Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 2PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 3Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 4Maxima Medical Center, Veldhoven, The Netherlands

PCN46 B13 THE TREATMENT PATTERNS OF CASTRATION RESISTANT PROSTATE CANCER IN JAPAN
Uemura H1, DiBonaventura MD2, Wang EC2, Ledesma D1, Concialdi K1, Atoku Y2, Yokohama City University Medical Center, Yokohama-city, Japan, 2Kantar Health, New York, NY, USA, 3Bayer Healthcare, Whippany, NJ, USA, 4Bayer Yakuhin, Osaka, Japan

PCN47 B14 USE PATTERN NARCOTIC ANALGESICS FOR CANCER PATIENT IN SOUTH KOREA : CLAIMS DATA ANALYSIS
Hyun M1, Dongguk University, Gyeongju-si, South Korea

PCN48 B15 CHANGES IN GLUCOSE LOWERING DRUG USE BEFORE AND AFTER A CANCER DIAGNOSIS AMONG INDIVIDUALS WITH DIABETES
Zanders MM1, Haak H1, van Herk-Sukel MP1, Herings RM1, van de Poll-Franse LV1, Johnson J1, Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 2Maxima Medical Center, Veldhoven, The Netherlands, 3PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 4Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 5School of Public Health, University of Alberta, Edmonton, AB, Canada

Stott-Miller M1, Vlahiotis A1, Palmer LA1, 2Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Bethesda, MD, USA

PCN50 B17 SYSTEMATIC REVIEW OF BURDEN OF CUTANEOUS T-CELL LYMPHOMA
Aggarwal S1, Topaloglu H1, Kumar S2, NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PCN51 B18 EVOLUTION OF THE NUMBER OF PATIENTS TREATED FOR METASTATIC CANCER BETWEEN 2003 AND 2013 IN FRANCE
Flinos A, Bonneyle G, Chabeneda H, Kantar Health, Montrouge, France

PCN52 B19 PREVALENCE AND RISK FACTORS OF SKIN CANCER IN MEXICO: AN OBSERVATIONAL STUDY
Zikl A1, Berdeaux G1, Pierre Fabre, Boulogne Billancourt, France

PCN53 B20 PATIENT CHARACTERISTICS AND HEALTHCARE BURDEN OF CANCER HOSPITALIZATIONS IN THE UNITED STATES
Shah S1, Rice B1, Blanchette CM1, 1University of North Carolina at Charlotte, Charlotte, NC, USA, 2Precision For Medicine, New York, NY, USA

PCN54 B21 ASSESSMENT OF RENAL FUNCTION AMONG PATIENTS WITH BONE METASTASES FROM SOLID TUMORS
Qian Y1, Bhowmik D2, Bond TC1, Wang X1, Colman S1, Aagen Inc, Thousand Oaks, CA, USA, 2Covance Market Access, Gaithersburg, MD, USA, 3Covance Pty Ltd, North Ryde, Australia

PCN55 B22 EPIDEMIOLOGY AND TREATMENT OF SOFT TISSUE SARCOMA IN THE EU5
Robinson D, Nersesyan K, Pomerantz D, Kantar Health, Horsham, PA, USA

PCN56 B23 SYSTEMATIC REVIEW OF BURDEN OF PANCREATIC CANCER
Aggarwal S1, Topaloglu H1, Kumar S2, NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PCN57 B24 THE EFFECT OF METFORMIN USE AND MORTALITY AMONG THOSE WITH PANCREATIC CANCER AND TYPE 2 DIABETES MELLITUS: FINDINGS FROM A NATIONWIDE POPULATION RETROSPECTIVE COHORT STUDY
Jo A1, Kim Y1, Kang S1, Kim M1, Ko M1, National Evidence Based Health-care Collaborating Agency, Seoul, South Korea, 2Korea Institute of Radiological & Medical Sciences, Seoul, South Korea

PCN58 B25 STATINS USE AND THE RISK OF HEMATOLOGICAL AND NON-HEMATOLOGICAL MALIGNANCIES: A META-ANALYSIS OF 53 OBSERVATIONAL STUDIES
Bhutani MK, Rai MK, Kaneria J, Goyal R, Kumar R, Raute L, Tata Consultancy Services, Mumbai, India

PCN59 B26 ADJUSTING FOR CROSS-OVER IN ONCOLOGY TRIALS: APPROACHES TAKEN TO SUPPORT DRUG REIMBURSEMENT IN AUSTRALIA
O'Leary BA1, Gordois AL1, McElroy H2, Covance Market Access Services Inc., Sydney, Australia, 2Covance (Asia) Pte Ltd, Singapore, Singapore

PCN60 B27 SAFETY AND INSURANCE PREMIUM IMPLICATIONS FOR HOSPITALS BASED ON SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF ONCOLOGY / HEMATOLOGY THERAPIES: CASE STUDIES WITH
**RITUXIMAB (MABTHERA) AND TRASTUZUMAB (HERCEPTIN)**


**PCN61 B28 ASSOCIATIONS OF METFORMIN USE WITH MORTALITY AND DISEASE PROGRESSION AFTER CURATIVE HEPATIC RESECTION IN HEPATOCELLULAR CARCINOMA WITH TYPE 2 DIABETES MELLITUS: A NATIONAL POPULATION-BASED STUDY**


**PCN62 B29 IMPROVED SURVIVAL WITH IPILMUMAB IN PATIENTS WITH ADVANCED MELANOMA IN REAL-WORLD CLINICAL PRACTICE: FIRST RESULTS OF THE DUTCH MELANOMA TREATMENT REGISTRY**

Leeneman B, Franken MG, Jochems A, Schouwenburg MG, Wouters MW, Van den Eertwegh AJ, Haanen JB, Van der Hoeven KJ, Uyl - de Groot CA, 1Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands, 3Leiden University Medical Center, Leiden, The Netherlands, 4Dutch Institute for Clinical Auditing, Deventer, The Netherlands, 5Netherlands Cancer Institute, Amsterdam, The Netherlands, 6VU University Medical Center, Amsterdam, The Netherlands

**PCN63 B30 WHEN “ALIVE AFTER 5 YEARS” DOES NOT MEAN “CURED”: INTERNATIONAL PATTERNS IN CANCER 10- TO 20-YEAR RELATIVE SURVIVAL RATES**

Martin A, Martin C, Crystallise Ltd., London, UK

**PCN64 B31 IMPROVED SURVIVAL IN PATIENTS WITH ADVANCED MELANOMA IN REAL-WORLD CLINICAL PRACTICE: FIRST RESULTS OF THE DUTCH MELANOMA TREATMENT REGISTRY**

Leeneman B, Franken MG, Jochems A, Schouwenburg MG, Wouters MW, Van den Eertwegh AJ, Haanen JB, Van der Hoeven KJ, Uyl - de Groot CA, 1Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands, 3Leiden University Medical Center, Leiden, The Netherlands, 4Dutch Institute for Clinical Auditing, Deventer, The Netherlands, 5Netherlands Cancer Institute, Amsterdam, The Netherlands, 6VU University Medical Center, Amsterdam, The Netherlands

**PCN65 B32 MORTALITY TRENDS IN CANCERS: A NEW MODEL TO VISUALISE THE CONTRIBUTION OF SPECIFIC DISEASES, COHORTS AND CODING CHANGES TO OVERALL MORTALITY IMPROVEMENT**

Martin C, Martin A, Crystallise Ltd., London, UK

**PCN66 B33 EVALUATION OF ‘REAL-WORLD’ IPILMUMAB DATA IN IRELAND**

McCullagh LM, Adams R, Barry M, Schmitz S, Walsh C, National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 3University of Limerick, Limerick, Ireland

**PCN67 C1 RETROSPECTIVE COMPARISON OF REAL-LIFE SURVIVAL DATA FROM SINGLE CENTRE TRIALS - THE CLINICAL OUTCOME OF VEMURAFENIB THERAPY IN METASTATIC MELANOMA PATIENTS**

Ponczey E, Czirbesz K, Toth E, Liszakay G, Boncz i, National Institute of Oncology, Budapest, Hungary, 1University of Pecs, Pecs, Hungary

**CANCER - Cost Studies**

**PCN68 C2 THE BUDGET IMPACT OF DENOSUMAB IN THE TREATMENT OF GIANT CELL TUMOR OF THE BONE (GCTB) IN BELGIUM**


**PCN69 C3 BUDGET IMPACT ANALYSIS OF DASATINIB AS A SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE RUSSIAN FEDERATION**

Kulikov A, Yagudina S, Protsenko MV, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

**PCN70 C4 RADIO-223 IN THE TREATMENT OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER WITH BONE METASTASES: BUDGET IMPACT ANALYSIS OF THE NATIONAL HEALTH SERVICE**

Di Matteo S, Valentino MC, Bruno GM, Colombo GL, S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy, 1University of Pavia, Milan, Italy

**PCN71 C5 ECONOMIC IMPACT OF THE DETECTION OF MEDICATION ERRORS IN ONCOLOGICAL PATIENTS WITH AFEBRILE NEUTROPENIA IN A CANCER HOSPITAL**

Hernández Martínez JF, Morales Perez M, Colin Gómez DP, Paredes García P, Toledo Vigueras I, Gutierrez García M, Toledo Vigueras E, Patricio Linero F, Sánchez Rodríguez I, Centro Oncológico Estatal, ISSEMyM, Toluca, Mexico, HS Estudios Farmacoeconómicos S.A. de C.V, Mexico City, Mexico

**PCN72 C6 WHAT IS THE MOST COST-EFFECTIVE WAY TO SET-UP ORGANISED CERVICAL CANCER SCREENING IN FRANCE? A BUDGET IMPACT ANALYSIS**

Massetti M, Leleu H, De Bels F, Barre S, 1PUBLIC HEALTH EXPERTISE, Paris, France, 2French Cancer Institut, Bourgogne, France

**PCN73 C7 BUDGET IMPACT ANALYSIS FOR PHARMACOLOGICAL THERAPY OF CHRONIC MYELOID LEUKEMIA (CML) WITH NILOTINIB AS THE SECOND-LINE TREATMENT IN RUSSIAN FEDERATION**

Serpik VG, Yagudina R, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
PCN74 C8 PHARMACOECONOMIC ANALYSIS OF THE USE OF EVEROLIMUS COMPARED TO AXITINIB IN SECOND LINE THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Kolbin A1, Frolov M2, Kurylev A1, Baltyskina Y3, Proskurin M1, First Pavlov State Medical University of St. Petersbourg, Saint Petersburg, Russia, Volgograd State Medical University, Volgograd, Russia, Saint Petersburg State University, Saint Petersburg, Russia

PCN75 C9 COST ANALYSIS IN IMPLEMENTING RITUXIMAB FOR NON-HODGKIN'S LYMPHOMA - INTRAVENOUSLY AND SUBCUTANEously - IN PATIENTS WITH SOCIAL COVERAGE IN LATAM
Renati L1, Najun Dubos L2, FASTA University, Mar Del Plata, Argentina, Roche Argentina, Buenos Aires, Argentina

PCN76 C10 AN ASSESSMENT OF ANNUAL COSTS OF PATIENTS HOSPITALIZED FOR SPINAL TUMORS IN FRANCE: ANALYSIS USING THE PMSI DATABASE
de Léotoing L1, Fernandes J1, Tournier C1, Jouaneton B1, Vainchtocht A3, HEVA, LYON, France, Oc-Santé, Montpellier, France, HEVA, Lyon, France

PCN77 C11 HEALTHCARE BURDEN AND ECONOMIC COST OF HOSPITALISATION DURING CHEMOTHERAPY FOR ADULT PATIENTS WITH PH-NEGATIVE B-PRECURSOR RELAPSED OR REFRACtory (R/R) acute lymphoblastic leukaemia (ALL) IN FRANCE
Dombret H1, Thomas X1, Chevallier P2, Nivot E3, Reitan J4, Barber BL5, Barlev A6, Mothy M1, Hôpital Saint-Louis, Paris, France, Hôpital Lyon-Sud, Lyon, France, CHU de Nantes, Nantes, France, Amgen, Boulogne, France, RJM Group, Crown Point, IN, USA, Amgen Inc, Thousand Oaks, CA, USA, Amgen Ltd, Thousand Oaks, CA, USA, Hôpital Saint-Antoine, Paris, France

PCN78 C12 RETROSPECTIVE CHART REVIEW OF HOSPITALISATIONS DURING CHEMOTHERAPY FOR ADULT PATIENTS WITH PH-NEGATIVE B-PRECURSOR RELAPSED OR REFRACtory (R/R) acute lymphoblastic leukaemia (ALL) IN ITALY
Pagano L1, Oberti M1, Esposito B3, Reitan J4, Barlev A6, Barber BL5, Ferrara F1, Università Cattolica del Sacro Cuore, Rome, Italy, Spedali Civili, Brescia, Italy, Amgen, Milan, Italy, RJM Group, Crown Point, IN, USA, Amgen Ltd, Thousand Oaks, CA, USA, Amgen Inc, Thousand Oaks, CA, USA, Cardarelli Hospital, Napoli, Italy

PCN79 C13 BUDGET IMPACT ANALYSIS OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TYROSINE KINASE INHIBITORS – NILOTINIB IN THE FIRST AND SECOND LINES OF THERAPY
Kolbin A1, Frolov M2, Kurylev A1, Vulim I1, Baltyskina Y3, Proskurin M1, First Pavlov State Medical University of St. Petersbourg, Saint Petersburg, Russia, Volgograd State Medical University, Volgograd, Russia, Saint Petersburg State University, Saint Petersburg, Russia

PCN80 C14 HOSPITALISATIONS AMONG ADULT PATIENTS WITH PH-NEGATIVE B-PRECURSOR RELAPSED OR REFRACtory (R/R) acute lymphoblastic leukaemia (ALL) RECEIVING CHEMOTHERAPY IN GERMANY: A RETROSPECTIVE CHART REVIEW
Kreuzer K1, Stuhlmann R2, Lebioda A1, Reitan J4, Barber BL5, Barlev A6, University of Cologne, Köln, Germany, Asklepios Hospital St Georg, Hamburg, Germany, Amgen, Munich, Germany, RJM Group, Crown Point, IN, USA, Amgen Ltd, Thousand Oaks, CA, USA, Amgen Inc, Thousand Oaks, CA, USA

PCN81 C15 PHARMACOECONOMIC ANALYSIS OF UROTHELIAL TRANSITIONAL CELL CANCER TREATMENT WITH VINFLUNINE IN PATIENTS RESISTANT TO THE PLATINUM-BASED TREATMENT REGIMES
Yagudina R1, Kulikov A, Rybchenko Y, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCN82 C16 PHARMACOECONOMIC ANALYSIS OF FERRIC CARBOXYMALTOSE IN PATIENTS WITH COLON CANCER AND ANEMIA
Ryazhnenov VV7, Gorokhova SG2, Maximkin SA3, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, Research Clinical Center of JSC Russian Railways, Moscow, Russia, Center for strategic research in healthcare, Moscow, Russia

PCN83 C17 RITUXIMAB SC VS RITUXIMAB IV FOR NON-HODGKIN'S LYMPHOMAS (NHLS): AN ECONOMIC EVALUATION FOR THE GREEK HEALTHCARE SYSTEM
Athanassakis K1, Papageorgiou L2, Tsiantou V3, Petropoulou A4, Boubouchairiopoulu N1, Tarantilis F1, Theodoropoulou F2, Kyriopoulos J1, National School of Public Health, Athens, Greece, Roche Hellas, Athens, Greece

PCN84 C18 DO PAYERS EQUALLY VALUE THE COST PER MONTH OF OVERALL SURVIVAL FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER WITHIN THE EU?
Foxon G1, Fox G1, Craddy P2, Remap Consulting, Cheshire, UK, Remap Consulting, Bern, Switzerland

PCN85 C19 PHARMACEUTICAL CHARACTERISTICS OF DIFFERENT STRATEGIES OF HEMOSTASIS DURING EXTENSIVE HEPATECTOMY
Ryazhnenov VV7, Maximkin SA2, Gorokhova SG1, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, Center for strategic research in healthcare, Moscow, Russia, Research Clinical Center of JSC Russian Railways, Moscow, Russia

PCN86 C20 COST COMPARISON OF ORAL VERSUS IV VINORLBINE IN FRANCE IN ADVANCED BREAST CANCER
Berdeaux G1, Mercier F1, Pierre Fabre, Boulogne Billancourt, France, STAT PROCESS, Paris, France

PCN87 C21 A TRIAL-BASED ECONOMIC EVALUATION OF RESOURCE USE AND COSTS IN THE EMILIA CLINICAL STUDY
McDougal J1, Masquel AS2, Barnett B2, Yoo B2, Sullivan SD1, University of Washington, Seattle, WA, USA, Genentech, Inc., South San Francisco, CA, USA
PCN88  C22  FIVE-YEARS EXPERIENCE OF ROBOTIC VS LAPAROSCOPIC COLORECTAL CANCER SURGERY IN A SINGLE CENTER: SURGICAL PARAMETERS AND COSTS
Morelli L1, Cobuccio L1, Lorenzoni V2, Guadagni S1, Palmeri M1, Di Franco G1, Gennai A1, Caprilli G1, D'Isidoro C1, Marciano E1, Di Candio G1, Mosca F1, Turchetti G1, University of Pisa, Pisa, Italy, 2Scuola Superiore Sant'Anna, Pisa, Italy

PCN89  C23  COSTS TO U.S. HEALTH INSURERS FOR HEMATOPOIETIC STEM CELL TRANSPLANT (HCT) RECIPIENTS WITH DOUBLE STRANDED DNA (psDNAs) VIRUS INFECTIONS FOLLOWING TRANSPLANT
Casciano R1, Mozaffari E2, Lee Y1, Patel V1, Schabert VF1, LASER Analytica, New York, NY, USA, 2Chimerix Inc., Durham, NC, USA

Defourny N1, Perrier L1, Dunscombe P1, Grau C1, Lievens Y1, Ghent university, Woluwe-Saint-Lambert, Belgium, 2Cancer Centre Léon Bérard, Lyon Cedex 08, France, 3University of Calgary, Calgary, AB, Canada, 4Aarhus University, Aarhus, Denmark, 5Ghent university, Ghent, Belgium

PCN91  C25  EXTENDED-RELEASE OXYCODONE HYDROCHLORIDE (OXYCONTIN®) FOR CANCER PAIN MANAGEMENT: A COST ANALYSIS FROM THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS PERSPECTIVES
Stefani S1, Saggia M1, Naves A2, Vasconcellos JF2, Teich V2, Instituto do Cancer Maé de Deus, Porto Alegre, Brazil, 2Asigma, Sao Paulo, Brazil, 3Mundipharma, São Paulo, Brazil, 4Sense Company, Rio de Janeiro, Brazil, 5Sense Company, São Paulo, Brazil

PCN92  C26  TOTAL ANNUAL COST ASSOCIATED WITH BEST SUPPORTIVE CARE OF PATIENTS WITH UNRESECTABLE ADVANCED NON-SMALL-CELL LUNG CANCER UNDER REAL-WORLD-CONDITIONS IN RELATION TO RESULTS OF INTERNATIONAL STUDIES
Feuerbach M, Freigang F, Lipp R, German Oncology GmbH, Hamburg, Germany

PCN93  C27  A COST COMPARISON OF TREATMENT WITH ABIRATERONE ACETATE PLUS PRENISONE IN THE PRECHEMOTHERAPY SETTING FOLLOWED BY ENZALUTAMIDE IN THE POST-CHEMOTHERAPY SETTING VERSUS THE OPPOSITE TREATMENT SEQUENCE IN METASTATIC CAstration Resistant Prostate Cancer Patients with Non-Visceral Metastases
Dearden L1, Girod i2, Majer i2, van de Wetering G3, Janssen EMEA HEMAR, High Wycombe, UK, 2Janssen, High Wycombe, UK, 3Pharmerit International, Rotterdam, The Netherlands

PCN94  C28  A COST-EFFECTIVENESS ANALYSIS OF GEFITINIB AS THE FIRST LINE TREATMENT IN PATIENTS WITH POSITIVE EGFR MUTATION IN METASTATIC OR LOCALLY ADVANCED NON-SMALL CELL
Piha T1, Barbosa D1, Fahham L2, AstraZeneca, Cota, Brazil, 2Sense Company, Sao Paulo, Brazil

PCN95  C29  ANALYSIS OF CLINICAL AND ECONOMIC IMPLICATIONS OF ESMO 2014 CLINICAL PRACTICE GUIDELINES FOR METASTATIC COLORECTAL CANCER TREATMENT
Suarez J, Merck, Madrid, Spain

PCN96  C30  ORAL VINORELBINE PLUS CISPLATIN VERSUS PEMETREXED PLUS CISPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: A COST MINIMIZATION ANALYSIS IN TWELVE EUROPEAN COUNTRIES
Bucher D1, Grossi F2, Pierre Fabre, Boulogne Billancourt, France, 2National Institute for Cancer Research, Genova, Italy

PCN97  C31  DECREASE OF PATIENT COSTS IN THE NETHERLANDS: A COST OF ILLNESS STUDY IN METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
Keusters WR1, Frederix GW1, de Weger VA1, Beijnen JH1, Hövels AM1, Schellens JH1, Utrecht University, Utrecht, The Netherlands, 2Netherlands Cancer Institute, Amsterdam, The Netherlands

PCN98  C32  THE ECONOMIC BURDEN OF PRIMARY BRAIN TUMORS IN CANADA
Lachaine J, Benmouhoub I, Mathurin K, University of Montreal, Montreal, QC, Canada

PCN99  C33  AN ASSESSMENT OF THE HOSPITALIZATION COSTS OF MELANOMA IN FRANCE IN THE ADVANCED/NEARLY ADVANCED SETTING: THE MELISSA STUDY (MELANOMA IN HOSPITAL COSTS ASSESSMENT) de Léotoing L1, Combemale P2, Fernandes J3, Bregman B1, Amaz C1, Vainchtock A1, Gaudin A1, HEVA, LYON, France, 2Centre Léon Bérard, Lyon, France, 3Occitane, Montpellier, France, 4Bristol-Myers Squibb, Rueil-Malmaison, France, 5HEVA, Lyon, France

PCN100  D1  BURDEN OF DISEASE OF OVARIAN CANCER IN SPAIN. OVARCOST STUDY
Delgado-Ortega L1, Gasco A1, Hidalgo A1, González-Domínguez A1, Villoro R1, Jimenez M1, Cordero L1, Cajal R1, AstraZeneca Spain, Madrid, Spain, 2University of Castilla-La Mancha, Toledo, Spain, 3Weber, Economia y Salud, S.L., Majadahonda, Spain

PCN101  D2  ECONOMIC BURDENS OF THE TOP 10 CANCERS DURING 2003-2012 IN TAIWAN
Tang C, Chuang P, Lu S, Tsiu C, Taipei Medical University, Taipei, Taiwan

PCN102  D3  THE SOCIETAL AND ECONOMIC IMPACT OF CERVICAL CANCER IN BRAZIL
Tsuchiya CT1, Pepe C1, Alves MR1, Roche Brazil, São Paulo, Brazil, 2MedInsight Decisions in HealthCare, São Paulo, Brazil

PCN103  D4  DIRECT MEDICAL COSTS ASSOCIATED WITH MULTIPLE MYELOMA IN CHINESE PATIENTS: ESTIMATIONS

PCN119 D20  TREATMENT STRATEGIES, HEALTH CARE RESOURCE USE AND COSTS OF AGGRESSIVE HISTOLOGICAL TYPES OF NON-HODGKIN LYMPHOMAS IN THE SLOVAK REPUBLIC. RESULTS FROM THE CROSS-SECTIONAL SURVEY IN THE HEMATOLOGICAL-Oncological CENTERS

Ondrusova M, Psenkova M, Suchansky M, Vranovsky A, Chudej J, Wild A, Pharm-In Ltd, Bratislava, Slovak Republic, 1National Cancer Institute, Bratislava, Slovak Republic, 2University Hospital Martin, Martin, Slovak Republic, 3University Hospital F. D. Roosevelt, Banska Bystrica, Slovak Republic

PCN120 D21  TREATMENT PATTERNS AND HEALTH CARE RESOURCE USE (HCRU) ASSOCIATED WITH REPEATEDLY TREATED METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE UNITED KINGDOM (UK)

Nash Smyth E, La E, Talbird S, Li L, Kaye JA, Lin AB, Bowman L, Eli Lilly and Company, Indianapolis, IN, USA, 2Rti Health Solutions, Research Triangle Park, NC, USA

PCN121 D22  CLINICAL, MEDICATION AND ECONOMICAL OUTCOME RESEARCH OF ADDED ADVANCED COLORECTAL CANCER RELAPSE USING REIMBURSEMENT AND CANCER REGISTRY DATABASES

Chang CJ, Chou T, Fann CS, Chang Gung University, Kwei Shan, Tao Yuan, Taiwan, 2Academia Sinica, Taipei, Taiwan

PCN122 D23  THE MANAGEMENT AND COSTS OF LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN GREECE

Kousoulakou H, Boukvinias I, Georgoulas V, Kosmidis P, Koumakis G, Makrantanakis P, Samantas E, Syrigos K, Krikelis D, Markouri A, Geitona M, University of Peloponessen, Corinth, Greece, 2Bioclinic, Thessaloniki, Greece, 3Medical School, University of Crete, Iraklion, Crete, Greece, 4Hygeia Hospital, Marousi, Greece, 5Agios Savvas Anticancer-Oncology Hospital of Athens, Athens, Greece, 6Theageneio Anticancer Hospital, Thessaloniki, Greece, 7Agioi Anargyroi Anticancer Hospital of Athens, Athens, Greece, 8Medical School, University of Athens, Athens, Greece, 9Novartis (Hellas) S.A.C.I., Metamorphosis, Greece

PCN123 D24  ESTIMATION OF DIRECT MEDICAL COSTS ASSOCIATED WITH TREATMENT OF METASTATIC MELANOMA IN SWITZERLAND

Christoffersen P, Khan N, Lucas J, Christodouloupolou A, Del Ponte A, Gutzwiller F, 1IMS Health, Basel, Switzerland, 2Angen Switzerland AG, Zug, Switzerland

PCN124 D25  ADDITIONAL COST OF VTE IN PATIENTS WITH CANCER: AN APPROACH BASED DATABASES

Bourquignon S, Mayeur D, Mahe i, Krakowski i, Stratégique Santé, Evry, France, 2Ch Versailles, Le Chesnay, France, 3Louris Mouriour Hospital, Colombes, France, 4Bergonié Institut, Bordeaux, France

PCN125 D26  INTERMEDIATE AND ADVANCED HEPATOCELLULAR CARCINOMA MANAGEMENT IN FOUR ITALIAN CENTERS: PATTERNS OF TREATMENT AND COSTS

Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Cortesi E, Turchetti G, University of Pavia, Milan, Italy, 2Di.Bi.M.I.S University of Palermo, Palermo, Italy, 3Università La Sapienza, Roma, Italy, 4Ospedale Brotzu, Cagliari, Italy, 5Seconda Università di Napoli policlinico, Napoli, Italy, 6Business Integration Partners, Milano, Italy, 7Università la Sapienza, Roma, Italy, 8Scuola Superiore Sant'Anna, Pisa, Italy

PCN126 D27  ECONOMIC BURDEN OF PATIENTS WITH ALK+ MUTATION NON-SMALL CELL LUNG CANCER AFTER TREATMENT WITH CRIZOTINIB: A CANADIAN RETROSPECTIVE OBSERVATIONAL STUDY

Kayaniyil S, Wilson J, Hurry M, Koch C, Zhang J, Liu G, 1ICON plc, Toronto, ON, Canada, 2ICON plc, Vancouver, ON, Canada, 3Novartis Pharmaceuticals Inc., Dorval, QC, Canada, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5Princess Margaret Cancer Centre, Toronto, ON, Canada

PCN127 D28  RESOURCE USE AND COST OF CHEMOTHERAPEUTIC TREATMENT FOR METASTATIC BREAST CANCER IN THE NETHERLANDS

Pouwels XG, Ramaekers BL, Joore MA, Maastricht University Medical Center+, Maastricht, The Netherlands

PCN128 D29  PROSTECTOMY: A COMPARISON OF COST-BENEFIT ANALYSIS BETWEEN OPEN SURGERY AND ROBOTIC TECHNIQUES

Franchini F, Borsari M, Frigieri F, Castanò C, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy

PCN129 D30  HEALTH-ECONOMIC COMPARISON OF A GNRH-ANTAGONIST (DEGARELIX) VS. GNRH-AGONISTS CONSIDERING THE NUMBER-NEEDED-TO-TREAT TO AVOID CARDIOVASCULAR EVENTS

Anderson D, Donatz V, Vosgerau S, Ecker + Ecker GmbH, Hamburg, Germany, 2Ferring Arzneimittel, Kiel, Germany

PCN130 D31  COLORECTAL CANCER: THE IMPORTANCE OF BEING RIGHT – A MODEL INVESTIGATING THE IMPACT OF BOWEL CLEANSING ON ADENOMA DETECTION IN A GERMAN SCREENING POPULATION


PCN131 D32  COST EFFECTIVENESS OF BORTEZOMIB, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR THE FIRST-LINE TREATMENT OF MANTEL CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION: A SCOTTISH PERSPECTIVE
TUMOR (GIST) IN CHINA
COST
Turkey, 
S1,1Bayer Turk Kimya San. Ltd Sti., Istanbul, Turkey, 2Haydarpasa Numune Training and Research Hospital, Istanbul, Deger C

GASTROINTESTINAL STROMAL TUMORS IN TURKEY
THE COST
Europe Ltd, Uxbridge, UK
Kumar G

A SCOTLAND BASED COST
UK, 
Pearson IV

COST
Oxford, UK, 
Sullivan W

WALES
THE COST EFFECTIVENESS OF IDELALISIB IN CHRONIC
CANCER SCREENING OF AVERAGE
REVISITING THE SIMULATION EVIDENCE FOR THE INCREMENTAL COST
PROGRESSION WITH IPILIMUMAB IN ENGLAND
COST
Félix J

BREAST CANCER
POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2/NEU NEGATIVE ADVANCED
THERAPEUTIC AND ECONOMIC VALUE OF EVEROLIMUS PLUS EXEMESTANE FOR THE TREATMENT OF
PCN133 E1

EFFECTIVENESS OF BREAST CANCER SCREENING OF AVERAGE-RISK WOMEN
O'Mahony JF

Trinity College Dublin, Dublin, Ireland

ECONOMIC ASSESSMENT OF EBIRULIN AGAINST TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN TAIWAN
Chang CJ, Chao Tz, Park Jz, Jones Tz, Majethia Uz, Ni Cz, Chang Gung University, Tao-Yun, Taiwan, 2Taipei Veterans General Hospital, Taipei, Taiwan, 3Eisai Korea Inc., Seoul, South Korea, 4Eisai Pharmaceuticals, Hatfield, UK, 5Eisai Inc., Woodcliff Lake, NJ, USA, 6Eisai Taiwan Inc., Taipei, Taiwan

AFFIBERCEPT IN COMBINATION WITH FOLFI RI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: COST-EFFECTIVENESS BASED ON VELOUR BEST EFFICACY SUBGROUP POST-HOC ANALYSIS
Echave M, Oyagüez I, Rubí M, Subirá R, Pharamacoconomics & Outcomes Research Iberia, Madrid, Spain, 2Complejo Hospitalario de Santiago de Compostela, Santiago de Compostela, Spain, 3Sanofi, Barcelona, Spain

EFFECTIVENESS OF CARDIOPROTECTIVE EFFECT OF DEXRAZOXANE (CARDIOXANE®) IN ADVANCED/METASTATIC BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINE-BASED CHEMOTHERAPY IN MÉXICO
Paladío-Hernández JÁ, Martinez-Morales Jz, 1Independent Consultant, Cuautitlán Izcalli, Mexico, 2UACH, Hidalgo del Parral, Mexico

EFFECTIVENESS ANALYSIS OF NEO-ADJUVANT PERTUZUMAB THERAPY IN WOMEN WITH LOCALLY ADVANCED, INFLAMMATORY, OR EARLY HER2-POSITIVE BREAST CANCER IN ITALY
Pradelli L, Bellone M, Era Sz, Campagnoni E, AdRes Srl, Torino, Italy, 2Roche Spa, Monza (MB), Italy

A COST UTILITY ANALYSIS OF CETUXIMAB FOR 1ST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER: A SUMMARY OF THE SUBMISSION TO ALL WALES MEDICINES STRATEGY GROUP (AWMSG)
Hnoosh A, Harty GTz, Sullivan L, Byrne B, von Honhorst Pz, 1Merck Serono Ltd., FELTHAM, UK, 2Merck Serono, London, UK, 3Merck KGaA, Darmstadt, Germany

THE COST EFFECTIVENESS OF IDELALISIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA IN ENGLAND AND WALES
Sullivan W, Hadlow Sz, Perard Rz, Mealing Sz, Cox Lz, 1Lee Dz, 1BresMed Health Solutions, Sheffield, UK, 2Gilead Sciences Ltd, London, UK, 3Gilead Sciences Europe Ltd, Uxbridge, UK, 4ICON Health Economics and Epidemiology, Oxford, UK, 5BresMed, Sheffield, UK

EFFECTIVENESS OF OFATUMUMAB PLUS CHLORAMBUCIL IN FIRST-LINE CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE UNITED KINGDOM
Pearson IV, Hawe Ez, Zuluaga Sz, Scuito Sz, Wolowacz Sz, Haiderali Az, 1RTI Health Solutions, Manchester, UK, 2GlaxoSmithKline, Uxbridge, UK, 3GlaxoSmithKline, Collegeville, PA, USA

A SCOTLAND BASED COST-EFFECTIVENESS ANALYSIS OF IDELALISIB (ZYDELIG®) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF ADULTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA CLL)

THE COST-EFFECTIVENESS OF REGORAFENIB IN THE TREATMENT OF METASTATIC/INOPERABLE GASTROINTESTINAL STROMAL TUMORS IN TURKEY
Deger C, Telli F, Gunaishi M, Keskin S, Saglam S, Ozdemir O, Sar C, Parali E, Erdal E, Sumer F, Ozel O, Asan S, 1Bayer Turk Kimya San. Ltd. St., Istanbul, Turkey, 2Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey, 3Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 4Memorial Sisli Hospital, Istanbul, Turkey, 5Istanbul Bilim University, Istanbul, Turkey, 6Yorum Consulting Ltd., Istanbul, Turkey

EFFECTIVENESS OF SUNITINIB AS SECOND-LINE TREATMENT FOR GASTROINTESTINAL STROMAL TUMOR (GIST) IN CHINA

PCN134 E2

PCN134 D33

PCN135 E3

PCN136 E4

PCN137 E5

PCN138 E6

PCN139 E7

PCN140 E8

PCN141 E9

PCN142 E10

PCN143 E11

PCN144 E12

PCN145 E13
COST-EFFECTIVENESS OF CERITINIB IN THE TREATMENT OF PREVIOUSLY TREATED ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL CELL LUNG CANCER IN THE UNITED KINGDOM

Zhou Z1, Zhang J2, Fan L1, Zhang C3, Xie J4,1Analysis Group Inc., New York, NY, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Analysis Group, Inc., Boston, MA, USA, 4Analysis Group, Inc., New York, NY, USA

COST-EFFECTIVENESS OF BORTZOIMIB FOR MULTIPLE MYELOMA: A SYSTEMATIC REVIEW

Chen W1, Yang Y2, Du F3, Li J4, Chen Y5,1Normin Health, Toronto, ON, Canada, 2Xian-Janssen China, Beijing, China, 3Normin Health Changsha Representative Office, Changsha, China

CONSEQUENCES OF BIOMARKER ANALYSIS ON THE COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN BASED CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER. STRATIFIED MEDICINE AT WORK?


COST-EFFECTIVENESS ANALYSIS OF GRANULOCYTE COLONY-STIMULATING FACTORS FOR THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN PATIENTS WITH BREAST CANCER IN GREECE

Kourlaba G1, Gourzoulidis G2, Aravantinos G3, Athanasiadis I4, Lyman GH5, Villa G6, Papagiannopoulou V7, Tritaki G8, Maniadakis N9,1Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, 2National School Of Public Health, Athens, Greece, 3Agioi Anargiroi Cancer Hospital, Athens, Greece, 4Mitera Hospital-Hygeia Group, Athens, Greece, 5Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 6Amgen (Europe) GmbH, Zug, Switzerland, 7AMGEN Hellas, Athens, Greece

VALUE OF PHYSICAL EXERCISE FOR CANCER SURVIVORS

Mewes JC1, Steuten L2, IJzerman MJ1, van Harten W3,1University of Twente, Enschede, The Netherlands, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 3Netherlands Cancer Institute, Amsterdam, The Netherlands

PHARMAECONOMICS OF RUXOLITINIB THERAPY IN PATIENTS WITH MYELOFIBROSIS

Vandewalle B1, Andreozzi V, Almeida J, Félix J,Exigo Consultores, Alhos Vedros, Portugal

COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB FOR METASTATIC HER2-POSITIVE BREAST CANCER IN JAPAN

Tange C1, Kunisawa S2, Maeda S3, Shimozuma K4,1Ritsumeikan University, Kusatsu City, Japan, 2Kyoto University, Kyoto, Japan, 3Ritsumeikan University, Kusatsu, Japan

COST-EFFECTIVENESS OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA ELIGIBLE TO START THE TREATMENT-FREE REMISSION PHASE IN ITALY

Aiello A1, Daniel F2, D’Ausilio A3, Sneideroc SJ4, Tomii M5,1Creativ Ceutical, Milano, Italy, 2Pharmerit International, Bethesda, MD, USA, 3Aix-Marseille University, Marseille, France

ESTIMATING THE COST-EFFECTIVENESS PROFILE OF A VACCINATION PROGRAMME WITH A NINE-VALENT HPV VACCINE IN ITALY

Mennini FS1, Bianco F2, Baio G3, Largeron N4, Plazzotta G5, Rinaldi A6, De Waure C7, Bonanni P8,1Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome, Rome, Italy, 2Mapi, Nanterre, France, 3University College London, London, London, UK, 4SPMSD, Lyon, France, 5Mapi, Uxbridge, UK, 6SPMSD, Roma, Italy, 7Catholic University of Rome, Roma, Italy, 8Universita’ degli Studi di Firenze, Firenze, Italy

A COST-EFFECTIVENESS ANALYSIS OF A GENOMIC TEST COMPARED TO STANDARD OF CARE IN BREAST CANCER PATIENTS IN FRANCE

Dorey J1, Dissat A2, Elmoctar Neine M1, Plun-Favreau J1, Tommi M2, Creativ-Ceutical, Paris, France, 1Genomic Health International, Geneva, Switzerland, 2University of Marseille, Marseille, France

COST-EFFECTIVENESS ANALYSIS OF GRANULOCYTE COLONY-STIMULATING FACTORS FOR THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA IN GREECE

Gourzoulidis G1, Kourlaba G2, Apostolidis J3, Lyman GH4, Villa G5, Papagiannopoulou V6, Tritaki G7, Maniadakis N8,1National School Of Public Health, Athens, Greece, 2Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, 3Evangelismos Hospital, Athens, Greece, 4Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 5Amgen (Europe) GmbH, Zug, Switzerland, 6AMGEN Hellas, Athens, Greece

COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US

Graham C1, Knox H1, Hess LM2, Jen M3, Cuyun Carter G4, Chandrawansa K5, Boye M6,1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly, Indianapolis, IN, USA

COMPARATIVE EFFICACY AND COSTS OF TREATMENT SEQUENCES IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Pérez-Alcántara F1, Martínez Llínas D2, Maroto JP3, Gallardo E4, Subirà R5, Rubio M6, OBLIKUE Consulting, Barcelona, Spain, 1Sant Pau Hospital, Barcelona, Spain, 2Corporació Sanitaria Parc Taulí, Sabadell, Spain, 3Sanofi,
PCN159 F10 THE COST–EFFECTIVENESS OF REGORafenib IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WHO HAVE PROGRESSED AFTER STANDARD THERAPIES IN TURKEY

Değer C1, Telli F2, Gunalid M3, Keskin S4, Saglam S5, Ozdemir O6, Sar C7, Parali E8, Erdal E9, Sumer F10, Ozel O11, Asan S12, Bayer Türk Kimya San. Ltd. Sti., Istanbul, Turkey, 1Haydarpaşa Numune Training and Research Hospital, Istanbul, Turkey, 2Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 3Memorial Sisli Hospital, Istanbul, Turkey, 12Istanbul Bilim University, Istanbul, Turkey, 13Yorum Consulting Ltd., Istanbul, Turkey

PCN160 F11 COST-EFFECTIVENESS OF FIRST-LINE TYROSINE KINASE INHIBITORS (TKIS) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN KOREA: COMPARISON OF DASATINIB (100MG), NILOTINIB (600MG) AND IMATINIB (400MG)


PCN161 F12 COST-EFFECTIVENESS OF DIRECTLY MAILED FOBT KITS TO PREVIOUS RESPONDERS BEING CALLED FOR SCREENING

Mittmann N1, Hassan S2, Patel J, Timnboth J, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2Sunnybrook Research Institute, Toronto, ON, Canada

PCN162 F13 MAMMOGRAPHY FOR BREAST CANCER SCREENING IN INDIA – A HEALTH TECHNOLOGY ASSESSMENT

Kachroo K1, Sharma J, Chahar A, Dang A, Ganji K, 1WHO Collaborating Centre for Priority Medical Devices & Health Technology Policy, NHSRC, New Delhi, India, 2MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

PCN163 F14 PHARMACOECONOMIC ANALYSIS OF AFATINIB AS 1ST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WITH DEL19 MUTATION OF EGFR GENE

Belousoy D1, Gorbunova V2, Orlov S3, Afanasieva E4, 1Center of Pharmacoeconomic Research LLC, Moscow, Russia, 2Russian Oncology Scientific Center named after N. Blokhin, Moscow, Russia, 31st Sankt-Petersburg State Medical University named after I. Pavlov, Moscow, Russia, 4LLC «Center of Pharmacoeconomic Research», Moscow, Russia

PCN164 F15 STUDY ON COST-EFFECTIVENESS ANALYSIS FOR MULTIPLE MYELOMA TREATMENT: A SYSTEMATIC REVIEW OF LITERATURE FROM 2004–2014

Yamabe K1, Hiroi S2, Inoue S3, Kobayashi M4, 1Takeda Pharmaceutical Company Ltd., Tokyo, Japan, 2CRECON Medical Assessment Inc., Tokyo, Japan

PCN165 F16 COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER IN THE UK: A SUMMARY OF ECONOMIC ANALYSES SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

Hnoosh A1, Harty GT2, Sullivan L2, Byrne B2, von Honhorst P3, 1Merck Serono Ltd., FELTHAM, UK, 2Merck Serono, London, UK, 3Merck KGaA, Darmstadt, Germany

PCN166 F17 SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF GEFITINIB IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN CHINA

Hu C1, Huang L2, Zhao D3, Xu L4, 1Astrazeneca(China), Beijing, China, 2Astrazeneca (China), Beijing, China

PCN167 G1 RESULTS OF A DUTCH COST-EFFECTIVENESS MODEL OF RADIUM-223 IN COMPARISON TO CABAZITAXEL, ABIRATERONE, AND ENZALUTAMIDE IN PATIENTS WITH METASTATIC PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL


PCN168 G2 ECONOMIC EVALUATION OF PEGFILGRASTIM AS PROPHYLAXIS FOR FEBRILE NEUTROPENIA IN PATIENTS WITH SOLID TUMORS OR LYMPHOMA RECEIVING CHEMOTHERAPY IN MEXICO

Alva ME1, Carlos F2, Espinosa K3, Barbosa V4, Naranjo M5, 1Amgen, Mexico City, Mexico, 2R A C Salud Consultores S.A. de C.V, Mexico City, Mexico, 3Amgen Mexico, Mexico City, Mexico

PCN169 G3 COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB/CHLORAMBUCIL VS RITUXIMAB/CHLORAMBUCIL IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Yagudina R, Kulikov A, Babyi VV, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCN170 G4 COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB FOR FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN WT RAS PATIENTS IN SPAIN

Suarez J1, Merck, Madrid, Spain

PCN171 G5 COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB + FOLFOX COMPARED TO CETUXIMAB + FOLFIRI AS FIRST-LINE TREATMENT FOR PATIENTS WITH WILD-TYPE (WT) RAS (EXONS 2, 3, AND 4 OF KRAS AND NRAS) METASTATIC COLORECTAL CANCER (MCRC) IN COLOMBIA

Vargas-Valencia J1, Garcia Peralaza J4, Econopharma Consulting, Mexico, Mexico, 2AMGEN, Bogotá, Colombia

PCN172 G6 DASATINIB, HIGH-DOSE IMatinib AND NILOTINIB IN CHINESE PATIENTS WITH CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB-RESISTANCE OR -INTOLERANCE: AN ECONOMIC EVALUATION
PCN173 G7  COST-EFFECTIVENESS OF IDELASIB PLUS RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKAEMIA
Leleu H1, Blacher M2, Mealing S2, PUBLIC HEALTH EXPERTISE, Paris, France, 1ICON Health Economics and Epidemiology, Oxford, UK

PCN174 G8  HEALTH ECONOMICS AND RADIUM-223 (XOFIGO®) IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). A CASE HISTORY AND A SYSTEMATIC REVIEW OF THE LITERATURE ON COST-EFFECTIVENESS ANALYSIS (CEA)
Norum J1, Trasdasdial E2, Toth A3, Nieder C4, Olsen JA1, UIT-The Arctic University of Norway, Tromsø, Norway, 2University Hospital of North Norway, Tromsø, Norway, 3Northern Norway Regional Health Authority trust, Bodø, Norway, 4Nordland Hospital, Bodø, Norway

PCN175 G9  ECONOMIC EVALUATION FOR FLUVESTRANT 500 MG IM VERSUS EXEMESTENE IN EGYPTIAN PATIENTS WITH METASTATIC BREAST CANCER
Amin M1, Abo Taleb AM1, astrazeneca, cairo, Egypt, 2WHO, Cairo, Egypt

PCN176 G10  ADDING BEVACIZUMAB TO SINGLE-AGENT CHEMOTHERAPY FOR THE TREATMENT OF PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: A COST-EFFECTIVENESS ANALYSIS OF THE AURELIA TRIAL
Schaffner EM1, Coles TM1, Wysham WZ2, Roque DR2, Kim KH2, Wheeler SB1, 1Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PCN177 G11  LITERATURE REVIEW OF ECONOMIC EVALUATIONS OF SCREENING TESTS FOR BREAST CANCER
Lachaine J1, Lambert-Obry V1, Lemay M. M1University of Montreal, Montreal, QC, Canada

PCN178 G12  ECONOMIC EVALUATIONS OF GliOBlastoma
Lachaine J1, Benmouhoub I1, Mathurin K1University of Montreal, Montreal, QC, Canada

PCN179 G13  FIXED COMBINATION NETUPITANT AND PALONOSETRON IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN THE UK
D’agostino P1, Cawston H1, Bourhis F2, Turini M1, Ruffo P1, Mcguire A3, 1Helsinn Healthcare SA, Pazzallo, Switzerland, 2Mapi, Nanterre, France, 3London School of Economics, London, UK

PCN180 G14  COST-EFFECTIVENESS OF IDELASIB IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHEMIA (CLL) IN PORTUGAL
Gouveia M1, Silva MG1, Alarcão J1, Fiorentino F2, Carda J2, Costa R3, Mariz JM4, Raposo J1, Costa J2, Borges M5, Católica Lisboa School of Business and Economics, Lisbon, Portugal, 4Instituto Português Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal, 5Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 6Centro Hospitalar Universitarió de Coimbra, Coimbra, Portugal, 7Hospital Garcia de Orta, Almada, Portugal, 8Instituto Português de Oncologia do Porto Francisco Gentil, Oporto, Portugal, 9Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 10Institute of Molecular Medicine, Lisbon, Portugal

PCN181 G15  LOSS OF OPPORTUNITY LINKED WITH THE SUBOPTIMAL COVERAGE RATE OF HPV VACCINATION IN FRANCE
Uhart M1, Dahlab A1, Bresse X1, Largeron N2, Sanofi Pasteur MSD, Lyon, France, 2SPMSD, Lyon, France

PCN182 G16  COST-EFFECTIVENESS OF CERTINIB IN PREVIOUSLY TREATED PATIENTS WITH CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL CELL LUNG CANCER IN CANADA
Zhou Z1, Hurry Mz, Zhang J1, Fan L1, Zhang C1, Xie J1, 1Analysis Group Inc., New York, NY, USA, 2Novartis Pharmaceuticals Inc., Dorval, QC, Canada, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Analysis Group, Inc., Boston, MA, USA, 5Analysis Group Inc., Boston, MA, USA

PCN183 G17  A COST-EFFECTIVENESS ANALYSIS OF ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES AND COLORECTAL CANCER
Soon S1, Chia WJ2, Redekop K3, Wee HL1, 1National University of Singapore, Singapore, Singapore, Singapore, 2National Cancer Centre of Singapore, Singapore, Singapore, 3Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam, DR Rotterdam, The Netherlands

PCN184 G18  COST-EFFECTIVENESS ANALYSIS ON STARTING PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON A HIGHLY POTENT TYROSINE KINASE INHIBITOR AND EARLY SWITCHING TO IMATINIB
Rochau U1, Vukicevic D1, Schmidt S1, Stenehjem D1, Brixner D1, Radich J1, Gastl G1, Siebert U1, 1UMIT - University for Health Sciences, Medical Informatics and Technology, Dept. of Public Health & HTA/ ONCOTYROL - Center for Personalized Cancer Medicine, Hall in Tyrol, Innsbruck, Austria, 2UMIT - University for Health Sciences, Medical Informatics and Technology, Dept. of Public Health & HTA, Hall in Tyrol, Austria, 3Medical University Innsbruck, Innsbruck, Austria, 4University of Utah, Pharmacotherapy Outcomes Research Center, Program in Personalized Health, Salt Lake City, UT, USA, 5Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 6Department of Health Policy & Management, Harvard Medical School, Institute for Technology Assessment & Department of Radiology, Hill i.T., Austria

PCN185 G19  ESTIMATING THE PUBLIC HEALTH IMPACT OF A VACCINATION PROGRAMME WITH A NONAVALENT HPV VACCINE IN GERMANY
Largeron N1, Petry K2, Jacob JA3, Bianic F3, Anger D2, Nikogloiu T1, SPMSD, Lyon, France, 2Klinikum Wolfsburg, Wolfsburg, Germany, 3MAPI Group, Uxbridge, UK, 4Mapi Group, Nanterre, France
PCN186 G20 COST-EFFECTIVENESS AND FEASIBILITY OF IMPLEMENTING MRI-GUIDED NEOADJUVANT CHEMOTHERAPY TO TREAT ER-POSITIVE HER2-NEGATIVE BREAST CANCERS IN THE NETHERLANDS
Miguel-Cases A, Steuten L, Rigter L, van Harten WH, Netherlands Cancer Institute, Amsterdam, The Netherlands, University of Washington and Panacea bv, Seattle, WA, USA

PCN187 G21 ECONOMIC EVALUATION OF ORAL CHEMOTHERAPY REGIMEN IN METASTATIC BREAST CANCER EGYPTIAN PROSPECTIVE
Abo Taleb AM, Saad AS A, Aboushady R, WHO, Cairo, Egypt, Ain Shams University, Cairo, Egypt, Central Administration for Pharmaceutical Affairs, Cairo, Egypt

PCN188 G22 SUBCUTANEOUS VS INTRAVENTOUS ADMINISTRATION OF TRASTUZUMAB IN HER2+ BREAST CANCER PATIENTS: A MACEDONIAN COST-MINIMIZATION ANALYSIS
Nestorovska A, Naumoska Z, Grozdanova A, Stoleski D, Ivanovska A, Risteski M, Vasev N, Ismaili I, Stefanovski P, Dimovski A, Suturkova L, Stervi Z, ISPOR Republic of Macedonia regional chapter, Skopje, Macedonia, Roche Macedon, DOEL, Skopje, Macedonia, University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, Clinical Hospital, Bitola, Macedonia, Faculty of Pharmacy, UKIM-Skopje, Skopje, Macedonia

PCN189 G23 PHARMACOECONOMIC EVALUATION OF THE USE OF TRASTUZUMAB FOR SUBCUTANEOUS ADMINISTRATION COMPARED TO INTRAVENTOUS DOSE FORM IN THE TREATMENT OF BREAST CANCER
Kulikov A, Rybczenko Y.I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCN190 G24 PHARMACOECONOMIC STUDY OF THE USE OF RITUXIMAB FOR SUBCUTANEOUS ADMINISTRATION IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Kulikov A, Rybczenko Y.I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCN191 G25 COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGUESE PATIENTS THAT ARE UNSUITABLE FOR FULL-DOSE FLUDARABINE BASED THERAPY
Paquete A, Miguel LS, Pereira C, Pinto CG, CISEP, Lisboa, Portugal, Roche Farmacêutica Bioquímica, Lda., Amadora, Portugal, University of Lisbon, Lisbon, Portugal

PCN192 G26 COST-EFFECTIVENESS OF CETUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER IN BELGIUM AND THE NETHERLANDS

PCN193 G27 A COST-UTILITY ANALYSIS OF NAB-PACLITAXEL (ABRAXANE) PLUS GEMCITABINE IN METASTATIC PANCREATIC CANCER IN SLOVAK REPUBLIC
Stetka R, Ondrusova M, Psenkova M, Pastorek T, Salek T, Pharm-In Ltd, Bratislava, Slovak Republic, Celgene Ltd., Bratislava, Slovak Republic, Narodny onkologicky ustav, Bratislava, Slovak Republic

PCN194 G28 ESTIMATION OF THE TRESHOLD PRICE OF REGORAFENIB IN THE TREATMENT OF UNRESECTABLE AND/OR METASTATIC GASTROINTESTINAL STROMAL TUMORS AFTER FAILURE ON IMATINIB AND SUNITINIB IN SPAIN: COST-UTILITY ANALYSIS
Sanz-Granda A, Hidalgo-Figuereuila F, Granell M, Weber Economía y Salud, Majadahonda (Madrid), Spain, Bayer HealthCare, Sant Joan Despí (Barcelona), Spain

PCN195 G29 THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING PLERIXAFOR FOR STEM CELL MOBILIZATION FOR AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION FOR NON-HODGKIN’S LYMPHOMA PATIENTS
Krysanova V, Krysanov I, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia

PCN196 G30 EFFICIENCY OF EXPENSES OF GEFITINIBUM IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AS A SECOND LINE THERAPY
Rudakov AV, Meshkoy DO, Khabriev RU, Bezmenchtsynya LY, St. Petersburg Chemical-Pharmaceutical Academy, St. Petersburg, Russia, National Research Institution for Public Health, Moscow, Russia

PCN197 G31 THE IMPACT OF PHARMACEUTICAL INNOVATION ON PREMATURE CANCER MORTALITY IN PORTUGAL
Lichtenberg F, Laires PA, Columbia University, New York, NY, USA, Merck Sharp & Dohme, Oeiras, Portugal

PCN198 G32 CANCER AND PREMATURE MORTALITY IN IRELAND: AN EMPLOYER’S PERSPECTIVE FOLLOWING THE FRICTION COST APPROACH
Hanly P, Pearce A, Sharp L, National College of Ireland, Dublin, Ireland, National Cancer Registry Ireland, Cork, Ireland, Newcastle University, Newcastle, UK

PCN199 G33 POTENTIAL SAVINGS TO EU ECONOMY DUE TO RETURNING TO WORK OF CANCER SURVIVORS WITH A DISABILITY
Macioch T, Hermanowski TR, Medical University of Warsaw, Warsaw, Poland

PCN200 H1 PREDICTING FUTURE NEED OF RESOURCES FOR ADENOMA SURVEILLANCE FROM A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAM THROUGH DISCRETE EVENT SIMULATION
Comas M, Andreu M, Guerrero-Ludeña RE, Bessa X, Balagú F, Castells X, IMIM (Hospital del Mar Medical Research Institute); Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Barcelona, Spain, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain, Institut d’Investigacions Biomèdiques
| PCN201 H2 | EVALUATION OF RESOURCE UTILIZATION FOR CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS TREATED WITH ANTHRACYLINE+CYCLOPHOSPHAMIDE (AC) FOR SOLID CANCERS WITH AND WITHOUT NK-1 BASED REGIMENS |
| PCN202 H3 | RESOURCE UTILIZATION IN PATIENTS WITH ADVANCED MELANOMA IN FRANCE |
| PCN203 H4 | RESOURCE AND COST SAVINGS DUE TO SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF ONCOLOGY THERAPIES: CASE STUDIES WITH RITUXIMAB (MABTHERA) AND TRASTUZUMAB (HERCEPTIN) |
| PCN204 H5 | DESCRIPTIVE EPIDEMIOLOGY AND TREATMENT STRATEGIES USED IN MULTIPLY MYELOMA IN THE SLOVAK REPUBLIC. RESULTS FROM THE CROSS-SECTIONAL SURVEY IN THE HAEMATOLOGY-ONCOLOGICAL CENTERS |
| PCN205 H6 | DIRECT COSTS AND HEALTHCARE RESOURCE USE ASSOCIATED WITH ADVANCED MELANOMA IN PORTUGAL |

**CANCER - Patient-Reported Outcomes & Patient Preference Studies**

| PCN206 H7 | SYSTEMATIC REVIEW OF ADHHERENCE TO ONCOLOGICAL TREATMENTS |
| PCN207 H8 | COGNITIVE DEBRIEFING AND USABILITY ASSESSMENT OF THE EORTC QLQ-C30 AND QLQ-BR23 AS PRESENTED ON TABLET AND HANDHELD DEVICES |
| PCN208 H9 | PREVALENCE AND REASONS FOR NONADHERENCE TO AROMATASE INHIBITORS IN AN OUTPATIENT ONCOLOGY CLINIC |
| PCN209 H10 | INFLUENCE OF THE METHOD OF ANALYSIS ON ESTIMATES OF QALY TREATMENT DIFFERENCE: PHASE III TRIAL OF VINFLUNINE VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH TCU |
| PCN210 H11 | LONG-TERM EQ-5D SCORE FOR PATIENTS WITH METASTATIC BREAST CANCER: A COMPARISON OF FIRST-LINE ORAL S-1 AND TAXANE THERAPIES IN THE RANDOMIZED "SELECT" TRIAL |
| PCN211 H12 | SENSITIVITY ANALYSIS IN DISCRETE CHOICE EXPERIMENTS FOR RARE DISEASES – AN ANALYSIS WITHIN THE PAINO-STUDY |
| PCN212 H13 | PATIENT PREFERENCES CONCERNING ALTERNATIVE NET TREATMENT OPTIONS – THE PAINO-STUDY |
| PCN213 H14 | IMPACT OF STAGING AND HORMONE SENSITIVITY ON QUALITY OF LIFE IN US PROSTATE CANCER PATIENTS |
| PCN214 H15 | ESTIMATING EORTC-8D HEALTH STATE UTILITY VALUES FROM EORTC QLQ-C30 SCORES IN RELAPSED
MULTIPLE MYELOMA
Ashaye AO 1, Altincat A 1, Bender RH 2, Zhang J 1, Panjabi S 3, Evidera, Lexington, MA, USA, 2 Evidera, Bethesda, MD, USA, 3 Onyx Pharmaceuticals Inc., An Amgen Subsidiary, San Francisco, CA, USA

PCN215 H16 MAPPING HEALTH STATE UTILITY VALUES FROM EORTC DATA COLLECTED FROM A CLINICAL TRIAL POPULATION WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Quinn C 1, Hirji I 2, Shingler SL 1, Davis C 2, PMRA Consulting, Fleet Hampshire, UK, 2 Bristol-Myers Squibb, Wallingford, CT, USA, 3 Bristol-Myers Squibb, Princeton, NJ, USA

PCN216 H17 Alternative regression methods for mapping utilities in oncology
Sabourin C 1, Crott R 1, Aballea S 2, Toumi M 3, Creatic-CEutical, London, UK, 2 Creative-CEutical, Paris, France, 3 Aix-Marseille University, Marseille, France

PCN217 H18 HRQOL AND HEALTH UTILITY IMPACT ON PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN US AND EUROPE: A SYSTEMATIC LITERATURE REVIEW
Ahuja A 1, Attri S, Kamra S, Kalra M, Marwaha IS, Paraxel International, Chandigarh, India

PCN218 H19 FIELD MONITORING OF THE Z BENEFITS FOR BREAST CANCER OF THE PHILIPPINE HEALTH INSURANCE CORPORATION
Santillan M 1, Reyes MR 1, Lanuza A 1, Tacang A 1, Vecina G 1, Cabalio DR 1, Soria, Jr. F 1, Lavina SM 2, 3 Philippine Health Insurance Corporation, Pasig City, Philippines, 2 University of the Philippines-Philippine General Hospital, Manila, Philippines

PCN219 H20 PREFMAB: FINAL ANALYSIS OF PATIENT SATISFACTION WITH SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED CD20+ DIFFUSE LARGE B-CELL LYMPHOMA OR FOLLICULAR LYMPHOMA
Rummel M 1, Kim TM 1, Plenteda C 1, Capochiani E 1, Mendoza M 1, Smith R 2, Osborne S 3, Grigg A 1, 4 University Hospital Giessen and Marburg, Giessen, Germany, 4 Seoul National University Hospital, Seoul, South Korea, 5 Universita Degli Studi Parma, Parma, Italy, 6 Centro Aziendale di Ematologia, Livorno, Italy, 7 F. Hoffmann-La Roche Ltd, Basel, Switzerland, 8 Austin Hospital, Heidelberg, Australia

PCN220 H21 QUALITATIVE INTERVIEWS TO PROVIDE IN-DEPTH UNDERSTANDING OF THE IMPACT OF NON-SMALL CELL LUNG CANCER (NSCLC) AND ITS TREATMENT ON THE LIVES OF PATIENTS AND THEIR FAMILIES/CAREGIVERS
Mulatero C 1, Lal R 1, Jewitt K 2, Tolley C 4, Wells J 1, Arbuckle R 2, Lloyd A 6, Brazier J 1, Devlin N 3, 4 Leeds Teaching Hospitals NHS Trust, Leeds, UK, 5 Guy’s and St Thomas’ NHS Foundation Trust, London, UK, 6 Novartis Pharmaceuticals UK Ltd, Camberley, UK, 3 Adelphi Values Ltd, Bollington, UK, 5 Adelphi Values Ltd., Bollington, UK, 3 ICON plc., Oxford, UK, 4 University of Sheffield, Sheffield, UK, 6 Office of Health Economics, London, UK

PCN221 H22 PREFERENCE ELICITATION ON BENEFITS AND RISKS OF MEDICINES USING A DISCRETE CHOICE EXPERIMENT
Beyer A 1, Hoekstra T 1, Selivanova A 7, Kingma B 1, Hillegel JL 1, Krabbe PF 2, 1 University Medical Center Groningen, Groningen, The Netherlands, 2 University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

PCN222 H23 DO EUROPEAN PATIENTS HAVE A SHARED PREFERENCE FOR THE BENEFITS AND RISKS OF MEDICINES?
Beyer A 1, Kingma B 1, Hoekstra T 1, Fasolo B 2, Hillegel JL 1, 1 University Medical Center Groningen, Groningen, The Netherlands, 2 London School of Economics and Political Science, London, UK

PCN223 H24 UNDERSTANDING THE IMPACT OF PATIENT AND PHYSICIAN PREFERENCES IN PERSONALIZED TREATMENT FOR MELANOMA USING A DISCRETE CHOICE EXPERIMENT
Stenehjem D 1, Korytowsky B 1, Oderda G 1, Wanishayakom T 1, Bauer H 1, Brinxer D 1, 1 University of Utah, Pharmacotherapy Outcomes Research Center, Program in Personalized Health, Salt Lake City, UT, USA, 2 Bristol-Myers Squibb, Plainsboro, NJ, USA

PCN224 H25 KNOWLEDGE ON BREAST CANCER AMONG WOMEN IN TOLNA AND BARANYA COUNTIES, HUNGARY
Vajda R 1, Sebestyén E 1, Horváthné Klívés Z 1, Pakai A 1, Gyúró M 1, Csákvári T 1, Boncz I 1, 1 University of Pécs, Pécs, Hungary, 2 University of Pécs, Zalaegerszeg, Hungary

PCN225 H26 A DISCRETE CHOICE EXPERIMENT FOR ENGAGING PATIENTS IN REIMBURSEMENT DECISION MAKING: PATIENT PREFERENCES ON ADJUVANT CHEMOTHERAPY IN BREAST CANCER
Liao C 1, Yang M 1, Hung Y 2, Chen S 1, Tang C 2, 1 National Taiwan University, Taipei, Taiwan, 2 Taipei Medical University, Taipei, Taiwan, 3 Chang Gung Memorial Hospital-Linkou, Taoyuan County, Taiwan

PCN226 H27 IS THERE A RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) POST-DOCETAXEL?
Traina S 1, Li T 1, Johnson K 1, Ho KP 1, Molina A 1, Cella D 1, Janssen Research & Development, Raritan, NJ, USA, 2 STAT-UT Inc., Toronto, ON, Canada, 3 Janssen Research & Development, Menlo Park, CA, USA, 4 Northwestern University Feinberg School of Medicine, Chicago, IL, USA

PCN227 H28 WILL RATING SCALE TYPES AND DISEASE CONDITIONS INFLUENCE CONCORDANCE BETWEEN COGNITIVE FUNCTION REPORTED BY CHILDREN AND THEIR PARENTS?
Lai J, Beaumont JL, Northwestern University, Chicago, IL, USA

PCN228 H29 THE WILLINGNESS OF CANCER OUTPATIENTS TO COMPLETE PATIENT-REPORTED OUTCOME MEASURES
OUTSIDE OF THE CLINIC

Höf V1, Song Y1, Brown C2, Vennettilli A1, Eng L1, Zarrin A1, Dobriyal A1, Chen L1, Mirshams M1, Patel D1, Hon H1, Pat V1, Ho A1, Solomon H1, Tiesssen K1, Thai H1, Irwin M1, Mahler M1, Xu W2, Liu G2, Howell D2, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, ON, Canada, 2Princess Margaret Cancer Centre, Toronto, ON, Canada

PCN229 H30 THE USE OF SOCIAL MEDIA TO GENERATE HEALTH DATA FOR EFFECTIVENESS RESEARCH: A SCOPING REVIEW

Kalf R1, Makady A1, Meijboom K1, Goetsch W2, The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2National Healthcare Institute (ZIN), Diemen, The Netherlands

PCN230 H31 THE IMPACT OF NON-MUSCLE INVASIVE BLADDER CANCER: QUALITATIVE RESEARCH WITH PATIENTS

Clark M1, Harris N2, Martin S1, Bartley K2, DeBusk K2, Abidoye O2, Shore N3, RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Genentech, South San Francisco, CA, USA, 4Carolina Urologic Research Center, Myrtle Beach, SC, USA

PCN231 H32 DO PATIENT REPORTED OUTCOMES (PRO) IN ONCOLOGY MATTER IN HEALTH TECHNOLOGY ASSESSMENTS (HTA)?

Casamayor M1, Palazzolo D2, Gubbels L3, Moise P4, Wijnands T4, Mantuano M5, Ivancescu C6, Quintiles, Barcelona, Spain, 2Quintiles, Reading, UK, 3Quintiles Advisory Services, Hoofddorp, The Netherlands, 4Quintiles, Levallois-Perret, France, 5Quintiles, Cassina de’ Pecchi (Milano), Italy

PCN232 H33 DEVELOPMENT OF A PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT OF CORE NON-SMALL CELL LUNG CANCER (NSCLC) SYMPTOMS

DeBusk K1, Johnson N2, Evans C2, Sandler A3, Ramalingam SS4, Campbell A5, Genentech, South San Francisco, CA, USA, 2Endpoint Outcomes, Boston, MA, USA, 3Emory University, Atlanta, GA, USA

PCN233 I1 CANCER IS ASSOCIATED WITH INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS

Engelhard J1, Jockwig A2, Kostev K1, 1IMS Health, Frankfurt am Main, Germany, 2Fresenius University of Applied Sciences, Idstein, Germany

PCN234 I2 TRANSLATION AND LINGUISTIC VALIDATION OF THE MODIFIED MYELOPROLIFERATIVE NEOPLASM SYMPTOM ASSESSMENT FORM - TOTAL SYMPTOM SCORE (MMPN-SAF TSS) FOR USE IN 26 COUNTRIES

Eremenco S1, Oko-osi H1, Arnold B2, Savic L3, Sterling K4, Athearn R5, Mesa RA6, Evidera, Inc., Bethesda, MD, USA, 2Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 3FACITtrans, Elmhurst, IL, USA, 4Gilead Sciences, Foster City, CA, USA, 5Mayo Clinic Cancer Center, Scottsdale, AZ, USA


Repo JP, Kask G, Barner-Rasmussen I, Blomqvist C, Tukiainen EJ, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

PCN236 I4 BREAST CANCER PATIENTS’ PERCEPTION ON HEALTH IMPACTS FROM RECEIVING CHEMOTHERAPY

Areepium N1, Chulalongkorn University, Bangkok, Thailand

PCN237 I5 HEALTH-RELATED QUALITY OF LIFE AND TREATMENT SATISFACTION AMONG PATIENTS RECEIVING NOVEL ANTI-ANDROGEN THERAPIES FOR THE TREATMENT OF METASTATIC CASTRATED-RESISTANT PROSTATE CANCER (MCRPC)

Dearden L1, Shalet N2, Artenie C3, Mills A4, Gater A5, Grant L6, Jackson C7, Janssen EMEA HEMAR, High Wycombe, UK, 2Janssen, High Wycombe, UK, 3Adelphi Research UK, Bollington, UK, 4Adelphi Values Ltd, Bollington, UK

PCN238 I6 REDUCING THE BARRIERS TO CAPTURING PATIENT REPORTED OUTCOMES IN ONCOLOGY STUDIES

Thilagathanath J1, O'Donohoe P2, CRF Health, London, UK

PCN239 I7 HOW CAN WE IMPROVE THE DESIGN OF PATIENT PREFERENCE RESEARCH IN ONCOLOGY? A CASE STUDY IN METASTATIC CASTRATED RESISTANT PROSTATE CANCER

Dearden L1, Eliasson L2, de Freitas H3, Shalet N4, Lloyd A5, Janssen EMEA HEMAR, High Wycombe, UK, 2ICON PRO, Oxford, UK, 3Janssen, High Wycombe, UK, 4ICON PRO, London, UK

PCN240 I8 PATIENTS’ PREFERENCES REGARDING THE SETTING OF ELECTRONIC PATIENT-REPORTED OUTCOME ASSESSMENTS

Holzner B1, Giesinger JM2, Zabernigg A3, Loth FL4, Rumpold G5, Wintner LM1, 1Medical University of Innsbruck, Innsbruck, Austria, 2Kufstein County Hospital, Kufstein, Austria

PCN241 I9 EFFECTS OF ADVERSE EVENTS ON QUALITY OF LIFE SCORES IN A RANDOMIZED CLINICAL TRIAL OF ADJUVANT CHEMOTHERAPY FOR BREAST CANCER: N-SAS BC 02

Kunisawa S1, Shimozuma K2, Tange C3, Maeda S4, Imanaka Y5, Watanebe T6, Ohashi Y7, Kyoto University, Kyoto, Japan, 2Ritsumeikan University, Kusatsu, Japan, 3Ritsumeikan University, Kusatsu City, Japan, 4Hamamatsu Oncology Center, Hamamatsu, Japan, 5Chuo University, Tokyo, Japan

PCN242 I10 MEASUREMENT OF HOPE IN PATIENTS WITH CANCER

Meyers O1, Higgins K2, Foley K3, 1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Ann Arbor, MI, USA, 3Pfizer, Philadelphia, PA, USA

PCN243 I11 DEVELOPMENT OF A WEB-BASED QUALITY OF LIFE PORTAL FOR BREAST CANCER PATIENTS
PCN244 112  HEALTH RELATED QUALITY OF LIFE OF CAREGIVERS AND PATIENTS TREATED FOR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH ORAL VINORELBINE

Linnet H1, Hansen O2, Meldgaard P3, Berdeaux G4, Mercier F5, 1Herning Hospital, Herning, Denmark, 2Odense hospital, Odense, Denmark, 3Hospital Aarhus, Arthus, Denmark, 4Pierre Fabre, Bouologne Billancourt, France, 5STAT PROCESS, Paris, France

PCN245 113  BURDEN OF ADVANCED BREAST CANCER FOR PATIENTS AND CAREGIVER IN EUROPE: COMPARISONS OF TWO TREATMENT FORMS OF VINORELBINE, ORAL AND INTRAVENOUS

Barni S1, Mousyset J2, Sediva M3, Zamagni C4, Garau I5, Feier B6, Berdeaux G7, Mercier F8, 1Ospedale TREVIGLIO-Caravaggio; 2Associazione Italiana di Oncologia Medica, Treviglio, BG, Italy, 3Clinique Provençale, Aix en Provence, France, 4Bulovka University Hospital, Prague, Czech Republic, 5Oncologia Medica Addarri Pollicino S.Osp. Malpighi, Bologna, Italy, 6Son Llatzer, Palma de Mallorca, Spain, 7Uniwersytecki Szpital Kliniczny, Worklow, Poland, 8Pierre Fabre, Bouologne Billancourt, France, 9STAT PROCESS, Paris, France

PCN246 114  QUALITY OF LIFE IN ADULT INTRADURAL PRIMARY SPINAL CORD TUMORS: SHORT FORM–36 CORRELATES WITH THE SCALES OF MCCORMICK AND AMINOFF-LOGUE

Nobre M1, Guirado V2, 1Heart Institute (InCor) São Paulo University, São Paulo, Brazil, 2Hospital da Clínicas - São Paulo University, São Paulo, Brazil

PCN247 115  PREDICTORS OF UTILITY OVER TIME AMONG PATIENTS WITH TREATMENT-NAÏVE ADVANCED MELANOMA FROM THE PHASE 3 CHECKMATE 066 TRIAL

Paly V1, Colby C2, Gilloteau I3, Exuzides A4, Briggs A5, 1ICON Plc, Morristown, NJ, USA, 2ICON plc, San Francisco, CA, USA, 3Bristol-Myers Squibb, Princeton, NJ, USA, 4ICON, plc., San Francisco, CA, USA, 5Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

PCN248 116  COST-UTILITY ANALYSIS OF ENZALUTAMIDE FOR PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY (ADT)

Vicente C1, Loblaw A2, North S3, Kassouf W4, Naidoo S5, Husein F6, Nakhaipour HR7, 1PIVINA Consulting Inc., Mississauga, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3University of Alberta, Edmonton, AB, Canada, 4McGill University Health Centre, Montreal, QC, Canada, 5Astellas, Chertsey, UK, 6Astellas, Markham, ON, Canada

PCN249 117  EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS (PS) IS AN INDEPENDENT PREDICTOR OF HRQOL IN UNRESECTABLE OR METASTATIC MELANOMA

Harrison JP1, Kim H2, Bristol-Myers Squibb Australia, Mulgrave, Australia

PCN250 118  HEALTH-RELATED QUALITY OF LIFE IN BLADDER CANCER: A SYSTEMATIC LITERATURE REVIEW

Bartley K1, DeBusk K1, Duff S2, 1Genentech, South San Francisco, CA, USA, 2Veritas Health Economics Consulting, Inc, Carlsbad, CA, USA

PCN251 119  STRUCTURED REVIEW OF PATIENT QUALITY OF LIFE FOLLOWING DIAGNOSIS WITH PROSTATE CANCER


PCN252 120  HEALTH-RELATED QUALITY OF LIFE (HRQOL) BENEFITS OF ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): AN IN-DEPTH ANALYSIS OF EQ-5D DATA FROM THE PREVAIL TRIAL


PCN253 121  PROGRESSIVE DISEASE DOES NOT IMPACT HRQOL IN PATIENTS RECEIVING NIVOLUMAB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA

Harrison JP1, Kim H2, Bristol-Myers Squibb Australia, Mulgrave, Australia

PCN254 122  QUALITY OF LIFE IN PATIENTS WITH BREAST CANCER IN SLOVAKIA

Matiskova I1, Bielik J2, Kormancova R3, Bystricky B4, Melus V5, 1Trencin University, Trencin, Slovak Republic, 2Trencin Hospital, Trencin, Slovak Republic

PCN255 123  QUALITY OF LIFE IN PATIENTS WITH KIDNEY CANCER IN SLOVAKIA

Mastilíkova D1, Bielik J2, Tuzincinova K3, Bystricky B4, Melus V5, Kliment J6, Sokol R7, 1Trencin University, Trencin, Slovak Republic, 2Trencin Hospital, Trencin, Slovak Republic, 3Martin University, Martin, Slovak Republic, 4Urology out patients, Trencin, Slovak Republic

PCN256 124  HEALTH PROFESSIONAL STUDENTS’ WILLINGNESS TO PAY FOR HUMAN PAPILLOMAVIRUS VACCINATION AND FACTORS INFLUENCING THEIR DECISION IN MALAYSIA

Mari Kannan M, Kingston R, Kelly Num S, Sue Chin N, Jin Yong N, Yun Lui L, Raymond How KC, International Medical
CANCER - Health Care Use & Policy Studies

PCN257  I25  INSURANCE PLAN SWITCH PATTERNS AMONG BREAST CANCER PATIENTS COMPARED TO NON-CANCER PATIENTS
Feinberg BA\textsuperscript{1}, Drenning J\textsuperscript{2}, Garofalo DF\textsuperscript{1}, Lal L\textsuperscript{3},Cardinal Health, Dublin, OH, USA, \textsuperscript{2}Cardinal Health, Dallas, TX, USA, \textsuperscript{3}Cardinal Health, Missouri City, TX, USA

PCN258  I26  SOCIAL BURDEN OF CHRONIC HCV INFECTION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Dimitrova M\textsuperscript{1}, Petrova G\textsuperscript{2}, Kamusheva M\textsuperscript{2}, Savova A\textsuperscript{2}, Doneva M\textsuperscript{2}, Medical University-Sofia, Faculty of Pharmacy, Sofia, Bulgaria, \textsuperscript{1}Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria

PCN259  I27  A LOSS OF CHANCE INDEX: A NEW TOOL FOR OPTIMIZING PATIENT ACCESS TO INNOVATIVE DRUGS
Gavin F\textsuperscript{1}, Sarkozy F\textsuperscript{2}, Jouan-Flahault C\textsuperscript{2}, Fumoleau P\textsuperscript{1}, ROCHE SAS - FRANCE, Boulogne Billancourt, France, \textsuperscript{2}FSNB Health & Care, Paris, France, \textsuperscript{3}LEEM, Paris, France, \textsuperscript{4}Centre Georges François Leclerc, Dijon, France

PCN260  I28  BURDEN OF METASTATIC RENAL CELL CARCINOMA IN FRANCE FROM 2008 TO 2013: ANALYSIS OF THE FRENCH NATIONAL HOSPITAL DATABASE
Maroun R\textsuperscript{1}, Maunoury F\textsuperscript{2}, Benjamin L\textsuperscript{1}, Nachbaur G\textsuperscript{1}, Durand-Zaleski i\textsuperscript{3}, GSK France, Marly le roi, France, \textsuperscript{2}Statesia, Le Mans, France, \textsuperscript{3}URC Eco, Paris, France

PCN261  I29  VALUE OF ASSESSING THE BURDEN OF HOSPITALIZATIONS FOR METASTATIC MELANOMA IN THE ERA OF TARGETED THERAPIES: ANALYSIS OF THE FRENCH NATIONAL HOSPITAL DATABASE FROM 2008 TO 2013
Maroun R\textsuperscript{1}, Maunoury F\textsuperscript{2}, Benjamin L\textsuperscript{1}, Nachbaur G\textsuperscript{1}, Durand-Zaleski i\textsuperscript{3}, GSK France, Marly le roi, France, \textsuperscript{2}Statesia, Le Mans, France, \textsuperscript{3}URC Eco, Paris, France

PCN262  I30  SEARCH FOR CLINICALLY AND ECONOMICALLY EFFECTIVE LYMPHOMAS TREATMENT
Lischchyschna O, Rubtsova I, Shilkina O, State Expert Centre of the Ministry of Health of Ukraine, Kyiv, Ukraine

PCN263  I31  MAPPING THE DIAGNOSTIC PATHWAY FOR BREAST CANCER IN ENGLAND AND COMPARISON TO EUROPE
Adams EJ\textsuperscript{1}, Midha D\textsuperscript{1}, Postula A\textsuperscript{2}, Vecino Ortiz Al\textsuperscript{1}, Aquarius Population Health, London, UK, \textsuperscript{2}Cepheid Europe, Maurens-Scopont, France

PCN264  I32  QUANTIFYING COSTS OF MEDICAL PERSONNEL INVOLVED WITH RADIATION THERAPY USING ADMINISTRATIVE DATABASES
Seung SJ\textsuperscript{1}, Cheng SY\textsuperscript{2}, Rahman F\textsuperscript{2}, Earle C\textsuperscript{2}, Mittmann N\textsuperscript{1}, Sunnybrook Research Institute, Toronto, ON, Canada, \textsuperscript{1}Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, \textsuperscript{2}Ontario Institute for Cancer Research, Toronto, ON, Canada

PCN265  I33  MEASURING THE IMPORTANCE OF DECISION MAKING CRITERIA FOR ANTICANCER DRUG REIMBURSEMENT IN KOREA
Kwon S, Park S, Lee E, College of Pharmacy, Sungkyunkwan University, Suwon, South Korea

PCN266  J1  EXPERIENCES WITH PRICE COMPETITION OF BIOSIMILAR DRUGS IN HUNGARY IN CASE OF COLONY-STIMULATING FACTOR PRODUCTS
Hornyák L\textsuperscript{1}, Nagy Z\textsuperscript{2}, Tálos Z\textsuperscript{2}, Endrei D\textsuperscript{1}, Ágoston I\textsuperscript{1}, Boncz T\textsuperscript{1}, Csonokny Ferenc Hospital, Veszprém, Hungary, \textsuperscript{2}University of Pécs, Pécs, Hungary, \textsuperscript{1}University of Pécs, Zalaegerszeg, Hungary

PCN267  J2  HOW CAN BIOSIMILARS COMPETE WITH EXISTING BIOLOGICS: UPDATE OF THE RESULTS OF A PREVIOUS STUDY
Loubiere A\textsuperscript{1}, Boquet F\textsuperscript{1}, Paubel P\textsuperscript{2}, Faculty of Pharmacy, University Paris Descartes, Sorbonne Paris Cité, Paris, France, \textsuperscript{1}Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France, \textsuperscript{2}Health Law Institute, Inserm, UMR S 1145, Paris Descartes Université, Sorbonne Paris Cité, Paris, France, Paris, France

PCN268  J3  APPRAISING THE VALUE OF LENVATINIB FOR RADIO-IODINE REFRACTORY DIFFERENTIATED THYROID CANCER (RR-DTC): A MULTI-COUNTRY STUDY APPLYING HOLISTIC MULTICRITERIA DECISION ANALYSIS (MCDA)
Wagner M\textsuperscript{1}, Khgury H\textsuperscript{1}, Bennetts L\textsuperscript{1}, Willet J\textsuperscript{2}, Lister J\textsuperscript{2}, Berto P\textsuperscript{4}, Ehreth J\textsuperscript{2}, Badia X\textsuperscript{6}, Grimaldi-Bensouda L\textsuperscript{7}, Goetghebeur M\textsuperscript{8}, LASER Analytica, Montreal, QC, Canada, \textsuperscript{9}LASER Analytica, New York, NY, USA, \textsuperscript{10}LASER Analytica, Lörrach, Germany, \textsuperscript{11}LASER Analytica, Milan, Italy, \textsuperscript{12}LASER Analytica and Omakase Consulting, Barcelona, Spain, \textsuperscript{13}LASER Research, Paris, France, \textsuperscript{14}LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada

PCN270  J4  COST PER QALY AS A POTENTIAL HURDLE IN ACCESSIBILITY TO INNOVATIVE CANCER CARE IN SELECTED CEE COUNTRIES
Chudziak D\textsuperscript{1}, Maci och T\textsuperscript{1}, Jakubczyk M\textsuperscript{1}, Skrzekowska-Baran I\textsuperscript{2}, Palejko-Podrecka B\textsuperscript{2}, Niewada M\textsuperscript{3}, HealthQuest, Warsaw, Poland, \textsuperscript{3}Janssen-Cilag Polska, Warsaw, Poland, \textsuperscript{3}Medical University of Warsaw, Warsaw, Poland

PCN271  J5  ARE YOU AT RISK OF CANCER? CONSIDER WHERE YOU LIVE IN ENGLAND FOR ACCESS TO THE MOST EXPENSIVE ONCOLOGY TREATMENTS

PCN272  J6  CANCER DRUG FUNDING DECISIONS IN THE UK: INNOVATION AND VALUE IN THE BIOLOGICS ERA
Godber E\textsuperscript{1}, Ni Choitir C\textsuperscript{2}, Ratcliffe M\textsuperscript{2}, Bailey O\textsuperscript{3}, Tatla S\textsuperscript{4}, H-LABS Ltd, London, UK, \textsuperscript{2}PHMR Ltd, London, UK, \textsuperscript{3}Methods Analytics Ltd, London, UK, \textsuperscript{4}Roche Products Ltd, Welwyn Garden City, UK
PCN273 J7  ARE TRENDS IN SPENDING ON ONCOLOGY TREATMENTS SUSTAINABLE?: ANALYSIS OF SALES PATTERNS IN MAJOR GLOBAL MARKETS
Manning R, Bates White Economic Consulting, Washington, DC, USA

PCN274 J8  ANALYSIS OF EVALUATIONS MADE BY THE UK CANCER DRUG FUND PANEL OF BREAST CANCER TREATMENTS IN RELATION TO OVERALL SCORES AND FINAL CDF DECISIONS
Chandler T, Wright A, Solaman DA, PHMR Ltd, London, UK

PCN275 J9  SIPULEUCET-L (PROVENGE®): AUTOPSY OF AN INNOVATIVE CHANGE OF PARADIGM IN CANCER TREATMENT
Jaroslawski S1, Caban A1, Toumi M2, 1Creativ-Ceutical, Krakow, Poland, 2University of Marseille, Marseille, France

PCN276 J10 A NEW PACE FOR THE SMC?
Macaulay R, PAREXEL, London, UK

PCN277 J11 THE ITALIAN REGIONAL ACCESS OF NEW CANCER DRUGS: AN EXAMPLE IN FOUR REGIONS
Visentin E, Heiman F, Ripellino C, IMS Health Information Solutions Medical Research S.r.l, Milan, Italy

PCN278 J12 GEOGRAPHICAL DISPARITIES IN COLON CANCER CARE IN EUROPE: IMPLICATIONS FOR ACCESS TO INNOVATIVE MEDICINES VIA THE UK CANCER DRUGS FUND

PCN279 J13 DRUG USE AMONG ELDERLY IN THE YEAR BEFORE COLON CANCER DIAGNOSIS VERSUS MATCHED CANCER-FREE CONTROLS
van Erning FN1, Zanders MM1, van Herk-Sukel MP2, Kuiper JG2, Lemmens VE1, Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 2PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

PCN280 J14 ANALYSIS OF ERIEULIN MESYLATE UTILIZATION IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) BY LINE OF THERAPY AND ASSOCIATED CHANGES OVER TIME
Feinberg BA1, Drenning J2, Garofalo DF3, Montgomery J4, 1Cardinal Health, Dublin, OH, USA, 2Cardinal Health, Dallas, TX, USA

PCN281 J15 PRIORITY ISSUES AND RECOMMENDATION SELECTION IN CANCER PAIN MANAGEMENT
Hyun M, Dongguk University, Gyeongju-si, South Korea

PCN282 J16 CHEMOTHERAPY EXPOSURE AND OUTCOMES AMONG PATIENTS DIAGNOSED WITH CHRONIC LYMPHOID LEUKEMIA
Kuiper JG1, Musingarimi P2, Taprich C1, Penning-van Beest FJ2, Gaudig M1, PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Janssen Health Economics & Market Access EMEA, High Wycombe, UK, 1Janssen Medical Affairs EMEA, Neuss, Germany

PCN283 J17 DESCRIPTIVE EVALUATION OF PATIENT CHARACTERISTICS AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS DIAGNOSED WITH BREAST CANCER
Greene N1, Greene M2, 1MCPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA

PCN284 J18 PATIENT CHARACTERISTICS AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS DIAGNOSED WITH NEOPLASM OF COLON
Greene N1, Greene M2, 1MCPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA

PCN285 J19 DESCRIPTIVE EVALUATION OF PATIENT CHARACTERISTICS AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS DIAGNOSED WITH MALIGNANT NEOPLASM OF ANUS
Greene N1, Greene M2, 1MCPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA

PCN286 J20 DESCRIPTIVE EVALUATION OF PATIENT CHARACTERISTICS AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS DIAGNOSED WITH OVARIAN CANCER
Greene N1, Greene M2, 1MCPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA

PCN287 J21 PATIENT CHARACTERISTICS AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS DIAGNOSED WITH PROSTATE CANCER
Greene N1, Greene M2, 1MCPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA

PCN288 J22 Abstract Title: DESCRIPTIVE EVALUATION OF PATIENT CHARACTERISTICS AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS DIAGNOSED WITH MALIGNANT NEOPLASM OF RECTUM
Greene N1, Greene M2, 1MCPHS University, Medford, MA, USA, 2Georgia State University, Medford, MA, USA

PCN289 J23 INTERNATIONAL DIFFERENCES IN THE ROLE OF PAYER AND ADMINISTRATIVE CONTROLS IN PRESCRIBING DECISIONS
Silvey M, Rider A, Wellam HW, Piercy J, Adelphi Real World, Bollington, UK

PCN290 J24 TIERED PRICING IN ONCOLOGY - DRIVERS FOR IMPROVED PATIENT ACCESS AND COMMERCIAL SUCCESS
Favaro A, Saraf S, ICON P&M, London, UK

PCN291 J25 BUILDING A REAL WORLD DATA NETWORK TO SUPPORT ACCESS TO ONCOLOGY MEDICINES IN FRANCE: THE PERSONALISED REIMBURSEMENT MODELS INITIATIVE
PCN292 J26 ASSESSING THE GAP BETWEEN EVIDENCE BASED INDICATIONS FOR RADIOThERAPY AND ACTUAL PRACTICE IN EUROPEAN COUNTRIES
Borras JM, Duncombe P, Barton M, Gasparotto C, Defourny N, Grau C, Lievens Y, University of Barcelona, Hospital de, Spain, 2University of Calgary, Calgary, AB, Canada, 3University South Wales, Liverpool, Australia, 4European Society Fo Radiotherapy and Oncology, Brussels, Belgium, 5Aarhus University, Aarhus, Denmark, 6Ghent university, Ghent, Belgium

PCN293 J27 USING GEOGRAPHIC INFORMATION SYSTEMS AND MULTI-CRITERIA DECISION ANALYSIS TO ADDRESS SPATIALLY EXPlicit PROBLEMS IN HEALTHCARE POLICY DECISION MAKING
Broekhuizen H, Broekhuizen MA, Ijzerman MJ,1 University of Twente, Enschede, The Netherlands, 2University of Utrecht, Utrecht, The Netherlands

PCN294 J28 PROGRESSIVE INNOVATION IN ONCOLOGY: VALUING OUTCOMES BEYOND SURVIVAL
Quinn C, Palmer S, Bruns J, Grant C, Sykes D, Kaura S, PRMA Consulting, Fleet Hampshire, UK, 1University of York, Heslington, York, UK, 2German Cancer Society, Berlin, Germany, 3PRMA Consulting, Hampshire, UK, 4Celgene Corporation, Summit, NJ, USA

PCN295 J29 USE OF QUALITY OF CARE (QC) METRICS AMONG ONCOLOGISTS IN THE UNITED STATES (US)
Narayan San, Hautamaki E, Ipsos Healthcare, Washington, DC, USA

PCN296 J30 THE PROSTATE CANCER REGISTRY: ANALYSIS OF MEDICAL RESOURCE UTILISATION (MRU) IN AN INTERNATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Chowdhury S, Birtle A, Bjaerthel A, Costa L, Feyerabend S, Galli L, Lumen N, Kalinka-Warchocha E, Maroto P, Matveev V, Paiss T, Spaeth D, Dearden L, Klumper E, Thingstad T, Wapenaar R, Lee E, Guy's Hospital, London, UK, 2Royal Preston Hospital, Preston, UK, 3Skåne University Hospital Malmö, Malmö, Sweden, 4Hospital de Santa Maria, Lisbon, Portugal, 5Studienpraxis Urologie, Nürtingen, Germany, 6Istituto Toscano Tumori, Pisa, Italy, 7Ghent University Hospital, Ghent, Belgium, 8Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland, 9Stant Pal Hospital, Barcelona, Spain, 10N.N. Blokhin Cancer Research Center, Moscow, Russia, 11Urologieteam Ulm, Ulm, Germany, 12Centre d'Oncologie de Gentilly, Nancy, France, 13Janssen EMEA HEMAR, High Wycombe, UK, 14SMS Oncology BV, Amsterdam, The Netherlands, 15Janssen-Cilag AS, Oslo, Norway, 16Janssen-Cilag BV, Tilburg, The Netherlands, 17Janssen Pharmaceutica, Beerse, Belgium

PCN297 J31 HEALTH CARE RESOURCE USE AND COSTS AMONG POLYCYTHEMIA VERA PATIENTS IN THE UNITED STATES: RESULTS FROM AN OBSERVATIONAL COHORT STUDY
Goyal RK, Davis KL, Côte I, Mounedj N, Kaye JA, RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Novartis Pharma SAS, Paris, France, 4RTI Health Solutions, Waltham, MA, USA

PCN298 J32 THE CLINICAL AND ECONOMIC BURDEN OF SKELETAL RELATED EVENTS IN AUSTRIA, CZECH REPUBLIC, GERMANY, GREECE, ITALY, SPAIN AND SWITZERLAND: A COMPARISON BETWEEN THE USE OF DENOSUMAB AND ZOLEDRONIC ACID IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES
Cristino J, Finkel J, Maniadakis N, Perez Encinas M, Ikenberg R, Campos Tapias I, Jandova P, Zahn DP, Moser C, Bolognese L, Tritaki G, Gatta F, Hechmati G, Amgen (Europe) GmbH, Zug, Switzerland, 2Clinic of Oncology and radiotherapy (FN v PLZN), Plzen, Czech Republic, 3Department of Health Services Organization, National School of Public Health, Athens, Greece, 4Hospital Universitario Fundacion Alcorcon, Madrid, Spain, 5Amgen GmbH, Munich, Germany, 6Amgen SA, Barcelona, Spain, 7Amgen s.r.o, Prague, Czech Republic, 8Amgen Switzerland AG, Zug, Switzerland, 9Amgen GmbH, Vienna, Austria, 10Amgen SrL, Milan, Italy, 11AMGEN Hellas Ltd, Athens, Greece

PCN299 J33 THE CLINICAL AND ECONOMIC BURDEN OF SKELETAL RELATED EVENTS IN AUSTRIA, CZECH REPUBLIC, GERMANY, GREECE, ITALY, SPAIN AND SWITZERLAND: A COMPARISON BETWEEN THE USE OF DENOSUMAB AND ZOLEDRONIC ACID IN PATIENTS WITH BREAST CANCER AND BONE METASTASES
Cristino J, Diel I, Finkel J, Perez Encinas M, Maniadakis N, Ikenberg R, Campos Tapias I, Jandova P, Zahn DP, Moser C, Bolognese L, Tritaki G, Gatta F, Hechmati G, Amgen (Europe) GmbH, Zug, Switzerland, 2Praxisklinik am Rosengarten, Mannheim, Germany, 3Clinic of Oncology and radiotherapy (FN v PLZN), Plzen, Czech Republic, 4Hospital Universitario Fundacion Alcorcon, Madrid, Spain, 5Department of Health Services Organization, National School of Public Health, Athens, Greece, 6Amgen GmbH, Munich, Germany, 7Amgen SA, Barcelona, Spain, 8Amgen s.r.o, Prague, Czech Republic, 9Amgen Switzerland AG, Zug, Switzerland, 10Amgen GmbH, Vienna, Austria, 11Amgen SrL, Milan, Italy, 12AMGEN Hellas Ltd, Athens, Greece

PCN300 K1 SWITCHING TO A 6-MONTHLY TRIPTORELIN FORMULATION FOR PROSTATE CANCER (PCA) REDUCES PATIENT–NHS INTERACTIONS AND HEALTHCARE RESOURCE USE: REAL WORLD EVIDENCE (RWE) FROM PROJECT DESERVE (DECAPTETYL SERVICE EVALUATION)
Cornford P, Jefferson K, Cole O, Gilbody JS, Nayar V, Audny G, Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK, 2University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, 3The Medical Specialist Group, St Martin's, Channel Islands, Ipsen Limited, Slough, UK, 4SVM Pharma, Winchfield, UK

PCN301 K2 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB IN TREATMENTING DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA
Qian L, China Pharmaceutical University, Beijing, China

PCN302 K3 DISEASE PREVALENCE AND HEALTHCARE RESOURCES CONSUMPTION IN PATIENTS WITH BASAL CELL
Carcinoma in Italian LHUS

Degli Esposti L1, Sangiorgi D1, Buda S1, Crovato E1, Cerra C1, CliCon S.r.l., Ravenna, Italy, 2Pavia LHU, Pavia, Italy

PCN303 K4 ASSESSMENT OF BURDEN AND ECONOMIC IMPACT OF THE VANDETANIB RESTRICTED DISTRIBUTION PROGRAM IN CANADA

Frise S1, Bergamasco A2, Kozmenko M1, Salvo F1, Moride Y1, AstraZeneca Canada, Mississauga, ON, Canada, 2YolaRx Consultants, Paris, France, 3INSERM Unité 657, Bordeaux, France, 4Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada

PCN304 K5 COMPARATIVE ANALYSIS OF EXPENDITURE OF DRUGS FOR MALIGNANCY

Sabo A1, Tomic Z1, Sklenarova Z1, Paut Kusturina M1, Milijasevic B2, Faculty of medicine, Novi Sad, Serbia and Montenegro, 2Faculty of Medicine, Novi Sad, Serbia and Montenegro

PCN305 K6 PATIENT COUNT FORECASTS OF ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS FROM THE UK, GERMANY, FRANCE, ITALY AND SPAIN (EU-5)

Kish JK1, O’Day K1, Manley-Daumont M1, Campbell DJ1, Penrod J1, Xcenda, Palm Harbor, FL, USA, 2Bristol Myers Squibb, Paris, FL, USA, 3Bristol Myers Squibb, New Brunswick, NJ, USA

PCN306 K7 THE CANCER DRUGS FUND AND PATIENT ACCES SCHEMES WITHIN THE UK: INCREASED ACCESS TO ONCOLOGY MEDICINES OR REDUCED VALUE FOR MONEY?

Maguire PT, Gibson E, Wickenstones, Goring Heath, UK

PCN307 K8 IMPACT OF DRUG’S PRESENTATION ON PATIENTS’ PERCEPTION OF TREATMENT’S RISKS & BENEFITS THROUGH NEW ORDINAL GEE MODELLING METHOD: RESULTS FROM IMI PROTECT WP6

Wieck W1, Karcher H1, Amzal B2, Beyer A1, Hoekstra T1, Basilect S1, Hoekstra J1, LASER Analytica, London, UK, 2Decision Analytics, LASER Analytica, London, UK and, Paris, France, 3University Medical Center Groningen, Groningen, The Netherlands, 4London School of Economics and Political Science, London, UK

PCN308 K9 COST OF QUESTIONNAIRE-BASED PROCESS TO IDENTIFY OCCUPATIONAL EXPOSURES AMONG PATIENTS WITH LUNG CANCER

Perrier L1, Neecha A1, Perol O1, Perol M1, Fayette J1, Rebattu P1, Bonnand S1, Philip T1, Charbotel B2, Fervers B1, Cancer Centre Léon Bérard, Lyon Cedex 08, France, 2Hospices civils de Lyon, Pierre-Bénite, France

PCN309 K10 INTERNATIONAL COMPARISON OF INTERNET INFORMATION SOURCE IN BREAST CANCER

Ogawa H1, Onishi Y2, Watanabe K1, Hisada K1, Watanabe K2, Recruit Career Co., Ltd, Tokyo, Japan, 2Creativ-Ceutical K.K., Tokyo, Japan, 3Big Globe Inc., Tokyo, Japan, 4Eisai Co., Ltd., Tokyo, Japan, 5Teikyo University, Tokyo, Japan

PCN310 K11 CLINICAL AND HEALTH-ECONOMIC CRITERIA FOR THE ASSESSMENT OF NEW IMMUNE-ONCOLOGIC DRUGS IN SPAIN

López-Bastida J1, Oliva Moreno J1, Sánchez Martínez F1, González García P1, Castilla La Mancha University, Talavera de la Reina, Spain, 2Castilla La Mancha University, Toledo, Spain, 3MURCIA University, Murcia, Spain, 4Bristol-Meyers Squibb, Madrid, Spain

PCN311 K12 A TIME AND MOTION STUDY OF DENOSUMAB SUBCUTANEOUS INJECTION AND ZOLEDRONIC ACID INTRAVENOUS INFUSION IN PATIENTS WITH METASTATIC BONE DISEASE IN BELGIUM

Body J1, Mebis J2, Peeters M1, Besse-Hammer T1, Fikkert V1, de Cock E1, Tao S1, Kritikou P1, Gatta F1, Hechmati G1, CHU Brugmann, Brussels, Belgium, 2Jessia Ziekenhuis, Hasselt, Belgium, 3Antwerp University Hospital, UZA, Edegem, Belgium, 4Amgen Belgium, Brussels, Belgium, 5United BioSource Corporation, Barcelona, Spain, 6United BioSource Corporation, Montreal, QC, Canada, 7United BioSource Corporation, London, UK, 8Amgen (Europe) GmbH, Zug, Switzerland

PCN312 K13 RESULTS FROM A TIME AND MOTION STUDY OF DENOSUMAB SUBCUTANEOUS INJECTION AND ZOLEDRONIC ACID INTRAVENOUS INFUSION IN PATIENTS WITH METASTATIC BONE DISEASE FROM ITALIAN SITES

Pedrazzoli P1, Caraceni A1, Beato A2, Adamo V2, Testore F2, Pigni A2, Body J1, Sgreccia L1, de Cock E1, Tao S1, Kritikou P1, Hechmati G1, Gatta F1, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy, 2Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy, 3Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy, 4Azienda Ospedaliero Ospedali Riuniti Paparo Piemonte, Messina, Italy, 5A.S.L. AT, Asti, Italy, 6CHU Brugmann, Brussels, Belgium, 7Amgen Srl, Milan, Italy, 8United BioSource Corporation, Barcelona, Spain, 9United BioSource Corporation, Montreal, QC, Canada, 10United BioSource Corporation, London, UK, 11Amgen (Europe) GmbH, Zug, Switzerland

PCN313 K14 DESCRIPTION OF BASELINE CHARACTERISTICS OF PATIENTS PROVIDED CANCER CARE WITHIN A NOVEL COMMERCIAL HEALTH PLAN CANCER CARE QUALITY PROGRAM IN THE FIRST YEAR

Tunceli O1, Willey V1, Quimbo R1, Mack M1, Malin J1, HealthCore Inc., Wilmington, DE, USA, 2Anthem, Woodland Hills, CA, USA

PCN314 K15 ONCOLOGIST SUPPORT FOR AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) CONSOLIDATED PAYMENTS FOR CANCER CARE MANAGEMENT IN THE UNITED STATES (US)

Narayanan S, Hautamaki E, Ipsos Healthcare, Washington, DC, USA

PCN315 K16 G-BA DOES NOT ADJUST EVIDENCE REQUIREMENTS IN EARLY BENEFIT ASSESSMENT IN CASES OF PRE-DEFINED, EFFICACY-BASED CROSS-OVER DECISIONS IN ONCOLOGY TRIALS

Isbary G1, Staab TR1, Amelung VE1, Dintsios C1, Ruof J1, Roche Pharma, Grenzach-Wyhlen, Germany, 2Institute for
PCN331 K17 QUALITATIVE ASSESSMENT OF SOCIETAL PREFERENCES FOR MARKET ACCESS OF CANCER DRUGS
Pauwels K, Huys I, Casteels M, Simoens S,KU Leuven, Leuven, Belgium

PCN331 K18 PRICE STRUCTURE ASSESSMENT OF SELECTED ONCOLOGY PRODUCTS IN CHINA, TAIWAN, SOUTH KOREA, BRAZIL, AND MEXICO
Napieck D, Shah S, Ramesh V,Market Access Solutions LLC, Raritan, NJ, USA

PCN331 K19 IMPACT ON TIME GAP BETWEEN APPROVAL AND REIMBURSEMENT OF TARGET THERAPY TO ADVANCED COLORECTAL CANCER
Chang CJ1, Chou T2, Chang S2, Chien L1, Fann CS3, Chang Gung University, Tao-Yun, Taiwan, 2Chang Gung University, Kwei Shan, Tao Yuan, Taiwan, 3Academia Sinica, Taipei, Taiwan

PCN331 K20 4+ YEARS OF AMNOG – CLINICAL DRIVERS FOR SUCCESSFUL DOSSIER SUBMISSIONS IN ONCOLOGY
Dehnen J, Goldhagen K, Petry D,IMS Consulting Group, Muenchen, Germany

PCN331 K21 COMPARATIVE COST-EFFECTIVENESS OF DRUGS IN EARLY VERSUS LATE STAGES OF CANCER; REVIEW OF THE LITERATURE AND A CASE STUDY IN BREAST CANCER
Dvortsin E1, Eijssen EM2, van Brussel J3, Gout-Zwart J1, Postma MJ2, 1University of Groningen, Leeuwarden, The Netherlands, 2University of Groningen, Groningen, The Netherlands

PCN331 K22 OPPORTUNITIES WITH ACCELERATED APPROVAL TIMES, BUT STUMBLES AT HTA? THE IMPACT OF A LIMITED EVIDENCE PACKAGE
McKendrick J, Dunsch A, Scott MA, Jones C, Sykes D,PRMA Consulting, Hampshire, UK

PCN332 K23 DOES BUDGET IMPACT AFFECT REIMBURSEMENT DECISIONS MADE BY THE CANCER DRUGS FUND IN ENGLAND?
Stewart G, Montgomery S, Kusel J, Costello Medical Consulting Ltd, Cambridge, UK

PCN332 K24 PATIENT REPORTED OUTCOMES (PRO) IN POSTPROGRESSION ONCOLOGY: IMPLICATIONS IN HEALTH TECHNOLOGY ASSESSMENTS (HTA) & PAYER DECISION MAKING
Hoque S1, Brogan AP1, DeMuro C1, D’Alessio D2, Bal V2, RTI Health Solutions, Research Triangle Park, NC, USA, 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCN332 K25 WHAT MAKES A PHARMACEUTICAL PRICING & REIMBURSEMENT PROCESS PATIENT-CENTRIC? A COMPARATIVE ANALYSIS OF 11 SYSTEMS
Candotti-Besson B, Cozzone J, Roche Products Limited, Welwyn Garden City, UK

PCN332 K26 DELAYS IN DIAGNOSIS OF BREAST CANCER IN GREECE: FINDINGS FROM A QUALITATIVE STUDY
Karampli E1, Maina A1, Tsiantou V1, Mylona K1, Skrumpelos A2, Pavi E1, Kyriopoulos J1, 1National School of Public Health, Athens, Greece, 2Roche (Hellas) S.A., Athens, Greece

PCN332 K27 A PRAGMATIC APPROACH TO DATA SOURCE SELECTION FOR USE IN REAL-WORLD EVIDENCE (RWE) GENERATION
Lie X, Ivanescu C, Nijhuis T, Quintiles Advisory Services, Hoofddorp, The Netherlands

PCN332 K28 WHAT LIFECYCLE MANAGEMENT LESSONS CAN WE LEARN FROM PD-1 IMMUNO-ONCOLOGY THERAPIES?
Carr DR, Anastasaki E, Chriv E, Bradshaw SE, Market Access Solutions Ltd, London, UK

PCN332 K29 REAL WORLD EVIDENCE IN ONCOLOGY – STATUS QUO IN GERMANY
Borchert K, Haas J, Mittendorf T, Braun S, Xcenda GmbH, Hannover, Germany

PCN333 K30 FROM DIAGNOSIS TO TREATMENT AND SURVIVAL: THE EMOTIONAL JOURNEY OF PATIENTS WITH BREAST CANCER
Tsiantou V1, Maina A1, Karampli E1, Mylona K1, Tzintziropoulo E2, Skrumpelos A2, Pavi E1, Kyriopoulos J1, 1National School of Public Health, Athens, Greece, 2Roche (Hellas) S.A., Athens, Greece

PCN333 K31 HOW HAS THE SMC PATIENT AND CLINICIAN ENGAGEMENT (PACE) PROCESS BEEN USED IN ASSESSMENTS OF END-OF-LIFE MEDICINES AND MEDICINES TO TREAT VERY RARE CONDITIONS?
Akesson C1, Jones C2, McKendrick J3, Grant C1, PRMA Consulting, Fleet, UK, 2PRMA Consulting, Hampshire, UK

PCN333 K32 FEMALE BREAST CANCER: BURDEN OF DISEASE IN PORTUGAL
Sousa R1, Fiorentino F1, Alarcão J1, Lopes Pereira C1, Jesus G1, Costa J2, Gouveia M1, Borges M2, Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 1Institute of Molecular Medicine, Lisbon, Portugal, 2Católica Lisbon School of Business and Economics, Lisbon, Portugal

PCN333 K33 APPLICATION OF ASCO VALUE FRAMEWORK EVALUATIONS OF NET HEALTH BENEFIT FOR ONCOLOGY DRUGS LAUNCHED IN THE UNITED STATES BETWEEN 2013 AND 2015
Li J, Asabere A, Kelly S, Cho Y, Dua D, Bastian A, GfK, San Francisco, CA, USA

PCN334 L1 FRENCH HEALTH TECHNOLOGY ASSESSMENT OF ANTI NEOPLASTIC DRUGS INDICATED IN THE TREATMENT OF SOLID TUMOURS: PERSPECTIVE FOR FUTURE TRENDS
Chouaid C1, Borget i1, Braun E2, Bazil M3, Schaezt D4, Remuzat C4, Touni M5, Centre Hospitalier Intercommunal, DHU-ATVB, Créteil, France, 2Institut Gustave Roussy, Villejuif, France, 3Janssen, Issy-les-Moulineaux, France, 4Creative-Ceutical, Paris, France, 5Aix-Marseille University, Marseille, France
PCN335 L2 DIFFERENCES AND SIMILARITIES IN HTA: A COMPARATIVE ANALYSIS OF THE DECISION-MAKING PROCESSES FOR CANCER DRUGS ACROSS 4 COUNTRIES
Visintín E, Nicod E1,2, London School of Economics and Political Sciences, London, UK, 1London School of Economics and Political Science, London, UK

PCN336 L3 TRENDS IN END-OF-LIFE APPRAISALS AND RECOMMENDATIONS BY NICE FOR ONCOLOGY THERAPIES

PCN337 L4 PAYER/HTA REQUIREMENTS IN METASTATIC BREAST CANCER
Holmstrom S1, Kooreman PJ2, Van Engen A3, Heemstra L3, Novak A1, Naidoo S4,1 Astellas Pharma Global Development, Leiden, The Netherlands, 1Quintiles, Hoofddorp, The Netherlands, 2Quintiles Advisory Services, Hoofddorp, The Netherlands, 3Astellas, Chertsey, UK

PCN338 L5 PERSONALISED BREAST SCREENING: KEY DRIVERS OF COST EFFECTIVENESS
Gray E, Jelonek A, Payne K, University of Manchester, Manchester, UK

PCN339 L6 ANALYSIS OF DIFFERENCES IN HTA REIMBURSEMENT DECISIONS OF STAGE IV (METASTATIC) BREAST CANCER MEDICATIONS ACROSS DIFFERENT COUNTRIES
Schoenherr N1, Gordon J2,1 Boehringer Ingelheim Ltd., Bracknell, UK, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany

PCN340 L7 TO WHAT EXTENT DO PAYERS’ ASSESSMENT OF CLINICALLY RELEVANT OUTCOMES ALIGN WITH CLINICIANS IN ONCOLOGY?
Ryan J1, van Engen A2, Heemstra L3, Kreeftmeijer J4, AstraZeneca, Cambridge, UK, 1Quintiles, Hoofddorp, The Netherlands, 2Quintiles Advisory Services, Hoofddorp, The Netherlands

PCN341 L8 RELATIONSHIP BETWEEN THE PREVALENCE OF CANCERS IN ENGLAND AND WALES AND THE PERFORMANCE OF TECHNOLOGY APPRAISALS
Hughes R1, Chawla R2, AccuScript Consultancy, Reading, UK, 1AccuScript Solutions, Ludhiana, India

PCN344 L9 THE DUTCH MELANOMA TREATMENT REGISTRY AS BLUEPRINT FOR USING REGISTRY DATA TO IMPROVE HEALTH CARE DECISION MAKING
Franken M1, Leeneman B2, Schouwenburg M3, Jochems A4, Wouters M5, Van den Eertwegh E6, Haanen J7, Van der Hoeven K8, Uyl - de Groot C9, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands, 1Dutch Institute for Clinical Auditing, Deventer, The Netherlands, 2Leiden University Medical Center, Leiden, The Netherlands, 3Amsterdam Cancer Institute, Amsterdam, The Netherlands, 4VU University Medical Center, Amsterdam, The Netherlands

PCN345 L10 UPTAKE OF FILGRASTIM ‘BIOSIMILARS’ IN THE UNITED STATES: ANALYSIS OF A MEDICAL TRANSCRIPTION DATABASE OF PATIENT OFFICE VISITS
Smoyer KE1, Jones CA2, Lane PB3, Envision Pharma Group, Philadelphia, PA, USA, 2Envision Pharma Group, London, UK, 1Envision Pharma Group, Horsham, UK

PCN346 L11 FRENCH PHYSICIAN SENSITIVITY TO AND CONSIDERATION OF THE COSTS OF CANCER TREATMENT
Chabernaud H, Infnos A, Bonnevye G, Kantar Health, Montrouge, France

PCN347 L12 REVIEW OF THE CURRENT STATUS OF RAS MUTATION TESTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): FLASH-RAS STUDY
Longin J, Merck Serono, LYON, France

PCN348 L13 EVALUATION OF PATIENT-CENTERED CARE IN SHORT-TERM CANCER SURVIVORS, THROUGH THE PATIENT ASSESSMENT OF CHRONIC ILLNESS CARE QUESTIONNAIRE
Escobar A1, Perez-Ruiz E2, Rueda A3, Trujillo-Martin Md4, Trancho Z5, Basurto University Hospital (Osakidetza) - REDISSEC, Bilbao, Spain, 1Agencia Sanitaria Costa del Sol. REDISSEC, Marbella, Spain, 2Servicio de Evaluación y Planificación. REDISSEC, Tenerife, Spain, 3Hospital Universitario Basurto. REDISSEC, Bilbao, Spain

PCN349 L14 EVALUATION OF A PAYMENT BY RESULTS SCHEME IN A CATALAN CANCER CENTER: GEFINITIB IN EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER
Simon S1, Clopes A2, Gasol-Boncompte M3, Cajal R4, Segu JL5, Crespo R6, Mora-Ripoll R7, Cordero L8, Calle C9, Gilabert-Perramon A10, Germa JR11, AstraZeneca Farmaceutica, S.A., Madrid, Spain, 1Institut Catala d'Oncologia, Barcelona, Spain, 2CatSalut, Barcelona, Spain, 3AstraZeneca Spain, Madrid, Spain, 4Oblikue Consulting, Barcelona, Spain, 5CatSalut, Catalan Health Service, Barcelona, Spain, 6AstraZeneca, Madrid, Spain, 7Government of Catalonia, Barcelona, Spain, 8Institut Catala D’Oncologia, Hospital de Llobregat, Barcelona, Spain

PCN350 L15 EXPLORING BEFORE AND AFTER RISK-SHARING SCHEME IMPLEMENTATION DURING 8.5 YEARS FOCUSED ON ANTICANCER DRUGS
Chae JY, Park HK, So SM, Health Insurance Review & Assessment Service (HIRA), Seoul, South Korea

PCN351 L16 ACCESS TO INNOVATION AND ECONOMIC BURDEN----A CASE OF NON-SMALL CELL LUNG CANCER IN A PATIENT ACCESS PROGRAM IN QINGDAO, CHINA
Chen W, Lin Y, Zhang L, Fudan University, Shanghai, China

PCN352 L17 PATIENT CHARACTERISTICS AND TREATMENT PATTERNS IN ER+/HER2- METASTATIC BREAST CANCER IN THE UK: RESULTS FROM A RETROSPECTIVE MEDICAL RECORD REVIEW
Kurosky S1, Mitra D2, Zanotti G3, Kaye JA4, RTI Health Solutions, Research Triangle Park, NC, USA, 1Pfizer, Inc., New York, USA
PCN353 L18  CURRENT TREATMENT PATTERNS IN PATIENTS WITH METASTATIC MELANOMA: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS IN THE UNITED STATES (US)
Chen Y1, Ma Q2, Hines DM1, Zhao Z2, Munakata J3, Barber BL1,1IMS Health, Fairfax, VA, USA, 2Amgen Inc, Thousand Oaks, CA, USA, 3IMS Health, San Francisco, CA, USA

PCN354 L19  TREATMENT PATTERNS AMONG FRONT-LINE Glioblastoma PATIENTS IN FIVE EUROPEAN COUNTRIES
Jiang S1, Hill K2, Patel D1, Worthington K2,1Pharmerit International, Bethesda, MD, USA, 2Celldex Therapeutics, Hampton, NJ, USA

PCN355 L20  BONE PAIN AND BONE TARGETING AGENT (BTA) TREATMENT PATTERNS IN PATIENTS WITH BONE METASTASES (BMS) FROM BREAST CANCER (BC) IN REAL WORLD SETTING IN EUROPE
von Moos R1, Henry D1, Body J1, Rider A2, De Courcy J2, Murray G3, Bhowmik D4, Gatta F6, Arellano J5, Hechmati G6, Qian Y5,1Kantonssspital Graubünden, Chur, Switzerland, 2Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA, USA, 3CHU Brugmann, Brussels, Belgium, 4Adelphi Real World, Bollington, UK, 5Amgen Inc., Thousand Oaks, CA, USA, 6Amgen (Europe) GmbH, Zug, Switzerland

PCN356 L21  BONE PAIN AND BONE TARGETING AGENT (BTA) TREATMENT PATTERNS IN PATIENTS WITH BONE METASTASES (BMS) FROM PROSTATE CANCER (PC) IN REAL WORLD SETTING IN EUROPE
Body J1, Henry D1, von Moos R1, Rider A2, De Courcy J2, Murray G3, Bhowmik D4, Gatta F6, Arellano J5, Hechmati G6, Qian Y5,1Kantonssspital Graubünden, Chur, Switzerland, 2Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA, USA, 3CHU Brugmann, Brussels, Belgium, 4Adelphi Real World, Bollington, UK, 5Amgen Inc., Thousand Oaks, CA, USA, 6Amgen (Europe) GmbH, Zug, Switzerland

PCN357 L22  SCREENING GUIDELINES AND CANCER STAGE: EARLY FINDINGS FROM MEDICARE
Hsu J, Price M, Harvard Medical School, Boston, MA, USA

PCN358 L23  A COMPARATIVE STUDY TO EVALUATE TREATMENT PATTERNS AND RESULTING UTILITY IN PATIENTS OF HEAD & NECK CANCERS UNDER PRIVATE PAYMENT SCHEME AND GOVERNMENT SCHEME
Himanshu Patel1, Avinash K2, Parthasarathi G1,3, Madhavi Y2, JSS College of Pharmacy, Mysore, JSS University, Mysore, Mysore, India, 2Bharath Hospital & Institute of Oncology, Mysore, India

RESPIRATORY-RELATED DISORDERS - Clinical Outcomes Studies

PRS1 L24  TORSADE DE POINTES AND QT PROLONGATION COULD RESULT FROM DESLORATADINE ANTI-ALLERGY TREATMENT
Ali AK, Eli Lilly and Company, Indianapolis, IN, USA

PRS3 L26  RISK OF PNEUMONIA ASSOCIATED WITH THE USE OF ICS/LABA: A RETROSPECTIVE COHORT STUDY IN KOREA
Park J1, Shin J2, Bae S3,1Ewha Womans University, AstraZeneca Korea, Seoul, South Korea, 2Korea institute of drug safety and risk management, Seoul, South Korea, 3Ewha Womans University, Seoul, South Korea

PRS4 L27  SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF COMBINATION THERAPY WITH GLYCOPIRRONIUM-INDACATEROL COMPARED WITH OTHER FIRST LINE THERAPIES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Rosselli D1, Karpe E2, Olaya A3, Castañeda-Cardona C4, Triana JJ5, Bayona JG5, Lasalvia P6, Restrepo P7, Laserna A8,3Pontificia Universidade Javeriana, Bogotá, Colombia, 2Novartis Colombia, Bogotá, D.C., Colombia, 1Pontificia Universidade Javeriana, Bogotá, Colombia

PRS5 L28  DOCTORS’ FAILURE IN OBSERVANCE OF THE COPD MANAGEMENT GUIDELINES: THE CZECH REPUBLIC 2015 UPDATE
Zigmund J1, Vitova V1, Koblizek V2, Zatloukal J3, Kolek V3,1CEEOR s.r.o., Prague, Czech Republic, 2Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic, 3Olonouc University Hospital, Olomouc, Czech Republic

PRS6 L29  BAYESIAN NETWORK META-ANALYSIS TO ASSESS THE COMPARATIVE EFFICACY AND SAFETY OF TREATMENTS FOR SEVERE OR UNCONTROLLED ASTHMA
Belhadi D1, Taieb V2, Nielsen AT3, Hemels M4, Van Laer J5,1Amaris, London, UK, 2Janssen-Cilag A/S, Birkerød, Denmark, 3Janssen Pharmaceutica N.V., Beerse, Belgium

PRS7 L30  COMPARATIVE EFFECTIVENESS ANALYSIS OF MAB IN ASTHMA: THE IMPORTANCE OF EXACERBATION DEFINITION
Torvinen S1, Rémuzaüt C2, Mzoughi O3, Plich A4, Toumi M5,1Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, 2Creative-Ceutical, Paris, France, 3Creative-Ceutical, Tunis, Tunisia, 4Aix-Marseille University, Marseille, France

PRS8 L31  BAYESIAN NETWORK META-ANALYSIS TO ASSESS THE COMPARATIVE EFFICACY AND SAFETY OF TREATMENTS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Taieb V1, Belhadi D2, Nielsen AT3, Hemels M4, Van Laer J5,1Amaris, London, UK, 2Janssen-Cilag A/S, Birkerød, Denmark, 3Janssen Pharmaceutica N.V., Beerse, Belgium

PRS9 L32  EVOLUTION OF Tiotropium EFFICACY VS. PLACEBO OVER TIME FOR THE MAINTENANCE THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FROM INVESTIGATIONAL PRODUCT TO ACTIVE REFERENCE
Thokagye vist K, Khemiri A, Dorey J, Toumi M, Creativ-CEPTical, Paris, France, Creativ-CEPTical, Tunis, Tunisia, Aix-Marseille University, Marseille, France

PRS10 L33 CAN WE IMPROVE THE INHALATION TECHNIQUES IN PATIENT WITH COPD?. TIEPOC STUDY

PRS11 M1 CLINICAL EVALUATION OF KANAKASAVA AND SWASANANDAM GULIKA IN BRONCHIAL ASTHMA
Kuvettu H, Archarya S, Rashin C, Nagappa AN, PG Dept. of Kayachikitsa, Munival Institute of Ayurveda Medical Sciences, Manipal, India, Dept. of Pharmacy Management, MCOPS, Manipal University, Manipal, India

PRS12 M2 USE OF XANTHINES IN THE TREATMENT OF CHRONIC RESPIRATORY DISEASES IN SERBIA, COMPARED WITH THE SCANDINAVIAN COUNTRIES FROM 2004 TO 2013
Milovic N, Milijašević B, Paut Kusturica M, Tomas A, Horvat O, Sabo A, Tomić Z, Faculty of Medicine, Novi Sad, Serbia and Montenegro

PRS13 M3 MANAGEMENT OF SORE THROAT IN COMMUNITY PHARMACY IN FRANCE: A NATIONAL OBSERVATIONAL STUDY
Berthélemy O, Berdeaux G, Auges M, Bruel P, Pa-Pri-Ka, Paris, France, Pierre Fabre, boulogne billancourt, France

PRS14 M4 IDENTIFICATION OF SUBGROUPS WITH LOW RATES OF SMOKING CESSION IN ISRAEL
Sruvolic E, Levinu-Zamir D, Leventer-Roberts M, Balicer R, Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel, Department of Health Education and Promotion, Clalit Health Services, Tel Aviv, Israel

PRS15 M5 PATTERN AND FACTORS ASSOCIATED WITH READMISSION IN PATIENTS HOSPITALIZED FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN TAIWAN
Cheng J, Ku H, Chang C, Chang Gung University, Tao-Yuan, Taiwan, Chang Gung University, Tao-Yun, Taiwan

RESPIRATORY-RELATED DISORDERS - Cost Studies

PRS16 M6 THE BUDGET IMPACT OF DUORESP® SPIROMAX® COMPARED WITH COMMONLY PRESCRIBED DRY POWDER INHALERS FOR THE MANAGEMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN ITALY: ESTIMATED IMPACT OF INHALATION TECHNIQUE

PRS17 M7 TIOROPTIUM+OLODATEROL RESPIMAT; BUDGET IMPACT IN THE UK

PRS18 M8 THE BUDGET IMPACT OF AN INHALER WITH PATIENT PREFERRED FEATURES FOR THE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE UK: ESTIMATED IMPACT ON UNSCHEDULED HEALTHCARE COSTS AND INHALER SATISFACTION
Nicolai JL, Torvinesis S, Howard DJ, Miles R, Greaney MH, Plick A, Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, Adelphi Values Ltd, Bollington, UK

PRS19 M9 ESTIMATING SEASONAL ALLERGIC CONJUNCTIVIS MARKET SIZE AND SPENDING
Murphy D, Vietri J, Vilachaki I, WG Access Ltd, London, UK, Kantar Health, Horsham, PA, USA

PRS20 M10 BUDGETARY IMPLICATIONS OF INTRODUCING THE GSK ELLIPTA PORTFOLIO FOR COPD IN THE UK

PRS21 M11 BUDGET IMPACT ANALYSIS OF FORMOTEROL EASYHALER IN THE TREATMENT OF ASTHMA IN CHILDREN IN THE RUSSIAN FEDERATION
Kulikov A, Kilimanova E, Moscow State Medical University, Moscow, Russia

PRS22 M12 COST SAVING STUDY OF FIVE GRASS POLLEN SLIT TABLET VERSUS SCIT'S & SYMPTOMATIC TREATMENT

PRS23 M13 BURDEN OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS OVER 18 YEARS OF AGE
Cuhadaroglu C, Alici DE, Hacibedel B, Saribas G, Kosar E, Acibadem University Faculty of Medicine, Pulmonary Medicine, Istanbul, Turkey, Pfizer Pharmaceuticals, Medical Department, Istanbul, Turkey, Pfizer Pharmaceuticals, Department of Health Economics and Outcomes Research, Istanbul, Turkey, Yedikule Pulmonary Diseases and Thoracic Surgery Training and Research Hospital, Department of Pulmonary Diseases, Istanbul, Turkey

PRS24 M14 THE ASSOCIATION BETWEEN SMOKING CESSATION OUTPATIENT VISITS AND TOTAL MEDICAL COSTS: AN ANALYSIS OF JAPANESE EMPLOYEE BASED PUBLIC HEALTH INSURANCE DATA
Suwa K, Nakamura Y, Yoshikawa R, Gunji T, Iwasaki K, Pfizer Japan Inc., Tokyo, Japan, University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan

PRS25 M15 COST CONSEQUENCE OF PREVENTIVE TREATMENT WITH OM 85 BACTERIAL LYSATE COMPARED TO THE SAME PATIENTS WITHOUT OM 85 THE PREVIOUS YEAR IN ALLERGIC RHINITIS, ASTHMA AND COPD IN ARGENTINA

**PRS43 M31**  
**COST-EFFECTIVENESS OF TIOTROPium VS GLYCOPHYRRONium IN MODERATE TO VERY SEVERE COPD IN SPAIN**  
Eklund O\(^1\), Afzal F\(^1\), Borgström F\(^1\), Ojjanguren ME\(^2\), Crespo C\(^3\), Baldwin M\(^4\), Quantify Research, Stockholm, Sweden, \(^1\)Boehringer Ingelheim Norway, Asker, Norway, \(^2\)Boehringer Ingelheim, Sant Cugat del Vallès (Barcelona), Spain, \(^3\)Boehringer Ingelheim Germany, Ingelheim, Germany

**PRS44 M32**  
**ECONOMIC EVALUATION OF FLUTICASONE PROPIONATE/FORMOTEROL FUMARATE (FLUTIFORM®) VS FLUTICASONE/SALMETEROL AND BUDESONIDE/FORMOTEROL IN SPAIN**  
Martínez-Moragón E\(^1\), Delgado J\(^2\), Ojeda P\(^3\), Pérez del Llano L\(^4\), Antón C\(^5\), Martín C\(^6\), Collar JM\(^7\), Hospital Dr. Peset, Valencia, Spain, \(^2\)Hospital Virgen Macarena, Seville, Spain, \(^3\)Clínica Dres. Ojeda, Madrid, Spain, \(^4\)Complexo Hospitalario Lucus Augusti, Lugo, Spain, \(^5\)Universidad Francisco de Vitoria, Pozuelo de Alarcón (Madrid), Spain, \(^6\)Mundipharma Pharmaceuticals, S.L., Madrid, Spain

**PRS45 M33**  
**COST – EFFECTIVENESS ANALYSIS OF BUDESONID EASYHALER IN THE TREATMENT OF ASTHMA IN CHILDREN IN THE RUSSIAN FEDERATION**  
Kulikov A, Kilimanova E, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

**PRS46 N1**  
**ECONOMIC EVALUATION OF RESPIRATORY MEDICATION THERAPY ADHERENCE CLINIC (RMTAC) ON ASThma PATIENTS IN MALAYSIA**  
Yong YV, Shafie AA, Universiti Sains Malaysia, Penang, Malaysia

**PRS47 N2**  
**COST-EFFECTIVENESS OF TIOTROPium IN THE TREATMENT OF PATIENTS WITH ASThma**  
Echave M, Ojjanguren ME\(^1\), Elías i\(^1\), de Andrés-Nogales F\(^1\), Oyagüez i\(^1\), Casado MA\(^2\), Crespo C\(^2\), Pharmacoeconomics & Outcomes Research Iberia, Pozuelo de Alarcón (Madrid), Spain, \(^3\)Boehringer Ingelheim, Sant Cugat del Vallès (Barcelona), Spain

**PRS48 N3**  
**A SYSTEMATIC REVIEW OF MARKOV MODELS EVALUATING MULTI-COMPONENT DISEASE MANAGEMENT PROGRAMS**  
Kirsch F, Ludwig-Maximilians-University Munich, Munich, Germany

**PRS49 N4**  
**COST-EFFECTIVENESS ANALYSIS OF TOBACCO DEPENDENCE TREATMENT IN THE CZECH REPUBLIC**  
Karbussicka M\(^1\), Kolek M\(^1\), Vothova P\(^1\), Duba J\(^1\), Králíková E\(^1\), Rublee D\(^1\), Doleckova J\(^1\), OAKS Consulting s.r.o., Prague 9, Czech Republic, \(^2\)Pfizer, spol. s r.o., Prague 5, Czech Republic, \(^3\)Centres for Tobacco-Dependent, Prague 2, Czech Republic, \(^4\)Pfizer Inc, New York City, NY, USA

**PRS50 N5**  
**COST-EFFECTIVENESS OF A 13-VALENT CONJUGATE PNEUMOCOCCAL VACCINATION PROGRAM IN COPD PATIENTS AGED 50+ YEARS IN SPAIN**  
Rodríguez-GonzálezMoro JM\(^1\), Menendez R\(^2\), Campins M\(^2\), Lwoff N\(^2\), Oyagüez i\(^2\), Echave M\(^2\), Rejas J\(^2\), Antoñanzas F\(^2\), Hospital Gregorio Marañón, Madrid, Spain, \(^3\)Hospital Universitario La Fe, Valencia, Spain, \(^4\)Hospital Vall d'Hebron, Barcelona, Spain, \(^5\)Pfizer SLU, Alcobendas, Spain, \(^6\)Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, \(^7\)University of La Rioja, La Rioja, Spain

**PRS51 N6**  
**ECONOMIC EVALUATION OF TIOTROPium ADMINISTRATED THROUGH THE RESPIMAT INHALER AS ADD-ON THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASThma IN POLAND**  
Pawlik M, Walczak J, Pieniazek J, Arcana Institute Ltd, Krakow, Poland

**PRS52 N7**  
**ECONOMIC EVALUATION OF TIOTROPium FOR SEVERE PERSISTENT ASThma IN PORTUGAL**  
Silva Miguel L\(^1\), Manaças M\(^2\), Pinheiro B\(^3\), CISEP (Research Centre on the Portuguese Economy), Lisbon, Portugal, \(^4\)Instituto de Medicina Preventiva e Saúde Pública, Lisbon, Portugal

**PRS53 N8**  
**SQ® HDM SLIT TABLETS IN ADDITION TO PHARMACOTHERAPY ARE COST-EFFECTIVE COMPARED TO PHARMACOTHERAPY ONLY IN TREATING PATIENTS WITH ALLERGIC ASTHMA**  

**PRS54 N9**  
**RECENT TRENDS IN ANAPHYLAXIS-RELATED HOSPITALIZATION IN THE UNITED STATES**  
Candrilli S, Kurosky SK, RTI Health Solutions, Research Triangle Park, NC, USA

**RESPIRATORY-RELATED DISORDERS - Patient-Reported Outcomes & Patient Preference Studies**

**PRS55 N10**  
**MEASURING GENERIC HEALTH-RELATED QUALITY OF LIFE AND IMPACT OF HEALTH RESOURCE UTILIZATION IN ADULTS WITH CYSTIC FIBROSIS**  
Yarlas A\(^1\), O’Callaghan L\(^2\), Lopes V\(^3\), Suthoff E\(^4\), Wagener J\(^4\), Optum Incorporated, Lincoln, RI, USA, \(^5\)Vertex Pharmaceuticals Incorporated, Boston, MA, USA, \(^6\)University of Colorado, Aurora, CO, USA

**PRS56 N11**  
**ASSESSING COPD PATIENTS BURDEN OF DISEASE IN A FOLD-IN-FOLD-OUT DISCRETE CHOICE EXPERIMENT**  
Goossens LM\(^1\), Stolk EA\(^1\), Donkers B\(^1\), Boland MR\(^2\), Rutten-van Mölken MP\(^2\), Erasmus University Rotterdam, Rotterdam, The Netherlands, \(^3\)University of Oxford, Oxford, UK

**PRS57 N12**  
**MAPPING THE ST GEORGE'S RESPIRATORY QUESTIONNAIRE TO THE EUROQOL 5 DIMENSIONS: A STUDY IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS**  

**PRS58 N13**  
**PATIENTS' PRIORITIES FOR TREATMENT IN MODERATE TO SEVERE COPD**
**PRS59 N14**

**PATIENTS' PRIORITIES FOR TREATMENT IN SEVERE ASTHMA**

*Whalley D*1, Hauber AB2, Crawford SR3, Posner J4, Doward L1, Levitan B3, Hemels M5, Valgardsson VS6,1RTI Health Solutions, Manchester, UK, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Janssen Research & Development, LLC, Titusville, NJ, USA, 4Janssen-Cilag A/S, Birkerod, Denmark, 5Janssen-Cilag AS, Oslo, Norway

**PRS60 N15**

**PATIENT-REPORTED OUTCOMES IN STUDIES PUBLISHED IN 2014: WHICH TOOLS HAVE BEEN MOST COMMONLY USED IN STUDIES OF RESPIRATORY DISORDERS?**

*Martin A* Crystallise Ltd., London, UK

---

**RESPIRATORY-RELATED DISORDERS - Health Care Use & Policy Studies**

**PRS64 N19**

**ASSESSMENT OF KNOWLEDGE AND AWARENESS REGARDING ASTHMA AMONG SCHOOL TEACHERS IN QUETTA**

*ul Haq N,* Iqbal Q, Nasim A, Razaq G, Shafi M, Akram A, Raiz S, Haque N, University of Balochistan, Quetta, Pakistan

**PRS65 N20**

**TITLE: FACTORS INFLUENCING CONSUMERS' PERCEIVED RISK OF TOBACCO PRODUCTS**

*Atkinson M*1, Chrea C2, Salzberger T3, Cano S4, Emilien G5, Mainy N6, Ramazzotti A7, Weitkunat R8, Lüdicke F9, Alfieri T10, Covance Inc., San Diego, CA, USA, 2Philip Morris International R&D, Neuchâtel, Switzerland, 3University of Economics and Business, Vienna, Austria, 4ScaleReport, Stotfold, UK, 5Philip Morris International Management S.A., Lausanne, Switzerland

**PRS66 N21**

**CONDITIONAL AGREEMENTS FOR INNOVATIVE THERAPIES IN ITALY: THE CASE OF PIRFENIDONE**

*Fasci A*1, Ferrario M2, Ravasio R3, Ena R4, Angelini S5, Hoffmann-La Roche, Monza, Italy, 2Health Publishing & Services, Milano, Italy, 3Roche SpA, Monza, Italy

**PRS67 N22**

**THE EPIPPEN4SCHOOLS® SURVEY: STAFF TRAINING AND USE OF EPINEPHRINE AUTO-INJECTORS FOR THE TREATMENT OF ANAPHYLAXIS IN LARGE US SCHOOL DISTRICTS**

*Hogue S*1, Hollis K2, Silvia S3, Wooddell M4, 1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI International, Research Triangle Park, NC, USA, 3Mylan Specialty LP, Canonsburg, PA, USA

**PRS68 N23**

**COPD PERFORMANCE INDICATORS IN AN INTEGRATED CARE PROGRAM AND ITS IMPACT ON HEALTH OUTCOMES: THE RECODE CLUSTER RANDOMIZED TRIAL**

*Boland MR*1, Tsiachristas A2, Rutten van Mölken M3, Erasmus University Rotterdam, Rotterdam, The Netherlands, 2University of Oxford, Oxford, UK

**PRS69 N24**

**PREVALENCE OF SWITCHING FROM BRAND TO GENERIC ASTHMA MEDICATIONS**

*Engelkes M1, van Blijderveen N2, Verhamme K3, Overbeek JA4, Kuiper JG5, Herings RM6, Strukvenboom M7, de Jongste J8, Janssens H9, Erasmus MC, Rotterdam, The Netherlands, 2PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 3Erasmus MC Sophia, Rotterdam, The Netherlands

**PRS70 N25**

**DO CLINICAL GUIDELINE IMPLEMENTATIONS REDUCE THE GOVERNMENT BUDGET? A CLINICAL GUIDELINE-BASED BUDGET IMPACT MODEL IN REIMBURSEMENT OF INHALER TREATMENTS IN COPD**

*Gungor C,* Konya A, Keskinaslan A, Novartis AG, Istanbul, Turkey

**PRS71 N26**

**STUDY OF ACUTE LOWER RESPIRATORY TRACT INFECTIONS IN CHILDREN OF AGE GROUP 1 MONTH TO 5 YEARS**

*Kanneganti S,* Acharya Nagarjuna University, Guntur, India

**PRS72 N27**

**AVAILABILITY OF DRUGS RECOMMENDED BY GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD) FOR UKRAINIAN PATIENTS WITH COPD**

*Iakovlieva L,* Bondarenko D, Matyashova N, Tkachova O, National University of Pharmacy, Kharkiv, Ukraine

**PRS73 N28**

**COST AND RESOURCE UTILIZATION OF UNCONTROLLED AND PERSISTENT ASTHMA IN CANADA: A SYSTEMATIC LITERATURE REVIEW**

*Lachaine J*, Bibeau J1, Castonguay A1, Barakat S2, University of Montreal, Montreal, QC, Canada, 1Teva Canada Innovation, Montreal, QC, Canada

**PRS74 N29**

**ASSESSING THE NET FISCAL CONSEQUENCES OF TOBACCO USE IN A HIGH CONSUMPTION AND HIGH TOBACCO TAX COUNTRY: THE CASE OF GREECE**

*Kotsopoulos N*1, Mergos G2, Postma M3, Connolly M3, 1Global Market Access Solutions, St-Prex,
URINARY/KIDNEY DISORDERS - Clinical Outcomes Studies

**PUK1 O4** CYCLOSPORINE IS NOT THE DRUG OF CHOICE FOR RENAL TRANSPLANTED PATIENTS AND INCREASES THE RISK OF CARDIOVASCULAR AND CEREBROVASCULAR ACCIDENTS

**Fazal J**, Universita' della Calabria, Cosenza, Italy

**PUK2 O5** CORRELATION BETWEEN EQUATION FOR ESTIMATING GLOMERULAR FILTRATION RATE: CHRONIC KIDNEY DISEASE EPIDEMIOLOGY COLLABORATION -CKD -EPI, COCKCROFT-GAULT -CG- AND MODIFICATION OF DIET AND RENAL DISEASE –MDRD4- IN COLOMBIA

**Acuña L**, Mejía C, Alvis LF, Sanchez P, Soler L, Cuenta de Alto Costo, Bogotá, Colombia

**PUK3 O6** PATIENT BENEFITS AND COST SAVINGS PREDICTED FOR MINERALOCORTICOID-RECEPTOR ANTAGONIST TREATMENT OF EARLY AND ADVANCED DIABETIC KIDNEY DISEASE

**Blankenburg M**, Pelkey R, Folse HJ, Bayer HealthCare Pharmaceuticals, Berlin, Germany

**PUK4 O7** DATA MINING BASED ON REAL WORLD DATA IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS: THE KEY ROLE OF EARLY HEMOGLOBIN LEVELS CONTROL

**Frimat L**, Pau D, Sinnaasse-Raymond G, Choukroun G, INSERM CIC-EC CIE6, Vandoeuvre, France

**PUK5 O8** PATTERNS OF MEDICATION USE IN CHRONIC KIDNEY DISEASE STAGE 5D: EMPHASIS ON MEDICATIONS FOR THE MANAGEMENT OF CKD-MBD

**Salman M**, Khan AH, Adnan AS, Syed Sulaiman SA, Hussain K, Mansoor S, Shehzadi N, University of the Punjab, Lahore, Pakistan

**PUK6 O9** PREVALENCE OF CHRONIC KIDNEY DISEASE IN INDIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES

**Ahlawat R**, Tiwari P, D'Cruz S, Singhal R, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India

**PUK7 O10** INTRODUCTION OF MIRABEGRON IN THE CZECH REPUBLIC FROM PAYER'S PERSPECTIVE – 1 YEAR OVERVIEW

**URINARY/KIDNEY DISORDERS - Cost Studies**
PUK8 011 ECONOMIC BURDEN OF ADPKD FROM THE SPANISH HEALTH SYSTEM AND PATIENT'S PERSPECTIVE: ADVANTAGES OF DELAYING DIALYSIS
Parramon M1, Peces R2, Peces C3, Selgas R4, Otsuka Pharmaceutical, Barcelona, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³SESCAM, Toledo, Spain

PUK9 012 DO SOCIOECONOMIC INEQUALITIES IMPACT THE SOCIAL COST OF CHRONIC KIDNEY DISEASE IN ITALY?
Bellelli S, Turchetti G, Scuola Superiore Sant'Anna, Pisa, Italy

PUK10 013 COSTS OF OVERACTIVE BLADDER SYMPTOMS TREATMENT WITH SOLIFENACIN
Avxentyeva M1, Gerasimova K2, Khachatryan GR3, Frolov M4, Avxentyev NA5, Pyudushkina E6, The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, ²I.M. Sechenov First Moscow State Medical University, Moscow, Russia, ³Volgograd State Medical University, Volgograd, Russia, ⁴Applied economic research Institute of Russian academy of national economy and public administration, Moscow, Russia

PUK11 014 COST-CONSEQUENCES ANALYSIS OF FESOTERODINE AT FLEXIBLE-DOSE IN THE THERAPY OF OVERACTIVE BLADDER IN ROUTINE MEDICAL PRACTICE
Peral C1, Rejas J2, Ramos J3, Sanchez-Ballester F4, Garcia-Mediero JM5, Pfizer S.L.U., Alcobendas (Madrid), Spain, ²Pfizer, Alcobendas, Spain, ³Department of Urology, Valencia, Spain, ⁴Hospital MD Anderson, Madrid, Spain

PUK12 015 HOSPITAL COSTS OF CONTRAST-INDUCED NEPHROPATHY
Brillet G1, Aubry P2, Schmidt A3, Catella L4, ²Centre de néphrologie de Châteauroux, Châteauroux, France, ³Hôpital Bichat-Claude Bernard, Paris, France, ⁴st[e]ve consultants, Oullins, France, ⁵GE Healthcare, Vélizy-Villacoublay, France

PUK13 016 COST-EFFECTIVENESS OF A FIXED-DOSE COMBINATION OF SOLIFENACIN PLUS TAMSULOSIN OCAS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA IN SPAIN
Toledo A1, Llopis A2, Mora A3, Rubio-Terrés C4, Rubio-Rodríguez D5, Nazir J6, Astellas Pharma SA, Madrid, Spain, ²Health Value, Madrid, Spain, ³Astellas Pharma EMEA, Chertsey, UK

PUK14 017 PROJECTED CLINICAL AND ECONOMIC IMPACT OF GRAZOPREVIR (GZR, MK-5172)/ELBASVIR (EBR, MK-8742) FOR CHRONIC HCV GENOTYPE 1 INFECTION IN CHRONIC KIDNEY DISEASE
Elbasha EH1, Ferrante S1, Agarwal E2, Greaves W3, Nwankwo C4, Merck & Co., Inc., Kenilworth, NJ, USA, ²NewAgeSys, Inc., Princeton Junction, NJ, USA

PUK15 018 INVESTIGATING THE COST-EFFECTIVENESS OF BACTERIAL WHOLE-GENOME SEQUENCING FOR ENABLING TARGETED ANTIBIOTIC SELECTION IN URINARY TRACT INFECTIONS
Buchanan-Hughes AM1, Griffiths A, Evans J, Slater D, Eddowes LA, Costello Medical Consulting Ltd, Cambridge, UK

PUK16 019 ECONOMIC EVALUATION OF MIRABEGRON VERSUS ANTIMUSCARINIC TREATMENTS IN PATIENTS WITH OVERACTIVE BLADDER FROM THE PERSPECTIVE OF THE SPANISH NATIONAL HEALTH SERVICE
Toledo A1, Álvarez-Novoa I2, Mora A3, Rubio-Terrés C4, Rubio-Rodríguez D5, Nazir J6, Astellas Pharma SA, Madrid, Spain, ²Health Value, Madrid, Spain, ³Astellas Pharma EMEA, Chertsey, UK

PUK17 020 PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION
Avxentyeva M1, Avxentyev NA2, Frolov M3, Derkach EV4, The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, ²Applied economic research Institute of Russian academy of national economy and public administration, Moscow, Russia, ³Volgograd State Medical University, Volgograd, Russia

PUK18 021 LAPAROSCOPIC SURGERY VERSUS TRADITIONAL OPEN SURGERY FOR KIDNEY IMPLANTATION: A COST-EFFECTIVENESS MODEL
Arun A, Pennington B, BresMed Health Solutions Pvt. Ltd., Panjim, India

PUK19 022 PHARMACOECONOMIC ANALYSIS: ANALYSIS OF COST-EFFECTIVENESS OF LANTHANUM-CARBONATE (LC) IN UNCONTROLLED HYPERPHOSPHATEMIA IN DIALYSIS
Giotta N, Marino AM, Cardinale Massaia Hospital, ASTI, Italy

URINARY/KIDNEY DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PUK20 02 P2 DELAY OF OPTIMAL NOCTURIA TREATMENT IS COSTLY: RESULTS OF A REAL WORLD SURVEY OF PATIENTS IN EUROPE AND THE USA
Andersson FL1, Anderson P2, Juul KV2, Wood R3, Piercy J4, Weiss JP5, ²Ferring Pharmaceuticals A/S, Copenhagen, Denmark, ³Adelphi Real World, Macclesfield, UK, ⁴Department of Urology, New York, NY, USA

PUK21 03 P3 IMPACT OF NOCTURIA ON QUALITY OF LIFE – MAPPING OF SF-12 TO UTILITY VALUES USING CLINICAL TRIAL DATA
Lee D1, Nielsen SK2, Kidd R3, Andersson FL4, BresMed, Sheffield, UK, ²BresMed, Panjim, India, ³Ferring Pharmaceuticals A/S, Copenhagen, Denmark

PUK22 04 P4 HRQOL AND UTILITY IN NOCTURIA ARE CORRELATED TO NUMBER OF VOIDS
Andersson FL1, Juul KV2, Raymond K3, Rosen RC4, ²Ferring Pharmaceuticals A/S, Copenhagen, Denmark, ³New England Research Institutes, Watertown, MA, USA

PUK23 05 P5 VALIDATION OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q; 1-WEEK RECALL) IN MEDICALLY
COMPLEX ELDERLY ADULTS WITH OVERACTIVE BLADDER
Barsdorf AI, Carlsson M, Bushmakin AG, Quinn S, Cappelleri JC, Pleil A, Pfizer, Inc, New York, NY, USA, Pfizer, Inc, Groton, CT, USA, Pfizer, Inc, San Diego, CA, USA

PUK24 P6 HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASURES IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

PUK25 P7 QUALITY OF LIFE IN WOMEN PATIENTS WITH URINARY INCONTINENCE IN SLOVAKIA
Gerlichova K, Bielik J, Papsova D, Melus V, Trencin University, Trencin, Slovak Republic

PUK28 P10 DOES OUT-PATIENT MEDICAL INSURANCE POLICY WORK AMONG CKD PATIENTS IN NON-DIALYSIS PHASES? EVIDENCE FROM TWO SAMPLE CITIES IN CHINA
Wu J, Liu J, Zhu B, Mao Y, Xi'an Jiaotong University, Xi'an, China

PUK29 P11 A CONCEPT FOR BEST-PRACTICE IN THERAPEUTIC DRUG MONITORING (TDM) FOR KIDNEY TRANSPLANT (K-T) - RESULTS FROM Q-PERIOR STUDY
Ossa D, Becker G, Bayer S, Novartis Pharma, Basel, Switzerland, Q-Perior AG, Zurich, Switzerland

PUK30 P12 EXPERIENCES WITH PRICE COMPETITION OF BIOSIMILAR DRUGS IN HUNGARY IN CASE OF ERYTHROPOIETIN PRODUCTS
Nagy Z, Hornyák L, Tálos Z, Endrei D, Ágoston I, Csákvari T, Boncz I, University of Pécs, Pécs, Hungary, Cslnoky Ferenc Hospital, Veszprém, Hungary, University of Pécs, Zalaegerszeg, Hungary

PUK31 P13 DISEASE BURDEN AND COSTS ASSOCIATED WITH URINARY TRACT INFECTIONS IN TYPE 2 DIABETES MELLITUS PATIENTS: AN ANALYSIS BASED ON A LARGE SAMPLE OF 456,586 GERMAN PATIENTS

PUK32 P14 AUTOSOMAL POLYCYSTIC KIDNEY DISEASE (ADPKD): COSTS AND RESOURCE UTILISATION IN THE NORDIC COUNTRIES
Eriksson D, Karlsson L, Eklund O, Dieperink H, Honkanen E, Melin J, Selvig K, Lundberg J, Quantify Research, Stockholm, Sweden, Odense University Hospital, Odense, Denmark, Helsinki University Central Hospital, Helsinki, Finland, Uppsala University Hospital, Uppsala, Sweden, Vestre Viken Hospital Trust, Drammen, Norway, Otsuka Pharma Scandinavia, Stockholm, Sweden

PUK33 P15 HEALTHCARE RESOURCE CONSUMPTION AND COSTS BEFORE AND AFTER KIDNEY TRANSPLANTATION IN LOMBARDY, ITALY
Roggeri DP, Roggeri A, Zocchetti C, Conte F, ProCure Solutions, Nembro (BG), Italy, Lombardy Region, Milan, Italy, S. Uboldo Hospital, Cernusco sul Naviglio (MI), Italy

PUK34 P16 CROSS-SECTIONAL DESCRIPTIVE STUDY OF THE IMPACT OF ANAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON HEALTHCARE RESOURCE UTILISATION AND WORK PRODUCTIVITY ACROSS EUROPE
Eriksson D, Teitsson S, Goldsmith D, Jackson J, van Nooeten FE, Quantify Research, Stockholm, Sweden, Guy's and St Thomas' NHS Foundation Hospital, London, UK, Adelphi Group, Bollington, UK, Astellas Pharma BV, Leiden, The Netherlands

PUK35 P17 ECONOMIC EVALUATION OF HEALTH SPENDING AND HEALTH OUTCOMES IN THE MANAGEMENT OF HEMODIALYSIS FOR TWO INSURANCE COMPANIES IN COLOMBIA
Acuna L, Bryon A, cuenta de alto costo, bogota, Colombia, Heort, Bogota, Colombia